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Abstract 
VEZF1 is a highly conserved vertebrate transcription factor that is essential for 
mammalian development. The gene regulatory functions of VEZF1 are largely 
undetermined. The generation of human cells depleted or absent of VEZF1 would greatly 
assist the study of VEZF1 functions and mechanism of action. This study makes use of 
synthetic biology technologies to either repress or knock out VEZF1 gene transcription to 
enable further studies of VEZF1 function. 
This study explores various strategies to use engineered DNA-binding proteins to direct 
the repression or mutation of a gene of interest. Zinc Finger (ZF) and Transcription 
Activator Like Effector (TALE) proteins that specifically recognise DNA sequences at the 
VEZF1 gene promoter were constructed using modular or Golden Gate assembly 
methods. The ability of TALE fusion proteins to function in human cells was studied. An 
expression vector system was created to assemble TALE Repressor (TALER) fusion 
proteins. The use of TALERs allowed for the rapid assessment of TALE protein binding at 
their chromosomal targets in human cells. Transient expression of most of the assembled 
TALE repressor proteins resulted in reduced VEZF1 transcription. A subset resulted in very 
substantial VEZF1 repression, making them useful tools for the study of VEZF1 function. 
Functional TALE domains were assembled into TALE nuclease (TALEN) fusion proteins. 
TALEN expression vectors were developed to assemble TALEN proteins with optimised 
expression, cleavage activity and target specificity. Transient expression of TALEN 
proteins in human cells was used to direct the cleavage and error-prone DNA repair of the 
VEZF1 promoter. Following development of the assays used to detect TALEN-directed 
mutations, several functional TALEN pairs were identified. Some TALENs resulted in over 
65% mutation rates, with some mutations removing the VEZF1 promoter. These TALENs 
will be useful for the development of VEZF1 knock out cell lines. Interestingly, our study 
reveals a correlation between TALE length and the activity of TALERs and TALENs that 
should be considered in the future application of TALE proteins.  
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Chapter 1 
1 Introduction 
1.1 Genome modification 
Reverse genetics is the analysis of a gene’s function through the modification of its 
phenotype.  With the advent of whole genome sequencing, many genes have been 
identified through sequence characteristics.  While information about the size, sequence, 
location and the RNA transcript of these genes is known, it is impossible to predict the 
role of the encoded protein from this data.  Phenotypic manipulations can be performed 
at defined genomic loci using a variety of procedures such as insertional mutagenesis, 
RNA interference (RNAi), targeted gene repression, mutation or gene knock-in/knockout 
(Hardy et al., 2010).  Introduction of a targeted double stranded break (DSB) at a defined 
chromosomal location can stimulate repair mechanisms in the cell up to 50,000 fold 
(Jasin, 1996).  This feature can be exploited to perform targeted gene modification by 
stimulating the cell’s natural repair mechanisms at a user-defined genetic locus, resulting 
in a modification intended to disrupt the gene’s capacity to produce its phenotype. 
1.2 DNA Repair Processes 
Nuclease-mediated genome editing involves inducing targeted double stranded breaks 
(DSBs) at predefined genomic locations. DNA DSBs are then repaired by either non-
homologous end joining (NHEJ) or homology directed repair (HDR) (Figure 1.1). NHEJ is an 
error prone DNA repair process, which introduces small insertions or deletions in repaired 
DNA strands (Figure 1.1, left) (Lieber, 2010). HDR-mediated repair involves the use of 
donor DNA which has sequence homology to the region surrounding the induced DSB. 
This donor DNA template is then used to faithfully repair DNA DSBs, and can be utilised to 
promote the insertion of targeted gene mutations (Figure 1.1, middle and right) (Moehle 
et al., 2007). This thesis aims to promote gene targeting by inducing DSBs at defined 
locations. 
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Figure 1.1 Double-strand break repair 
DNA double-strand breaks can be repaired via two mechanisms: non-homologous end joining 
(NHEJ) or homology directed repair (HDR). NHEJ repair is erroneous and introduces mutations 
in the form of insertions or deletions (indels). HDR is a faithful method of DNA repair, which 
can be employed to introduce targeted DNA mutations by means of insertion of a donor DNA 
template (Joung and Sander, 2013). 
1.3 Zinc Finger Proteins 
Zinc finger proteins can be fused to nucleases, creating zinc finger nucleases (ZFNs). The 
DNA-binding properties of zinc fingers can be utilised to direct nucleases to induce 
targeted DSBs at defined locations. The zinc finger was first identified as being involved in 
protein-DNA interactions by Miller et al. (1985) in a study of TFIIIA, a 40 kDa transcription 
factor involved in the regulation of the 5S RNA genes of Xenopus laevis.  TFIIIA was found 
to be composed of a repeating structure containing zinc ions (Miller et al., 1985).  This 
region was responsible for DNA-binding, mediated through globular looped Cys2-His2 
domains.  These domains were described as grasping or gripping the DNA – a description 
leading to the name zinc “fingers”.  Since their identification, zinc fingers have been found 
to be among the most common DNA-binding proteins found in eukaryotes (Emerson and 
Thomas, 2009, Jacobs and Michaels, 1990, Bateman et al., 2002). 
1.3.1 Structure 
Each zinc finger is composed of ~30 amino acids coordinated around a zinc ion, forming 
an independent structural domain (Miller et al., 1985). Each zinc finger module is 
composed of an α-helix and two anti-parallel β-sheets (Parraga et al., 1988, Lee et al., 
1989). In every module, a zinc ion is co-ordinated by two cysteines in the β-sheet and two 
histidines in the α-helix (Figure 1.2). The zinc finger provides a structurally stable 
architecture with the ability to harbour various peptide sequences that can interact with 
DNA (Wolfe et al., 2000). Each zinc finger module binds to its DNA recognition sequence 
through the α-helix, which fits neatly into the major groove of the DNA.  Amino acid 
residues at positions -1, 3 & 6 (relative to the start of the α-helix) contact 3 bp of DNA 
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(Figure 1.3), and were initially identified as those responsible for DNA-binding specificity 
(Pavletich and Pabo, 1991).  This was later expanded upon, as residue 2 was also shown 
to be involved in interactions with a DNA base on the other DNA strand (Fairall et al., 
1993, Isalan et al., 1997).  Having identified the particular residues involved in DNA-
binding, and the overall modular structure of zinc fingers, the idea of generating designer 
DNA-binding proteins became an attractive and attainable prospect. 
 
Figure 1.2 Zinc finger structure and DNA binding mechanism 
Crystal structure of zinc finger proteins bound to DNA.  Each zinc finger is composed of an α-
helix and two antiparallel β-sheets and contains a zinc ion between two cysteine and two 
histidine residues. Each zinc finger contacts 4 bp DNA via residues -1, 2, 3 and 6 of the α-helix 
(Gaj et al., 2013). 
 
Figure 1.3 Cross-strand DNA contacts involved in zinc finger DNA-binding 
Residues -1, 3 and 6 in the zinc finger α-helix recognise 3 bp DNA on one DNA strand. Residue 
2 binds to a fourth base on the opposite DNA strand. The overall binding site of a zinc finger 
protein spans 4 bp and overlaps with the binding site of the preceding finger (Dawson, 2007). 
1.3.2 Devising a zinc finger DNA recognition code 
Desjarlais and Berg (1993) demonstrated that it was possible to alter the DNA binding 
characteristics of a zinc finger by changing the DNA-binding residues, and that zinc finger 
proteins preferentially bind to their designed target sequence, suggesting that it was 
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possible to assemble custom zinc fingers which would bind to desired DNA sequences.  
Since then, countless studies have attempted to identify a systematic code of amino acid-
DNA binding within a zinc finger protein (reviewed in Papworth et al., 2006). It became 
apparent, however, that the intricacies involved in the DNA-binding capabilities of a 
multi-fingered protein were more complex than originally envisaged.  A simple 
recognition code of zinc-finger monomer to DNA triplet, while applicable on its own, 
appeared to be subject to combinatorial issues when linked together side-by-side, 
demonstrated in Figure 1.3. The amino acid residue in position 2 makes cross-strand 
contact with the DNA base immediately adjacent to the three base pair recognition site 
originally identified (Isalan et al., 1997, Isalan et al., 1998, Cornu et al., 2008, Ramirez et 
al., 2008). 
Several groups began to construct libraries of zinc finger modules which would function 
together when used as part of a zinc finger protein.  The initial studies validated modules 
which would bind to GNN triplets; libraries of ANN, CNN and selected TNN triplets were 
developed later (Dreier et al., 2000, Dreier et al., 2001, Dreier et al., 2005, Segal et al., 
1999).  Zinc finger modules to target all of the 16 possible GNN subsites have been 
constructed from a variety of different natural sources and artificial development 
methods, and they have been well characterised in a number of contexts (discussed 
below). 
1.3.3 Assembly of zinc finger proteins 
Since the identification of a zinc finger-DNA recognition code and the creation of libraries 
of zinc finger modules to target predefined DNA triplets in a given position within a zinc 
finger protein, the development of a DIY assembly kit for the generation of designed zinc 
finger proteins was in the grasp of non-commercial research labs.  A few basic assembly 
methods were available, but the first comprehensive kit was developed by the Zinc Finger 
Consortium (www.zincfingers.org). 
1.3.3.1 Zinc finger modules 
The zinc finger encoding “modules” were characterised by three different groups: the 
Barbas research group and the companies Sangamo and ToolGen, as detailed below. 
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1.3.3.1.1 Barbas Modules 
The DNA-binding domain of the murine transcription factor Zif268, also known as Egr1, 
was used as a template to create novel zinc fingers of desired sequence specificity. Zif268 
contains an array of three Cys2-His2 zinc fingers. The known DNA recognition residues in 
the α-helix of finger 2 of Zif268 were randomised to generate phage display libraries of 
zinc finger proteins of varied specificities (Segal et al., 1999, Dreier et al., 2000, Dreier et 
al., 2001, Dreier et al., 2005). This approach ensured that any novel fingers are capable of 
working within a zinc finger array. Phage display was used to identify novel zinc fingers 
that recognise all GNN, most ANN and CNN and some TNN triplet sequences. These zinc 
finger proteins were then characterised to determine their binding specificities in an 
ELISA assay.  Where any protein demonstrated a high degree of cross reactivity with 
another DNA binding sequence, it was modified by site-directed mutagenesis in an 
attempt to generate zinc finger proteins with the highest on-target binding specificity. 
The greatest improvements to DNA binding specificity in proteins modified by site-
directed mutagenesis were observed when residues 1 and 5, which are not directly 
involved in DNA recognition, were exchanged (Segal et al., 1999).  The combination of 
phage-display and mutagenesis offers an opportunity to overcome the complexities of 
DNA-sequence recognition that would not be highlighted when zinc finger modules are 
constructed using DNA recognition codes, which only consider those residues directly 
responsible for DNA binding. 
The zinc finger modules identified by Barbas and co-workers represent a toolbox capable 
of constructing many new zinc finger proteins with designed DNA-binding specificities.  
However, the identification of such context-dependent effects demonstrates the difficulty 
of treating the DNA-binding specificities of zinc finger proteins in a modular sense. These 
Barbas modules offer a partially optimised library for use in the construction of designed 
zinc finger proteins. 
1.3.3.1.2 Sangamo Modules 
Sangamo Biosciences (Richmond, California) developed zinc finger modules to target 
most GNN targets using an in-house developed recognition code and systematic testing of 
the DNA binding abilities of zinc finger modules in electrophoretic mobility shift assays 
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(EMSAs) (Liu et al., 2002).  Every ZF module’s ability to bind its predicted DNA target was 
assessed at each position (F1, F2 or F3) in the zinc finger protein.  This method of testing 
ZF-DNA binding resulted in the first evidence of position effects within a zinc finger array.  
A particular DNA target would be efficiently bound by a zinc finger module in one position 
of a ZFP but not in other positions.  For example, a zinc finger with the amino acid 
sequence QSSNLAR effectively bound the triplet GAT when in the F1 position of a ZFP but 
recognised GAA when in positions F2 or F3.  Instead the module TSGNLVR was used when 
binding to the triplet GAT in positions F2 or F3 (Liu et al., 2002). Sangamo modules offer a 
well characterised library for use in the construction of designed zinc finger proteins. 
1.3.3.1.3 ToolGen Modules 
ToolGen, a bioscience company based in Seoul, Korea, took the approach to characterise 
the properties of naturally occurring human zinc finger domains (Bae et al., 2003). Zinc 
finger 3 of Zif268 was exchanged with isolated human zinc fingers and the resulting arrays 
were tested for binding to all 64 possible triplets in vitro. The performance and specificity 
of these novel finger combinations was confirmed using a gene reporter assay in 
transfected cells. The results indicated that a zinc finger proteins composed of naturally 
occurring fingers were more likely to be functional than their synthetic counterparts. 
Proteins composed of both naturally occurring and engineered zinc fingers performed 
moderately, but not as well as proteins composed exclusively of human zinc fingers (Bae 
et al., 2003). ToolGen modules offer a well characterised library for use in the 
construction of designed zinc finger proteins, especially when the modules are placed at 
the end of an array. 
1.3.3.1.4 Recommended Module Sets 
Despite the efforts of several groups to identify and characterise zinc fingers that 
recognise known DNA triplets, the performance of zinc fingers in the context of zinc finger 
nucleases can be unpredictable. One large study of 315 ZFN pairs created by modular 
assembly found that 44% demonstrated cleavage activity in vitro but only 7.3% were 
functional nucleases at their intended targets in cultured HEK293 cells (Kim et al., 2009). 
The study further reinforced the concept that modular assembly could produce highly 
active zinc finger nucleases, provided that the module sets were chosen from validated 
sets.  This study was used to identify a reliable subset of 37 zinc fingers, comprised mostly 
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of ToolGen modules, (Table 1.1) that could be used in different arrays without risk of 
incompatibility. These recommended modules should be preferred when designing zinc 
finger nucleases. 
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ZF module number Source DNA recognition residues DNA recognition sequence 
ZF107 ToolGen CSNR GAC 
N/A ToolGen DSAR GTC 
ZF108 ToolGen DSCR GCC 
N/A ToolGen DSNR GAC 
ZF112 ToolGen ISNR GAT 
ZF113 ToolGen KSNR GAG 
N/A ToolGen QNTQ ATA 
ZF117 ToolGen QSHR GGA 
ZF120 ToolGen QSHV YGA 
ZF121 ToolGen QSNI AAA 
ZF123 ToolGen QSNR GAA 
ZF125 ToolGen QSNV CAA 
ZF126 ToolGen QSSR GYA 
ZF128 ToolGen QTHQ AGA 
ZF130 ToolGen RDER1 GYG 
N/A ToolGen RDER2 GYG 
ZF131 ToolGen RDHR GGG 
ZF132 ToolGen RDHT YGG 
ZF133 ToolGen RDKR AGG 
ZF134 ToolGen RSHR GGG 
N/A ToolGen VDYK TAT 
ZF137 ToolGen VSNV AAT 
ZF139 ToolGen VSTR GCT 
ZF140 ToolGen WSNR GGT 
ZF52 Sangamo RDNQ AAG 
ZF61 Barbas DGHR GGC 
ZF75 Barbas DGNV AAC 
ZF78 Barbas SADR ACA 
ZF81 Barbas TLDR ACT 
ZF90 Barbas SKAE CAC 
ZF91 Barbas RDNE CAG 
ZF93 Barbas THSE CCA 
ZF95 Barbas RDTE CCG 
ZF96 Barbas TNSE CCT 
ZF98 Barbas HGHE CGC 
ZF100 Barbas SRTA CGT 
ZF104 Barbas RDNT TAG 
Table 1.1 Recommended zinc finger modules (Kim et al., 2009) 
Zinc finger module numbers refer to numbering scheme of Zinc Finger Consortium Modular 
Assembly Kit. Modules indicated in bold were chosen to be used in this study (Chapter 3). 
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1.3.3.2 Modular assembly 
The Zinc Finger Consortium developed a standardised kit and protocol for the 
straightforward assembly of zinc finger arrays (Wright et al., 2006).  The pre-characterised 
zinc fingers, from the Sangamo, ToolGen and Barbas module sets, were distributed as a 
set of 141 plasmids which each encoded a single zinc finger module. The zinc finger 
modules were amenable to being cloned together sequentially via standard restriction 
enzyme based cloning techniques to create a multi-fingered array of any desired length 
(Figure 1.4). 
 
Figure 1.4 Overview of Modular Assembly Cloning Procedure 
Plasmids encoding individual zinc finger expression sequences are digested and ligated 
together to create the desired expression sequence for a zinc finger array (Wright et al., 2006). 
Modular assembly is a straightforward and simple method to assemble custom ZFN 
expression vectors. However, success rates of modularly assembled ZFNs are reportedly 
low. ZF proteins shown to bind the intended DNA target in a bacterial two-hybrid assay 
have been reported to have up to a 76% failure rate when used in vivo (Ramirez et al., 
2008, Kim et al., 2009). This high failure rate is likely to be due to the lack of consideration 
for context dependent effects faced when linking multiple zinc finger modules side by 
side in an array (Elrod-Erickson et al., 1998, Wolfe et al., 1999, Cornu et al., 2008). 
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Selecting ZF modules from a recommended module set (Kim et al., 2009) can more 
reliably generate functional ZFNs. Context dependent behaviour of zinc finger has been 
taken into account in further assembly methods, OPEN and CoDA (described below) and 
these methods offer a more stringent selection and testing processes when compared to 
modular assembly. 
1.3.3.3 OPEN 
Oligomerised pool engineering (OPEN) was developed by the Zinc Finger Consortium 
(Maeder et al., 2008, Maeder et al., 2009) following the reported low efficacy of ZFNs 
made by modular assembly (Cornu et al., 2008, Pruett-Miller et al., 2008, Ramirez et al., 
2008). OPEN involves greater stringency in the selection of zinc finger proteins, resulting 
in the production of zinc fingers with greater activity and lower toxicity than those 
assembled via modular assembly methods. OPEN employs a series of pools, each 
containing zinc finger modules that target a 3 bp subsite in a given position of a zinc finger 
protein (F1, F2 or 3). Zinc finger expression sequences are PCR amplified from a pool of 
fingers which bind the desired 3 bp target and PCR products are stitched together 
randomly, creating zinc finger arrays to target the desired DNA target sequence (Figure 
1.5 A). The arrays are then subjected to two rounds of selection in bacterial reporter 
assays, permitting selection of active arrays and quantifying their DNA binding affinities, 
governing the identification of highly active zinc finger proteins (Figure 1.5 B). 
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Figure 1.5 Overview of OPEN method for construction of zinc finger proteins 
(A) Schematic representation of assembly of randomised zinc finger pools by overlapping PCR. 
Pools of zinc fingers to target a given 3 bp subsite in a predetermined position of a zinc finger 
array are amplified via PCR and each PCR product is “stitched” together to create an array. The 
arrays are expressed as a fusion to Gal11P to be tested in a bacterial two-hybrid system. (B) 
Bacterial two-hybrid selection of assembled zinc finger arrays. Zinc finger binding activates a 
reporter gene which can be used to select and quantify the efficacy of zinc finger arrays which 
bind to their target site (Maeder et al., 2009). 
ZFNs assembled by OPEN have been reported to have equal or greater in vitro efficacy 
than ZFNs constructed by modular assembly (Townsend et al., 2009, Lee et al., 2010). 
However, the overall likelihood of constructing ZFNs that will actually function at the 
intended target site in vivo is reportedly ~67%, which is much greater than would be 
achieved with modular assembly (Maeder et al., 2008). OPEN, while providing a reliable 
and effective method for assembling ZFNs, is highly labour intensive, is not amenable to 
25 
 
the production of multiple ZFNs in parallel, and interpretation of selection results can 
require considerable expertise (Kim et al., 2010, Sander et al., 2011b). I attempted to 
create bacterial two-hybrid selection vectors to test the binding affinities of ZF arrays 
assembled in this study. However, the cloning procedure was found to be highly 
inefficient, further adding to the labour intensive, low throughput nature of this 
procedure. This, and the subsequent development of a higher-throughput assembly 
method, has restricted the broad application of OPEN.  
1.3.3.4 CoDA 
Expanding on the current zinc finger assembly methods available, the Zinc Finger 
Consortium developed CoDA (Context Dependent Assembly). CoDA addressed 
combinatorial issues associated with combining zinc finger modules into an array, rather 
than treating zinc fingers as individual modules (Sander et al., 2011b). CoDA makes use of 
libraries of three fingered arrays in which the N- and C-terminal modules have been 
previously characterised in an array with a common F2 module (Figure 1.6). 
 
Figure 1.6 Principle of CoDA 
Two separate zinc finger arrays, each binding different 9 bp target sites are shown, which each 
share a common F2 module. A new zinc finger array to bind a different DNA sequence can be 
assembled by joining together the F1 module from one array and the F3 module from the 
other, with the common F2 module (Sander et al., 2011b). 
Half of ZFNs assembled by CoDA have been demonstrated to be functional at their 
intended target (Sander et al., 2011b). CoDA has provided a rapid and non-labour 
intensive procedure to assemble ZFNs whilst considering context dependent issues. 
1.3.4 Zinc finger nucleases 
Designing and constructing zinc finger arrays which bind to predefined sequences is with 
the ultimate aim of directing an effector domain, such as a nuclease, to the target 
sequence. The induction of targeted DSBs via custom nucleases can be utilised to create 
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mutations in a gene of interest. Kim and Chandrasegaran (1994) demonstrated the first 
fusion of a DNA-binding protein to the non-specific cleavage domain of FokI.  The 
drosophila Ubx homeodomain, which recognises a 9 bp DNA sequence through a helix-
turn-helix motif, was fused to FokI to create a chimeric restriction endonuclease with 
designed sequence specificity.  This fuelled the construction of zinc finger nucleases (Kim 
et al., 1996).  Expression sequences of previously characterised zinc finger proteins were 
cloned into plasmid vectors immediately upstream of the cleavage domain of FokI 
nuclease, separated by a glycine linker.  These zinc finger nucleases were demonstrated 
to cleave λ-DNA with sequence specificity (Kim et al., 1996). ZFNs were shown initially to 
promote homologous recombination of extrachromosomal DNA in Xenopus oocyte nuclei. 
Pairs of ZFN recognition sites, located on opposite DNA strands, and separated by a 6-8 
bp spacer (Figure 1.7) were found to promote optimal cleavage of DNA substrate 
(Bibikova et al., 2001). This study was extended to demonstrate ZFN-mediated mutations 
in chromosomal DNA of Drosophila and offered the first evidence of permanent genetic 
alterations induced by ZFNs (Bibikova et al., 2002). Numerous studies then commenced to 
develop and assess mutations induced by DNA cleavage with customisable zinc finger 
nucleases (ZFNs). 
ZFNs were first demonstrated to induce gene targeting in human cells via NHEJ-mediated 
repair of a stably integrated GFP transgene in HEK293 cells (Porteus and Baltimore, 2003). 
ZFNs have now been utilised to target a range of genes in various cell types such as 
mammalian cells, including ES cells, and in many organisms for example Drosophila, sea 
urchins, zebrafish, mice and pigs (reviewed in Hauschild-Quintern et al., 2013). Targeting 
efficiencies with ZFNs are variable due to differences in ZFN functionality and target site 
accessibility, however ZFNs generally stimulate gene targeting at a rate where 
modifications occur in around 10 % of transfected cells (Carroll, 2011). 
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Figure 1.7 ZFNs DNA binding mechanism 
Schematic of a pair of four-fingered ZFNs binding to DNA. Each zinc finger module contacts 4 
bp DNA and module target sites overlap by 1 bp. Zinc finger arrays are fused to the non-
specific DNA cleavage domain of FokI nuclease. ZFNs in a pair are separated by a spacer of 5 – 
7 bp, where FokI dimerisation and DNA cleavage occurs, resulting in a 4 bp 5’overhang  (Isalan, 
2012). 
1.3.4.1 Optimisations to ZFN architecture 
1.3.4.1.1 Linker choice and spacing between ZFN pairs 
Various studies have investigated the optimal conditions for ZFN activity. In agreement 
with studies of the natural FokI enzyme, it was revealed that FokI domains in ZFNs 
required dimerisation in order to perform DNA cleavage (Bitinaite et al., 1998, Smith et 
al., 2000). Cleavage was observed where the binding sites of the ZFNs were positioned in 
an inverted orientation from each other, as shown in Figure 1.7 (Smith et al., 2000, 
Bibikova et al., 2001). The optimal length of the DNA spacer between a zinc finger pair has 
also been subject to much debate. The current consensus is a 6 bp spacer using the 
common architectures employed by the Zinc Finger Consortium (Wright et al., 2006, 
Maeder et al., 2009, Sander et al., 2011b). However, this seems to be subject to the 
length and composition of the amino acid linker between ZF DNA binding domain and 
FokI nuclease. Studies suggest that the commonly used four amino acid linker promotes 
cleavage at both 5- and 6 bp spacers, although spacers of 6 bp are favoured (Handel et al., 
2009, Wilson et al., 2013). Another study suggests that a six amino acid linker is sufficient 
to restrict DNA cleavage to sites separated by a 6 bp spacer (Shimizu et al., 2009). 
1.3.4.1.2 FokI variants 
Improvements to promote specific ZFN cleavage at the desired target site have focussed 
around modification of the FokI domain and its dimerisation interface. The development 
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of obligate heterodimer mutants of FokI has improved the activity and faithfulness of 
ZFNs (Figure 1.8). Dimerisation of the two domains in WT FokI is not selective for 
heterologous zinc finger DNA binding domains. The result is that dimerisation can occur 
between two “left” or two “right” ZFNs at off-target sites containing relevant binding 
sites, or perhaps by weak interactions between one DNA-bound and one unbound ZFN 
(Smith et al., 2000, Miller et al., 2007). Introduction of obligate heterodimer mutations in 
the FokI domains mean that a “left” ZFN is only able to interact with the “right” ZFN when 
the relevant cognate mutations are found in the “right” domain, and that it is not possible 
for two “left” or two “right” domains to facilitate DNA cleavage (Figure 1.8).  Obligate 
heterodimer ZFNs were demonstrated to produce lower levels of cellular cytotoxicity, as 
measured by γH2AX staining (Doyon et al., 2011). ZFNs with the obligate heterodimer 
architecture did not promote cleavage at off target locations which had been shown to be 
cleaved by homodimer versions of the same ZFNs (Doyon et al., 2011). A summary of the 
most commonly adopted FokI obligate heterodimer mutants developed to date is given in 
Table 1.2. 
 
Figure 1.8 FokI obligate heterodimers offer improved specificity 
(A)Top: Intended on-target activity of a ZFN pair involves interaction of a left (L) and a right (R) 
ZFN across a spacer where FokI nuclease dimerises and cleaves DNA. Middle and bottom: off-
target DNA cleavage mediated by the dimerisation of either two left (L) or two right (R) ZFNs 
where homodimer WT FokI domains are used. (B) Obligate heterodimer FokI variants promote 
the dimerisation of heterologous ZFN pairs (top) and exclude the dimerisation of homodimer 
species (middle and bottom)(Miller et al., 2007). 
Variant Mutations (Left/Right) References 
EL/KK Q486E, I499L / E490K, I538K (Miller et al., 2007) 
D/R R478D / D483R (Szczepek et al., 2007) 
ELD/KKR Q486E, I499L, N496D / E490K, I538K, H537R (Doyon et al., 2011) 
DD/RR R478D, N496D / D483R, H537R (Doyon et al., 2011) 
Table 1.2 Obligate heterodimer FokI mutants 
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Despite the obvious advantage of obligate heterodimer FokI to reduce off-target cleavage 
events and the associated cytotoxicity, this came at the cost of a threefold reduction in 
cleavage activity of obligate heterodimers when compared to WT FokI (Miller et al., 
2007). This loss of activity observed was restored by the development of a variant with 
enhanced cleavage activity, which showed no increase in cytotoxicity (Guo et al., 2010). 
This variant, dubbed “Sharkey”, contained the mutations S418P and K441E  on both sides 
of the FokI dimer and has been successfully employed in combination with obligate 
heterodimer variants (Doyon et al., 2011, Perez-Pinera et al., 2012). 
1.3.4.1.3 Number of zinc fingers 
Adding additional zinc fingers to a ZFN increases the length of the DNA binding domain. 
Designing ZFNs that target longer DNA sequences was postulated to increase on-target 
specificity by reducing the likelihood that ZFN binding sites would occur elsewhere in the 
genome by chance. A study tested the DNA cleavage abilities of ZFNs composed of 
variable numbers of zinc fingers ranging from 1 zinc finger module to 6 zinc finger 
modules per array (Shimizu et al., 2011). This study systematically tested ZFNs targeting 
the same genomic locus but with additional ZF modules per array and utilised the same 
FokI variant in all ZFNs tested. The results demonstrated that the use of ZFNs with 5 or 6 
modules per array was in fact detrimental to ZFN activity. ZFNs containing one or two 
modules were not active but ZFNs with 3 or 4 modules per array demonstrated the 
greatest cleavage activity. The reduced cleavage with longer arrays may be due to the use 
of an inappropriate linker to promote optimal ZF-DNA contact or perhaps due to 
confounding combinatorial effects of zinc finger modules. Many studies have 
demonstrated the effective use of 3- and 4-fingered ZFNs, and reports on the activity 
levels of 3- versus 4-fingered ZFNs have been inconclusive (Urnov et al., 2005, Durai et al., 
2005, Pruett-Miller et al., 2008, Kim et al., 2009). This may be due to differences in target 
site accessibility, DNA-binding affinities, or combinatorial effects of zinc fingers in an 
array, as very few direct and systematic comparisons have been made. In general, four 
fingered ZFNs have been demonstrated to promote an equal, if not greater, level of 
specific DNA cleavage than three fingered ZFNs (Durai et al., 2005, Kim et al., 2009, 
Shimizu et al., 2011, Pattanayak et al., 2011).  
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1.3.5 Applications 
The prospect of inducing targeted DSBs in cells presents a paradigm shift for the potential 
of customised gene therapy. ZFNs have the potential to offer a precise and permanent 
solution to gene correction in disease studies. To date, notable applications of ZFN-
mediated gene therapy include corrections of mutations associated with X-SCID (Urnov et 
al., 2005), Parkinson’s disease (Soldner et al., 2011), haemophilia B (Li et al., 2011a) and 
sickle cell disease (Sebastiano et al., 2011, Zou et al., 2011) via HDR gene targeting 
methods in cultured cells and mouse models. NHEJ-mediated gene editing using ZFNs has 
been employed to confer resistance to HIV-1 via disruption of the CCR5 gene (Perez et al., 
2008, Holt et al., 2010). This is part of an ongoing clinical trial (NCT00842634) and initial 
results suggest that viral load has dropped to below a detectable limit in 3 of 7 subjects, 
all of whom entered the trial with a heterozygous deletion of CCR5. One patient has 
remained aviremic and continues to possess an undetectable HIV viral load despite the 
discontinuation of HIV therapy (Sangamo Biosciences, 2013). 
1.3.6 Limitations 
Despite the obvious potential of ZFN technology, some pitfalls remain in the design and 
development. A substantial proportion of assembled ZFN pairs fail (Ramirez et al., 2008) 
and, for this reason, it is advisable that multiple ZFN pairs are assembled and tested for 
any intended target. While advanced construction methods such as OPEN and CoDA and 
the use of recommended module sets have improved success rates of assembled ZFNs, 
failure of ZFN arrays is most likely due to a combination of context dependent effects 
within a zinc finger protein, DNA-binding affinity and target site accessibility due to 
chromatin environment (Cornu et al., 2008, van Rensburg et al., 2013). 
Obligate heterodimer FokI variants have reduced levels of off target cleavage observed 
(Doyon et al., 2011) but the level of cytotoxicity observed can obviously be variable 
between different zinc finger arrays. 
ZFNs offer a robust and widely attainable platform for customised gene editing, which 
have been demonstrated to be highly efficient in a variety of contexts. However, the lack 
of a definitive DNA-recognition code, leading to combinatorial issues, high failure rate of 
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assembled nucleases and cytotoxicity arising from off target cleavage, have resulted in 
concerns about the ease of production of reliable zinc finger nucleases.  
1.4 TALE Proteins 
Another way to target a nuclease to a particular DNA sequence is using transcription 
activator like effectors (TALEs). TALEs are virulence factors from the plant pathogen 
Xanthomonas spp. They promote virulence in host cells by mimicking eukaryotic 
transcription factors via DNA binding through a repetitive amino acid domain (Kay et al., 
2007). Some TALE proteins are virulent and others are avirulent, they can modify gene 
expression to either promote or evade the plant immune response (Kay et al., 2005). Each 
TALE is composed of a repeat domain, a nuclear localisation signal (NLS) and a 
transcriptional activation domain (AD) (Figure 1.9 A). The repeat domain contains 
multiple repeats of a 34 amino acid DNA binding domain, each of which recognises one 
DNA base.  The DNA binding domain is composed of two closely positioned α-helices in a 
helix-loop-helix configuration, with two variable amino acids – the repeat variable 
diresidue (RVD) - that recognise a single base pair of DNA (Van den Ackerveken et al., 
1996, Zhu et al., 1998, Schornack et al., 2006). It is the second of the two residues that 
makes direct contact with the DNA (Boch et al., 2009, Moscou and Bogdanove, 2009). 
Each repeat is named according to the two amino acids in the RVD. For example, repeat 
NN contains two asparagines in the RVD.  Each repeat domain is tightly packed in close 
proximity to the adjacent repeat in order to bind DNA in a modular fashion (Figure 1.9 B). 
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Figure 1.9 TALE Structure 
(A) TALEs are composed of a repeating amino acid domain, nuclear localisation signal (NLS) 
and transcriptional activation domain (AD). Each repeat is composed of 34 amino acids and 
residues at positions 12/13 comprise the repeat variable diresidue (RVD, highlighted), 
responsible for DNA binding specificity (Boch et al., 2009). (B) Crystal structure of two TALE 
domains interacting with DNA. Each RVD binds 1 bp DNA (Mak et al., 2012). 
1.4.1 DNA recognition code 
Observations of TALE-DNA interactions had demonstrated that TALE proteins which 
contained similar RVD codes had the capability to activate each other’s target genes 
(Schornack et al., 2008). This led to the hypothesis that modularity existed between TALE 
RVDs and DNA bases. A DNA-RVD code was established by Boch, Muscou and Bogdanove 
in two separate studies (Table 1.3) (Boch et al., 2009, Moscou and Bogdanove, 2009). 
While some flexibility exists between RVDs and bp (for example, NN recognises G/A), 
TALEs generally appear to be highly specific for their intended target. Studies have 
demonstrated that RVD NK can bind to G (Morbitzer et al., 2010, Miller et al., 2011) but 
TALE nucleases (TALENs) employing this RVD are less active than ones which use NN to 
target G (Huang et al., 2011). NH has subsequently been identified as binding to G and 
has been demonstrated to target G with higher efficiency than NK (Cong et al., 2012, 
Streubel et al., 2012). In addition to the recognition code, TALE binding sites are normally 
preceded by a thymine base, which can interact with the protein region preceding the 
RVD repeats (Bogdanove et al., 2010). 
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RVD NI HD NG IG NN NK NH 
DNA specificity A C T T G or A G G 
Table 1.3 DNA binding specificity of TALE RVDs 
1.4.2 TALE nucleases (TALENs) 
Following the use of ZFNs as tools to direct targeted genetic modifications, the desire to 
construct custom TALE nucleases (TALENs) was a natural progression. Both technologies 
rely on the same fundamental principle – a DNA-binding domain with bespoke target 
specificity, fused to the non-specific nuclease domain FokI. However, the simple and 
modular TALE-DNA recognition code (Boch et al., 2009, Moscou and Bogdanove, 2009) 
means that TALENs provide the potential to create custom nucleases without the 
complexities faced in the design of custom ZFNs. 
Naturally occurring TALE proteins were demonstrated to be able to induce DSBs when 
fused to FokI (Christian et al., 2010, Li et al., 2011b). TALENs constructed using the RVD 
recognition code could initiate targeted DSBs in an in vivo yeast assay (Christian et al., 
2010). The design or identification of TALEN target sites was approached in a similar 
fashion to ZFN targets. TALE binding sites are positioned in an inverted orientation to 
each other, centred around a spacer, where DNA cleavage by FokI occurs (Figure 1.10). 
Typically, each TALE is composed of 15 – 20 RVDs targeting 15 – 20 bp (so the total 
recognition sequence for a TALEN is 30 – 40 bp long). The TALEN pair is separated by a 
spacer of 15 – 30 bp, which is much longer than the 6 bp spacer typically used by ZFNs. 
This is due to the length of the amino acid linker between the TALE and FokI domains 
(Christian et al., 2010, Miller et al., 2011, Cermak et al., 2011). 
 
Figure 1.10 DNA binding and cleavage by TALENs 
Schematic of a TALEN pair binding to DNA. Each TALE RVD module contacts 1 bp DNA. TALE 
DNA-binding domains are fused to the non-specific DNA cleavage domain of FokI nuclease. A 
TALEN pair is separated by a spacer of 15 – 30  bp, where FokI dimerisation and DNA cleavage 
occurs (Sanjana et al., 2012). 
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1.4.3 Optimisations of TALE architectures 
1.4.3.1 FokI nuclease domain 
TALENs have employed the same FokI domain modifications as were developed for ZFNs. 
The use of an obligate heterodimer FokI domain in TALENs is now becoming widely 
adopted (Huang et al., 2011, Hockemeyer et al., 2011, Cade et al., 2012) and is considered 
the most efficient adaptation to reduce off target cleavage resulting from the 
dimerisation of two “left” or two “right” DNA binding monomers (Figure 1.8). 
1.4.3.2 RVD domain choice 
DNA contacts from TALE RVDs are made via the second residue in the RVD. The first 
residue in the RVD stabilises the conformation of the RVD containing loop. DNA binding 
affinities of some RVDs are stronger than others. RVD NI makes van der Waals contacts 
with DNA base adenine, as do RVDs NG and HG with thymine. Hydrogen bonds, which are 
much stronger than van der Walls, are formed between HD and C bases and also between 
NN and G or A bases. It has been suggested that TALENs composed of a greater number 
of stronger RVDs are more efficient and have greater target specificity than those 
comprising weaker RVDs (Streubel et al., 2012, Sun and Zhao, 2013). 
The lack of a definitive RVD choice for G may promote off-target specificity. The RVD NK 
was identified as a substitute RVD to target G bases with greater specificity than NN 
RVDs, showing a much stronger preference for guanine than adenine (Morbitzer et al., 
2010, Miller et al., 2011). However, employment of the RVD NK in TALEN pairs was 
demonstrated to lower TALEN activities in plants, mammalian cells and zebrafish embryos 
(Cong et al., 2012, Streubel et al., 2012, Huang et al., 2011). The RVD NH was 
demonstrated to be specific for guanine bases, without sacrificing TALEN activity (Cong et 
al., 2012, Streubel et al., 2012). This RVD is now available as part of the Golden Gate 
TALEN assembly kit. 
1.4.3.3 Target sequence requirements 
The majority of natural TALE binding sites are preceded by a 5’ T. Custom TALEs that bind 
to a target site preceded by a T have been demonstrated to be much more highly active 
than those that do not (Lamb et al., 2013). The N-terminal region immediately before the 
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repeat RVDs has been demonstrated to facilitate some interactions with the  DNA 
sequence preceding the TALE binding site (usually a 5’ T) (Mak et al., 2012). TALE design 
tools now incorporate this parameter into target site identification (Doyle et al., 2012). 
Recent studies have designed alternative TALE architectures to avoid this constraint 
(Lamb et al., 2013, Tsuji et al., 2013, Sun et al., 2012). Further recommendations are that 
RVDs in positions one and two should not be those binding T and A, respectively, and that 
recognition sites should not end with a G (Boch et al., 2009, Moscou and Bogdanove, 
2009, Cermak et al., 2011). 
1.4.3.4 N- and C-terminal truncations 
The first 152 residues of the TALE N-terminus have been demonstrated to be responsible 
for transport of a TALE into a plant cell but dispensable for mediating TALE binding 
(Szurek et al., 2002). A truncation of these residues, named Δ152, was shown to be 
sufficient for the assembly of functional TALE transcriptional activators (Miller et al., 
2011). It was reasoned that shortening of the C-terminus would provide an optimal 
framework for expressing TALEs fused to FokI. Truncation of the C-terminus to +63 
residues was also demonstrated to produce highly functional TALEN pairs (Miller et al., 
2011). This “Miller” architecture comprising truncated N and C termini has been widely 
adopted in TALE assembly kits (Sanjana et al., 2012). 
1.4.4 Applications 
To date, TALENs have been employed to facilitate gene editing in human somatic cells, 
iPSCs, Drosophila, zebrafish, rats and livestock (Christian et al., 2010, Hockemeyer et al., 
2011, Liu et al., 2012, Sander et al., 2011a, Tesson et al., 2011, Carlson et al., 2012).  
TALENs have been utilised in conjunction with HDR to repair a mutation in the human β-
globin gene responsible for sickle cell disease (Sun et al., 2012, Voit et al., 2014). TALENs 
and a homology-containing donor vector were delivered to human cells, where it was 
demonstrated that TALEN-mediated DSBs were repaired via HDR insertion of the donor, 
correcting the mutation responsible for sickle cell disease. TALENs have also been 
employed to create a large animal model for atherosclerosis utilising NHEJ-mediated 
mutations in the low density lipoprotein detector (LDLR) gene  (Carlson et al., 2012).  
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These studies paved the way for development and assessment of custom TALEs in both 
somatic cells and induced pluripotent stem cells (IPSCs) (Miller et al., 2011, Hockemeyer 
et al., 2011) and in model organisms such as Drosophila, zebrafish and rats (Liu et al., 
2012, Huang et al., 2011, Sander et al., 2011a, Tesson et al., 2011). TALENs have been 
demonstrated to induce mutations at a frequency of around 20% on average (Chen et al., 
2013). 
1.4.5 TALE Transcriptional Modifiers 
TALEs function as transcriptional modulators in nature, altering the gene expression of 
host genes in infected plants (Szurek et al., 2002, Büttner and Bonas, 2002). Following the 
identification of the TALE-DNA binding recognition code, engineered TALEs were 
demonstrated to activate plant genes via a designed DNA binding domain (Morbitzer et 
al., 2010). Subsequently, designed TALEs were demonstrated to activate mammalian 
target genes via fusion of a TALE-DNA binding domain with a transcriptional regulator 
(Miller et al., 2011, Geissler et al., 2011). TALEs can be used to direct a transcriptional 
effector domain (ED) to alter expression of a gene of interest by designing a TALE-DNA 
binding domain that binds to the promoter of the target gene (Figure 1.11). 
Transcriptional activation mediated by custom TALEs has been performed via fusion to 
activation domains such as VP64 and NF-KB p65 (Zhang et al., 2011, Maeder et al., 
2013b). Repressor domains, SID and KRAB, have been employed to facilitate targeted 
gene repression with custom TALEs (Cong et al., 2012, Garg et al., 2012).  
 
Figure 1.11 TALE Transcriptional Effector activity 
Schematic of a TALE effector binding to DNA. A TALE DNA-binding domain is fused to a 
transcriptional effector domain (ED). Binding of the effector domain to a target sequence in a 
gene promoter recruits a transcriptional effector complex, which is composed of factors that 
facilitate transcriptional activation or repression of the gene of interest, immediately 
downstream of the TALE target site(adapted from Sanjana et al., 2012). 
1.4.5.1 VP64-mediated activation 
The VP64 activation domain is tetrameric version of the VP16 transcription factor from 
Herpes Simplex Virus (HSV) Type 1 (Beerli et al., 1998). VP16 was found to be one of the 
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most potent transcriptional activation domains and was widely used until the adaptation 
of the tertameric version VP64, which was demonstrated to promote higher levels of 
gene activation (Beerli et al., 1998). The transcriptional activation domain can be directed 
to specific gene promotes via a DNA binding domain, in this case a TALE domain (Figure 
1.11) (Zhang et al., 2011, Miller et al., 2011). The VP64 activation domain mediates gene 
transcription through interactions with many other transcription factors, for example 
TFIIA, B, D, F and H (Hall and Struhl, 2002, Xiao et al., 1994, Kobayashi et al., 1995), 
recruitment of histone acetyltransferases such as pCAF and p300 (Tumbar et al., 1999) 
and recruitment of SAGA and SWI/SNF complexes (Hall and Struhl, 2002, Hirai et al., 
2010). The interaction and recruitment of these partners promotes the acetylation of 
histones and widespread chromatin decondensation, leading to active gene transcription 
(Utley et al., 1998, Carpenter et al., 2005, Tumbar et al., 1999). 
1.4.5.2 SID-mediated repression 
The SIN Interaction Domain (SID) from the transcriptional repressor Mad1 mediates gene 
repression by the recruitment of the SIN3A co-repressor complex (Ayer et al., 1996). SID 
can be directed to DNA via fusion to a heterologous DNA-binding domain, such as a TALE 
(Figure 1.11). Components of the SIN3A repressor complex are recruited in the presence 
of SID. Gene repression is mediated via a histone deacetylase complex composed of 
histone deacetylases HDAC1 and HDAC2, sin associated proteins SAP18 and SAP30 and 
retinol binding protein, and RBBP4 and RBBP7 (Kadamb et al., 2013). Factors such as 
KDM5A, SUV39H1 and ESET are recruited by the SIN3A complex, resulting in 
demethylation of lysine 4 of histone H3 (KDM5A) and methylation of lysine 9 of H3 
(SUV39H1, ESET) which promote the formation of an inactive chromatin state (van 
Oevelen et al., 2008, Yang et al., 2003). 
1.4.5.3 KRAB-mediated repression 
The Krüppel Associated Box (KRAB) repressor has also been utilised to mediate gene 
repression as a fusion to TALE DNA-binding domains (Figure 1.11). The KRAB repression 
domain originates from KRAB-containing zinc finger transcription factors and mediates 
transcriptional repression in a similar manner to SID, as described previously (Margolin et 
al., 1994). KRAB recruits the nucleosome remodelling deacetylase (NuRD) complex, which 
contains factors such as TIF1β (also called KAP1), CHD3 and histone methyltransferase 
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SET/DB1. KRAB-mediated recruitment of chromatin modifying factors promotes 
heterochromatin spreading (Groner et al., 2010). Transcriptional gene silencing mediated 
by KRAB results in the deposition of repressive histone marks, such as methylation of 
lysine 9 on histone H3 (H3K9me) and deacetlyation of lysines 9 and 14 of histone H3 
(H3K9 and H3K14, respectively) (Ivanov et al., 2007). 
1.4.5.4 Transcriptional Modification by TALE Transcription Factors 
TALE transcription factors have been employed in a variety of cell types from plants to 
human cell lines and IPSCs (Morbitzer et al., 2010, Zhang et al., 2011, Zhang et al., 2013) 
and have also been demonstrated to modify transcription in Drosophila (Crocker and 
Stern, 2013). TALEs have been used to direct transcription factors to a variety of genes, 
including Oct4, Sox2, Nanog, and VEGFA (Bultmann et al., 2012, Zhang et al., 2011, 
Maeder et al., 2013b) and also non-coding regions such as miR-302/367 (Maeder et al., 
2013b, Zhang et al., 2013). In addition to the traditional approach of targeting gene 
promoters, studies have also shown that efficient gene knockdown can be achieved via 
targeting TALE Repressor proteins to specific gene enhancers (Gao et al., 2014, Crocker 
and Stern, 2013). Interestingly, it has been found that the use of multiple TALE 
transcriptional activators targeting the same regions simultaneously has a synergistic 
effect and this can be utilised to achieve greater levels of target gene expression (Maeder 
et al., 2013b, Perez-Pinera, 2013). 
While studies described above have achieved high levels of transcriptional modification at 
target genes, it has also been demonstrated that TALE transcriptional effectors can fail to 
significantly alter gene expression in some cases, summarised by Maeder et al. (2013b). 
The factors governing the optimal conditions for TALE mediated transcriptional regulation 
are still somewhat unclear. Many of the issues encountered with TALENs, such as binding 
site location, target site competition and methylation of DNA target sequence are also 
known to impair the functionality of TALE transcription factors (Bultmann et al., 2012, 
Werner and Gossen, 2014, Maeder et al., 2013b). Future studies will no doubt focus on 
outlining a set of recommended guidelines, similar to that developed for the design of 
TALENs and ZFNs. 
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1.4.6 Assembly of custom TALEs 
Following directly on from the construction of ZFNs, TALEs were first tested in 
conjunction with FokI nuclease to determine if the DNA binding domain of a TALE could 
be synthetically constructed and fused with another effector module to direct the 
production of targeted double strand breaks (DSBs). In a preliminary study, five custom 
TALEs to target DNA sequences from Arabidopsis and zebrafish were constructed and 
expressed as fusions with FokI (Christian et al., 2010). The propensity of custom TALENs 
to induce DSBs was tested in an in vivo yeast assay. Two TALENs demonstrated robust 
nuclease activity and one showed modest levels of cleavage. This study demonstrated 
that custom TALEs could be designed to target novel DNA sequences and could be used in 
conjunction with nucleases to mediate gene targeting in a similar fashion to ZFNs. This 
fuelled the development of comprehensive assembly kits, similar to those developed for 
ZFN construction. Unlike ZFN assembly methods, there have been no context dependent 
issues described with TALEN assembly.  Highly functional TALEs have been produced using 
each of the assembly methods described below. All of the kits described are available 
from www.addgene.org.  
1.4.6.1 Golden Gate assembly (Voytas Kit) 
The Golden Gate (GG) TALEN assembly kit comprises 86 plasmids;  each RVD is provided 
in multiple plasmids with different overhang sequences, each one corresponding to a 
different position of that RVD within a 10-repeat array (Cermak et al., 2011). GG utilises 
type IIS restriction enzymes, which cleave a number of bases away from their recognition 
sequence. This creates DNA sticky ends that are unique to each position within the array, 
and thus are only compatible with ligation of the RVDs in the desired arrangement (Figure 
1.12). This is a rapid assembly platform that allows digestion and ligation to occur in one 
reaction and facilitates assembly of multiple TALENs simultaneously. TALENs constructed 
via this method were demonstrated to be active in a yeast DNA cleavage assay and were 
effective at inducing targeted mutations in human cells and Arabidopsis protoplasts. 
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Figure 1.12 Principle of golden gate TALEN assembly 
Plasmids encoding TALE RVD modules are digested using type IIS restriction enzymes creating 
compatible overhangs for ligation in the desired assembly. Digestion and ligation takes place in 
a single reaction as the plasmid overhangs are designed such that the reaction can only 
progress in one direction (Cermak et al., 2011). 
1.4.6.2 REAL Assembly 
Restriction Enzyme And Ligation (REAL) assembly employs standard cloning techniques to 
assemble TALEs from a kit of 28 plasmids each of which encode a single TALE RVD 
expression sequence (Figure 1.13 A) (Sander et al., 2011a). This method has been recently 
updated, called REAL-FAST, which incorporates plasmids containing up to four pre-
assembled TALE RVDs, enabling higher throughput with fewer cloning steps (Figure 1.13 
B) (Reyon et al., 2012a). Both of these methods rely on standard cloning techniques and 
TALE assembly requires the use of highly repetitive sequences, which can be prone to 
recombination. 
 
Figure 1.13 Overview of REAL and REAL-FAST TALE assemblies 
Schematic showing the stages involved in (A) REAL and (B) REAL-FAST assembly methods. (A) 
Individual TALE RVD modules are digested and ligated together in stages to create a final TALE 
array. (B) Pre-assembled TALEs of up to 4 RVD modules are digested and ligated together to 
create a final TALE array (Reyon et al., 2012a). 
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TALENs assembled via REAL assembly have been demonstrated to induce high rates of 
NHEJ-mediated mutations in somatic zebrafish cells (Sander et al., 2011a). However, the 
TALENs assembled in this study were designed to target DNA sequences that have been 
previously targeted using ZFNs, so it is not an unbiased study. 
1.4.6.3 PCR-based assembly (Zhang kit) 
The TAL Effector Toolbox kit is a PCR-based assembly procedure that involves addition of 
position-specific Type IIS recognition sequences to each RVD using PCR, followed by 
restriction digestion-based cloning to assemble the RVDs in the desired order (Figure 
1.14) (Zhang et al., 2011). To reduce issues faced with cloning of highly repetitive 
sequences, the RVD expression sequences have been codon optimised. However, PCR 
amplification of RVD expression sequences must be performed with high fidelity. This 
method provides TALE RVD sequences that are human codon optimised, and it is 
amenable to the assembly of multiple TALEs at a time. The Toolbox kit has now been 
extended to include expression vectors for assembly of TALE nucleases and TALE 
transcription activators for mammalian expression (Sanjana et al., 2012). 
 
Figure 1.14 Schematic of TAL Effector Toolbox Kit assembly method 
Overview of PCR-based TALE assembly. Each TALE RVD is PCR amplified from a plasmid 
provided in the kit in order to add adaptors for subsequent cloning using Type IIS restriction 
enzymes. As described in GG assembly, the RVDs can only be assembled in one predefined 
order. RVDs are ligated to create 4mers, which are PCR amplified to add adapters for ligation, 
as before. Final TALE arrays are assembled by ligation of digested 4mers (Zhang et al., 2011). 
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TALEs assembled in the study which first describes this construction method were fused 
to a transcriptional activator and assessed for their ability to activate an exogenous 
fluorescence reporter gene (Zhang et al., 2011). All TALEs were demonstrated to activate 
reporter gene expression by binding to their intended target sequence. However, the 
levels of gene activation varied largely between different TALEs. This may have been due 
to differences in TALE-DNA interactions, as the TALEs were designed to target a range of 
binding sites, varying largely in sequence composition and GC content (Zhang et al., 
2011). 
1.4.6.4 FLASH assembly 
While many manual and modular TALE assembly procedures had been developed 
(described above), there was a lack of any high-throughput publically available systems. 
Fast Ligation-based Automatable Solid-phase High-throughput (FLASH) assembly is an 
automatable system that can enable the construction of up to 96 TALE arrays in one day 
(Reyon et al., 2012b). TALE RVD modules are provided as a set of 376 plasmids, which 
contain individual and pre-assembled RVDs (Figure 1.15 A). The first TALE RVD is PCR 
amplified using a biotinylated forward primer, is attached to streptavidin coated magnetic 
beads, and then subsequent RVDs are ligated in sequence (Figure 1.15 B). FLASH utilises 
solid-phase synthesis by means of magnetic beads, which avoids any requirement for 
analysis of intermediate constructs. However, the initial preparation of RVD modules still 
relies upon PCR, restriction digest and column purification of RVD expression sequences, 
and for this reason the system is not fully automatable. 
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Figure 1.15 FLASH assembly methods to create custom TALEs 
Overview of FLASH assembly kit and method. (A) The kit contains plasmids containing TALE 
RVDs either as individual RVDs (1-mers), 2-mers, 3-mers or 4-mers to be utilised in TALE 
assembly. (B) FLASH assembly procedure. The first TALE RVD is labelled on the 5’ end with 
biotin (blue circle). A pre-assembled 4-mer is then ligated on to the first RVD and then 
attached to a streptavidin bead (orange circle). Subsequent RVDs are ligated until the desired 
array is assembled. The full length TALE array is then cleaved from the bead by restriction 
digest (Reyon et al., 2012b). 
FLASH has been reported to have an ~88% success rate in producing functional TALEs 
(Reyon et al., 2012b). However, FLASH has been demonstrated to produce TALENs which 
were not active. Inactivity may have been due to target site accessibility due to localised 
chromatin structure or DNA modifications. It is possible that inactivity of these TALENs 
was as a result of low expression or inefficient folding of TALE proteins. The outcome 
showing production of inactive TALENs by this method is perhaps due to the high-
throughput nature of FLASH assembly, permitting the generation of better quality 
statistics demonstrating the success rate of TALE assembly. 
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1.4.7 Comparison to ZFN technology 
While some ZFNs have been demonstrated to induce mutations at a similar rate to 
TALENs (Beumer et al., 2008, Beumer et al., 2013), TALENs are generally considered to be 
more mutagenic than ZFNs (Chen et al., 2013, Beumer et al., 2013, Voit et al., 2014). 
TALENs have been demonstrated to promote fewer off-target events than ZFNs and are 
considered to promote the formation of larger deletions, which may be due to the larger 
spacer when compared to ZFNs (Beumer et al., 2013). There are still unanswered 
questions when it comes to TALEN design and success rate as it is unclear why certain 
TALEN pairs are non-functional, particularly those which target a site previously targeted 
by a ZFN. Certain target sites may only be accessible to smaller proteins, making ZFNs 
more favourable in these instances (Beumer et al., 2013). TALE activity has been 
demonstrated to be reduced at methylated targets, while there have been no 
comprehensive studies to support or refute this effect in ZFN targeting (Bultmann et al., 
2012). Due to the greater mutagenicity and lower off-target activity, coupled with the 
ease of TALEN construction and the greater likelihood of assembling functional nucleases, 
TALENs are now considered the custom nuclease of choice, having now out-performed 
ZFNs. However, ZFNs still hold a major advantage over TALENs as they have been 
demonstrated in human trials (see section 1.3.5) and for this reason, ZFNs still remain a 
major player for use in human gene editing. 
1.5 VEZF1 
In this study, I intend to use custom nucleases as an alternative to RNAi to create targeted 
modifications at the VEZF1 gene promoter. VEZF1 (Vascular Endothelial Zinc Finger 1) is a 
highly conserved vertebrate transcription factor that is essential for the development of 
the vascular system (Zou et al., 2010).   VEZF1 is expressed broadly across all somatic cell 
types and seems to have its major role in the vascular system, where it is involved in 
regulating the development of endothelial cells (Xiong et al., 1999, Aitsebaomo et al., 
2001, Zou et al., 2010) and also in the regulation of the angiogenic and lymphangiogenic 
phases in wound healing in adults (Gerald et al., 2013).   Knockout of VEZF1 results in 
embryonic lethality in mice, due to disrupted organisation of the extracellular matrix and 
defective adhesion between vascular endothelial cells which leads to extensive 
haemorrhaging.  The action of VEZF1 in regulation of vascular development has been 
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demonstrated to be in a dose dependent manner, with heterozygous embryos displaying 
haploinsufficienciency (Kuhnert et al., 2005).   
VEZF1 has been demonstrated to have binding sites in the promoters of active genes, 
enhancer elements and barrier elements (Koyano-Nakagawa et al., 1994, Miyashita et al., 
2004, Aitsebaomo et al., 2001, Zou et al., 2010). VEZF1 contains six C2H2 zinc finger (ZF) 
domains that are likely to be responsible for its DNA binding activity.  VEZF1 has been 
found to bind to sequences containing runs of G found at promoter and insulator 
elements (Koyano-Nakagawa et al., 1994, Aitsebaomo et al., 2001, Dickson et al., 2010).  
VEZF1 has been shown to have transcription activity in promoter assays in vitro, binding 
at the promoters of genes such as interleukin-3 (IL-3), endothelin-1 (ET-1) and 
stathmin/OP18 (Koyano-Nakagawa et al., 1994, Miyashita et al., 2004, Aitsebaomo et al., 
2001, Zou et al., 2010). Insulator elements are defined by two characteristics – the ability 
to act as an enhancer-blocker when positioned between an enhancer and a promoter and 
preventing the spreading of chromosomal silencing by acting as a barrier (Yusufzai and 
Felsenfeld, 2004).  The HS4 insulator element is a DNAse I hypersensitive region of the 
chicken β-globin locus (Chung et al., 1993).  The enhancer-blocking activity of HS4 is 
mediated by the protein CTCF, while its barrier activity is associated with VEZF1 (Bell et 
al., 1999).  This role of VEZF1 in barrier activity has been shown to be associated with the 
protection of DNA from de novo methylation. It has also been shown that VEZF1 has a 
role in protecting CpG island promoters from de novo DNA methylation and therefore 
preventing gene silencing (Dickson et al., 2010).  Counter intuitively, VEZF1 also has a role 
in promoting DNA methylation in mouse ES cells as it is required for the expression of the 
de novo DNA methyltransferase Dnmt3b gene (Gowher et al., 2008). 
In a recent study, VEZF1 was shown to form a complex with RhoB and play a role in the 
regulation of angiogenesis and lymphangiogenesis (Gerald et al., 2013). The VEZF1-RhoB 
transcription factor complex participates in ensuring the delay in lymphangiogenesis and 
promotes successful wound healing.  In a mouse model of oxygen induced retinopathy, 
DNA-binding by VEZF1 was prevented using a small molecule inhibitor and the emergence 
of blood vessels with a normal morphology was increased in mice which had been treated 
with the inhibitor molecule. This suggests that the VEZF1-RhoB complex may serve as a 
potential therapeutic target for development of treatment against numerous diseases 
46 
 
which contain a vascular component. Targeting the VEZF1-DNA binding interface could 
promote the formation of normal vasculature following ischaemia. 
Due to the conflicting and varied roles suggested for VEZF1, a robust knockdown or 
knockout is required. RNAi-mediated knockdown of VEZF1 by up to 70% of WT expression 
levels has resulted in depletion of VEZF1 at around half of its putative binding sites 
(Strogantsev, 2009). VEZF1 knockdown to greater levels was not attainable by RNAi prior 
to the inception of this project. Therefore, I intend to perform targeted modifications of 
the VEZF1 gene promoter using custom designed ZFNs, TALE Repressors and TALENs. 
1.6 Aims and objectives of this thesis 
This project was established with the view of designing a robust and targeted gene 
knockout system to investigate VEZF1 gene function. It is proposed to target the VEZF1 
gene promoter using custom nucleases and design a strategy for future generation of 
VEZF1 knockout cell lines via insertion of a transgene system. The general aims of this 
work were: 
1. Assemble custom ZFNs and TALENs to create targeted DSBs at the VEZF1 gene 
promoter. 
2. Create a modified expression vector to express TALE Repressors and assess the 
level of VEZF1 gene repression directed by custom TALE proteins. 
3. Design and assemble a targeting vector system and perform targeted transgene 
insertion at the site of nuclease-mediated DSBs in the VEZF1 gene promoter. 
4. Characterise the rate at which custom nucleases create targeted mutations at the 
VEZF1 promoter, and analyse the types of mutations induced. 
5. Assay the phenotype of cells which have been targeted using custom nucleases 
and repressors. 
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2 Chapter 2 
       Materials & Methods 
2.1 Cell Lines 
Cell Line Reference Source 
HEK293 T17  ATCC®  CRL-11268™ 
K562 (Lozzio and Lozzio, 1975) Prof Tony Green, School of Clinical Medicine, 
University of Cambridge, via Dr David Vetrie, 
Institute of Cancer Sciences Epigenetics Unit, 
University of Glasgow 
 
2.2 Reagents 
2.2.1 Cell culture reagents 
Product Manufacturer Product Code 
DMEM Medium (1X) + GlutaMAXTM - I Life Technologies 10564029 
DMSO Riedel-de Haen 60153 
Foetal Bovine Serum Sigma F9665 
Lipofectamine® 2000 Transfection Reagent Life Technologies 11668019 
Optimem® Reduced Serum Medium - I Life Technologies 31985088 
Penicillin/Streptomycin Sigma P0781 
RPMI Medium 1640 (1X) + GlutaMAX™ - I Life Technologies 72400146 
Trypsin Life Technologies 12604013 
 
2.2.2 Antibodies 
Target Protein Manufacturer Product Number 
Anti-rabbit IgG-HRP Pierce 1858415 
VEZF1 In-house raised  (Gowher et al., 2008) 
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2.2.3 Enzymes 
Enzyme Manufacturer Product Number 
AflII NEB R0520 
AgeI NEB R0552 
AscI NEB R0558 
BamHI NEB R3136 
BglII NEB R0144 
BsaI NEB R0535 
BsrBI NEB R0102 
BsrGI NEB R0575 
BstEII-HF NEB R3162 
CIP NEB M0290 
EcoRI HF NEB R3101 
Esp3I (BsmBI) NEB R0580 
HindIII HF NEB R3104 
KpnI HF NEB R3142 
NcoI NEB R0193 
NheI HF NEB R3131 
NotI HF NEB R3189 
Maximase Polymerase Transgenomic 703205 
MspI NEB R0106 
OneTaq Polymerase NEB M0480 
Pfu Polymerase Promega M7741 
Plasmid Safe™ DNase Epicentre E3101K 
Platinum Taq Polymerase Life Technologies 109668018 
PmlI NEB R0532 
RsaI NEB R0167 
RNase H NEB M0297 
SacI HF NEB R3156 
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StuI NEB R0187 
T4 DNA Ligase Invitrogen 15224041 
T7 Endonuclease I NEB M0302 
Taq DNA Polymerase NEB M0267 
XbaI NEB R0145 
XhoI NEB R0146 
XmaI NEB R0180 
 
2.2.4 Chemicals & reagents 
Reagent Manufacturer Product Number 
1 kb DNA Ladder NEB N32315 
100 bp DNA Ladder Life Technologies 10787-018 
100 mM dNTP set Life Technologies 10297018 
AEBSF Sigma A8456 
Agar Formedium AGA02 
Agarose Roche 11388991001 
Ampicillin Sigma A0166 
BCP Sigma B9673 
BSA 10 mg/ml NEB B9001S 
DH5α Subcloning Efficiency Competent Cells Life Technologies 18265017 
DTT Melford Laboratories 
Ltd 
MB1015 
Ethidium Bromide Sigma E1510 
FastStart Universal SYBR Green Master (Rox) Roche 04913914001 
IPTG Sigma I5502 
LB Broth Sigma L1900 
Leupeptin Sigma L2884 
NuPAGE® Antioxidant Life Technologies NP0005 
 NuPAGE® LDS sample Buffer (4X) Life Technologies NP0007 
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NuPAGE® MOPS SDS Running Buffer (20X) Life Technologies NP0001 
NuPAGE® Sample Reducing Agent (10X) Life Technologies NP0004 
NuPAGE® Transfer Buffer (20X) Life Technologies NP0006 
Pepstatin Sigma P5318 
Phosphate buffered saline (PBS) Sigma D8662 
Ponceau S Sigma P7170 
Puromycin Sigma P8833 
Safeview ABM G108 
Sodium dodecyl sulphate Sigma L3771 
Spectinomycin Sigma S4014 
SuperSignal West Dura  
Extended Duration Substrate 
Thermo 34075 
Trizol Life Technologies 15596026 
Tween® 20 Sigma P1379 
X-gal Fisher Scientific 7240-90-6 
 
2.2.5 Reagent Kits 
Reagent Manufacturer Product Number 
DNeasy Blood & Tissue Kit Qiagen 69581 
Gateway® LR Clonase® II Enzyme Mix Life Technologies 11791020 
MinElute PCR Purification Kit Qiagen 28004 
NanoOrange® Protein Quantification Kit Life Technologies N-6666 
pGEM®-T Easy Vector System I Promega A1360 
QiaPrep Miniprep Spin Kit Qiagen 27104 
QiaQuick Gel Extraction Kit Qiagen 28704 
Superscript III Kit Life Technologies 12574026 
Surveyor® Mutation Detection Kit Transgenomic 706020 
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2.2.6 Oligonucleotide primers 
Custom oligonucleotide primers were purchased from Biomers or MWG Eurofins.  
Sequences are listed in appendix. 
2.2.7 Plasmids 
Zinc finger plasmids were obtained from The Zinc Finger Consortium 
(www.zincfingers.org) Modular Assembly Kit (Wright et al., 2006), purchased from 
www.addgene.org.  
Golden Gate TALEN Assembly kit was developed by The Voytas Lab (Cermak et al., 2011) 
and purchased from www.addgene.org. 
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Plasmid Source References 
pFOKI-EL (pMLM292) www.addgene.org  Addgene plasmid 21873 
pFOKI-KK (pMLM290) www.addgene.org Addgene plasmid 21872 
pBlueScript_Sharkey GeneCust (synthesis) (Guo et al., 2010) 
pCAG-T7_TALEN www.addgene.org  Addgene plasmid 37184 
pTALETF_v2 www.addgene.org  Addgene plasmid 32186 
pUC57_p2A_SID GeneCust (synthesis) (Cong et al., 2012) 
pUC57_TALE NT ShineGene (synthesis) (Miller et al., 2011) 
pUC57_TALE CT WT ShineGene (synthesis) (Miller et al., 2011) 
pUC57_TALE CT ELD-S ShineGene (synthesis) (Miller et al., 2011) 
pUC57_TALE CT KKR-S ShineGene (synthesis) (Miller et al., 2011) 
pSHTLR3 GeneCust (synthesis) Ileana Guerrini 
pSHTLR5 GeneCust (synthesis) Ileana Guerrini 
pSHTLRmid In-house assembly Ileana Guerrini 
pDESTR4-R3 In-house assembly Ileana Guerrini 
pTRIPZ Thermo RHS4740 
pEGFP-N1 CloneTech 6085-1 
 
2.3 Buffers 
2.3.1  Buffers for Gel Electrophoresis 
5X TBE Buffer 
1.1 M Tris 
900 mM Boric Acid 
25 mM EDTA 
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6X Gel Loading Buffer 
30 % Glycerol 
0.02 % Bromophenol Blue 
0.02 % Xylene Cyanol 
2.3.2  Buffers for Western Blotting 
Cell Lysis Buffer (50 ml) 
4.5 ml 0.5 M Tris-HCl pH 8.5 
100 µl 0.5 M EDTA 
5 ml 10% SDS 
5 ml Glyerol 
 
Immediately prior to use, 10 ml buffer was pipetted into a new tube and supplemented 
with the following: 
25 mg/ml AEBSF 
0.5 mg/ml Pepstatin 
0.7 mg/ml Leupeptin 
1X Transfer Buffer (1L) 
50 ml 20X NuPAGE® Transfer Buffer 
1ml NuPAGE® Antioxidant 
100 ml Methanol 
10X TBST (500ml) 
250mM Tris pH8 
1.5M NaCl 
27mM KCl 
2% Tween 
Blocking Buffer (100 ml) 
5% Non-fat Dried Milk Powder (Marvel) 
To 100ml with 1x TBST 
2.4 Modular Assembly of ZFNs 
Modular assembly was carried out using the Zinc Finger Consortium Modular Assembly 
Kit (www.zincfinges.org, www.addgene.org) and construction was carried out according 
to the protocol by Wright et al. (2006). 
54 
 
2.4.1 ZFN designs using Zinc Finger Targeter (ZiFiT) software 
400 bp of the VEZF1 core promoter, 200 bp either side of the TSS, was searched using 
ZiFiT (Sander et al., 2007).  Suggested ZFN design outputs were chosen based on the 
number of zinc fingers in the array (3 or 4), the zinc finger module source and genomic 
location with respect to VEZF1 TSS and nucleosome positioning.  
2.4.2  Restriction digest of zinc finger plasmids for modular assembly 
1 µg vector backbone plasmid DNA was digested as follows: 
10 x NEB Buffer 1   4 µl 
AgeI (50 U/µl)   1 µl 
BamHI HF (20 U/µl)  1 µl 
BSA (10mg/ml)  1 µl 
DNA    1 µg 
H2O    to 40 µl 
Reactions were incubated in a 37°C hotblock for 3 hours.  1µl CIP was added to each 
reaction and incubated at 37°C for a further 10 minutes.  Digest products were resolved 
using a 0.8% TBE-agarose gel stained post run with 1 µg/ml ethidium bromide.  The 
desired band was visualised using a UV luminometer and was excised using a scalpel.  The 
digested plasmid DNA was purified using a QiaQuick Gel Extraction Kit. 
2µg vector insert plasmid DNA was digested as follows: 
10 x NEB Buffer 4   4 µl 
BamHI HF (20 U/µl)  1 µl 
XmaI (10 U/µl)  1 µl 
BSA (10 mg/ml)  1 µl 
DNA    2 µg 
H2O    to 40 µl 
Reactions were incubated in a 37°C hotblock for 3 hours.  Digest products were resolved 
using a 2% TBE-agarose gel stained post run with 1 µg/ml ethidium bromide.  The desired 
band was visualised using a UV luminometer and was excised using a scalpel.  The 
digested plasmid DNA was purified using a QiaQuick Gel Extraction Kit. Digested DNA 
fragments were ligated as outlined in 2.4.8. 
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2.4.3 Analytical Restriction Digest to Screen ZF Assemblies 
2µg plasmid DNA was digested as follows: 
10 x NEB Buffer 4   4 µl 
BamHI HF (20 U/µl)  1 µl 
XbaI (20 U/µl)   1 µl 
BSA (1 mg/ml)   1 µl 
DNA    2 µg 
H2O    to 40 µl 
Reactions were incubated at 37°C for 3 hours.  The digest products were resolved on a 2% 
TBE-agarose gel to confirm if cloning had been successful. The gel was stained prior to 
running with 2µl Safeview per 100 ml TBE buffer. Gels were imaged using a Fujifilm FLA-
5000 scanner. 
2.4.4  Restriction Digest of Zinc Finger Plasmids and FokI Expression Plasmids for 
Cloning ZFNs 
1µg vector backbone or 2µg vector insert plasmid DNA was digested as follows: 
10 x NEB Buffer 4   4 µl 
BamHI HF (20 U/µl)  1 µl 
XbaI (20 U/µl)   1 µl 
BSA (1 mg/ml)   1 µl 
DNA    1 or 2 µg 
H2O    to 40 µl 
Reactions were incubated in a 37°C hotblock for 3 hours.  1µl CIP was added to each 
digest of vector backbone and incubated at 37°C for a further 10 minutes.  Digest 
products were resolved using a 0.8% TBE-agarose gel (backbones) or 2% TBE-agarose gel 
(inserts). Gels were stained post run with 1 µg/ml ethidium bromide. The desired bands 
were visualised using a UV luminometer and was excised using a scalpel.  The digested 
plasmid DNA was purified using a QiaQuick Gel Extraction Kit and fragments were ligated 
together following the procedure described in section 2.4.8. 
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2.4.5 Screening ZFs Ligated to FokI 
2 µg plasmid DNA was digested as follows: 
10 x NEB Buffer 4   4 µl 
EcoRI HF (20 U/µl)  1 µl 
NheI HF (20 U/µl)  1 µl 
BSA (1 mg/ml)   1 µl 
DNA    2 µg 
H2O    to 40 µl 
Reactions were incubated at 37°C for 3 hours.  The digest products were resolved on a 2% 
TBE-agarose gel, stained with Safeview, to confirm if cloning had been successful. Gels 
were imaged using a Fujifilm FLA-5000 scanner. 
2.4.6 Sharkey FokI variant assembly in EL and KK FokI 
1 µg vector backbone (pFOKI-EL or pFOKI-KK) or 2 µg vector insert (pBluescript_Sharkey) 
plasmid DNA were digested as follows: 
10 x NEB Buffer 4   4 µl 
HindIII HF (20 U/µl)  1 µl 
BSA (1 mg/ml)   1 µl 
DNA    1 or 2 µg 
H2O    to 40 µl 
Reactions were incubated in a 37°C hotblock for 3 hours.  1µl CIP was added to each 
digest of vector backbone and incubated at 37°C for a further 10 minutes.  Digest 
products were resolved using a 0.8% TBE-agarose gel (backbones) or 2% TBE-agarose gel 
(inserts).  Gels were stained with Safeview. The desired bands were visualised using a UV 
luminometer and excised using a scalpel.  The digested plasmid DNA was purified using a 
QiaQuick Gel Extraction Kit. Sharkey was ligated into FokI vectors as described in section 
2.4.8. 
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2.4.7 Analytical Restriction Digests – Confirmation of Sharkey Assembly 
2 µg plasmid DNA was digested as follows: 
10 x NEB Buffer 1   4 µl 
AgeI (50 U/µl)   1 µl 
BamHI HF (20 U/µl)  1 µl 
BSA (1 mg/ml)   1 µl 
DNA    2 µg 
H2O    to 40 µl 
Reactions were incubated in a 37°C hotblock for 3 hours.  The digest products were 
resolved on a 1% TBE-agarose gel to confirm if cloning had been successful. Gels were 
stained with prior to running with 2 µl Safeview per 100 ml TBE buffer. Gels were imaged 
using a Fujifilm FLA-5000 scanner. 
2.4.8 Ligation of Restriction Fragments 
Ligation reactions were set up using 50 ng of plasmid vector backbone and the 
corresponding nanogram amount of vector insert to gain the desired ratio of 
backbone:insert.  Typical ratios used were 3:1, 1:1 1:3 & 1:10.  Calculations were based on 
the following equation:  
 
5 x Reaction Buffer  4 µl 
Vector Backbone  50 ng 
Vector Insert   as above 
T4 DNA Ligase (5 U/µl) 1 µl 
H2O    to 20 µl 
Additional controls were set up which included a backbone only ligation, without addition 
of insert, to test the degree of self-ligation occurring within the reaction.  Reactions were 
incubated at 15°C overnight and transformed into DH5α competent cells the following 
day. 
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2.4.9  Transformation of Competent Cells 
DH5α competent cells were thawed on ice and 50 µl per transformation was aliquoted 
into pre-chilled eppendorfs.  To this, 2.5 µl DNA was added and the reaction was 
incubated on ice for 30 minutes.  The cells were heat shocked at 42°C for 30 seconds in a 
water bath and returned to ice for 2 minutes.  950 µl SOC was added to each reaction 
under sterile conditions and the reactions were incubated for 1.5-2 hours at 37°C with 
shaking at 225 rpm.  50 µl and 100 µl of each reaction was spread onto pre-warmed LB 
agar plates containing 100 µg/ml ampicillin.  The plates were incubated at 37°C overnight. 
2.4.10  Plasmid Isolation 
Several colonies were isolated from a transformation reaction using a sterile pipette tip.  
This was then used to inoculate a 5ml LB broth containing 100 µg/ml ampicillin in a 50 ml 
falcon tube.  The culture was grown at 37°C with shaking at 225 rpm overnight.  1ml of 
the culture was transferred to a 1.5 ml eppendorf and the bacterial cells recovered by 
centrifugation at 13000 rpm for 5 minutes.  The supernatant was discarded and plasmid 
DNA was isolated from the bacterial cell pellet using a QiaPrep Miniprep Spin Kit, 
following the standard protocol. 
2.4.11  Preparation of Glycerol Stocks 
0.5 ml of an overnight bacterial culture was added to 0.5 ml 50% glycerol and stored at -
80°C. 
2.5 Golden Gate TALE Assembly 
Golden Gate assembly was carried out using the Voytas Lab Assembly Kit 
(www.addgene.org) and construction was carried out according to protocol by Cermak et 
al.(2011). 
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2.5.1 TALE Nucleotide Targeter (TALE-NT) 
400 bp of the VEZF1 core promoter, 200 bp either side of the TSS, was searched using 
TALE-NT (Doyle et al., 2012).  Suggested TALE design outputs were chosen based on the 
number of RVDs in the array, the spacer between TALE pairs (15 or 30 bp) and genomic 
location with respect to VEZF1 TSS and nucleosome positioning. 
2.5.2 Golden Gate Assembly of pTAL_A, B & C vectors 
TALE RVDs are assembled in pTAL vectors up to 10 RVDs at a time. The first 10 RVDs are 
assembled into pTAL_A, the next 10 into pTAL_B and the final 10 into pTAL_C. Plasmids 
for all four RVDs in any position of a TALE array are selected from the kit and assembled 
into the necessary pTAL vectors. The Golden Gate reactions were set up as follows: 
10 x DNA Ligase Buffer 2 µl 
BSA (2 mg/ml)   1 µl 
pTAL vector   150 ng 
RVD DNA   150 ng each RVD plasmid, up to 10 plasmids 
BsaI (10 U/µl)   1 µl 
T4 DNA Ligase (5 U/µl) 2 µl 
H2O    to 20µl 
Samples were subjected to a simultaneous digestion and ligation reaction using a 
thermocycler programmed to perform the following temperature cycles: 
Temperature Time Number of Cycles 
37°C 5 minutes 
10 
16°C 10 minutes 
50°C 5 minutes 1 
80°C 5 minutes 1 
Reactions were then treated with Plasmid Safe Nuclease treatment to remove unligated 
linear dsDNA. 1 µl 10mM ATP and 1 µl Plasmid Safe Nuclease (10 U/µl) were added to 
reactions and incubated at 37°C for 1 hour. 
Golden Gate reactions were then transformed into DH5α competent cells as detailed in 
section 2.4.9. Transformation reactions were plated on LB Agar plates containing 50 
µg/ml spectinomycin, 20 mg/ml X-gal and 0.1M IPTG to perform blue/white screening of 
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clones containing inserted RVDs. The plates were incubated at 37°C overnight and were 
then incubated at 4°C overnight to allow blue colour to fully develop.  
2.5.3 Colony PCR to confirm assembly of RVDs in pTAL vectors 
Three white colonies from each assembly were selected and subjected to screening by 
colony PCR. Isolated colonies were inoculated into 50 µl H2O and a 5 µl aliquot was taken 
into the following PCR reaction: 
10 x ThermoPol Buffer  5 µl 
10 mM dNTPs    1 µl 
10 µM F Primer pCR8_F1  1 µl 
10 µM R Primer pCR8_R1  1 µl 
Colony suspension   5 µl 
NEB Taq Polymerase (5 U/µl)  0.25 µl 
H2O     to 50 µl 
PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
Temperature Time Number of Cycles 
95°C 30 seconds 1 
95°C 30 seconds 
33 55°C 30 seconds 
68°C 1.75 minutes 
68°C 5 minutes 1 
 
PCR products were resolved using a 1% TBE-agarose gel stained with Safeview. Gels were 
imaged using a Fujifilm FLA-5000 scanner. Colony suspensions from correct clones 
identified were cultured overnight by inoculating the remaining suspension into 2 ml LB 
containing 50 µg/ml spectinomycin and shaking at 37°C for 16 hours. Plasmid DNA was 
isolated following the procedure outlined in section 2.4.10. 
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2.5.4 Restriction digest to confirm pTAL assemblies 
Miniprepped DNA was analysed by restriction digestion, set up as follows: 
10 x NEB Buffer 4 2 µl 
BSA (1 mg/ml)  1 µl 
DNA   1 µg 
AflII (20 U/µl)  0.5 µl 
XbaI (20 U/µl)  0.5 µl 
H2O   to 20 µl 
Reactions were incubated in a 37°C hotblock for 3 hours. Digest products were visualised 
using a 1% TBE-agarose gel stained with Safeview. Gels were imaged using a Fujifilm FLA-
5000 scanner. Correct clones were confirmed by sequencing using primers pCR_8F1 and 
pCR_8R1. 
2.6 Construction of SID-Repressor Vector 
2.6.1 Creation of pRFPturbo 
RFPturbo was PCR amplified from pTRIPZ using primers which facilitated the addition of 
restriction enzyme recognition sites. PCR reaction was set up as follows: 
10 x Buffer    5 µl 
10 mM dNTPs    4 µl 
10 µM F Primer RFP5_Nhe_Age 1 µl 
10 µM R Primer RFP3_Bam_Not 1 µl 
pTRIPZ     50 ng 
Pfu Polymerase (2.5 U/µl)  0.5 µl 
H2O     to 50 µl 
PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
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Temperature Time Number of Cycles 
95°C 2 minutes 1 
95°C 30 seconds 
33 55°C 30 seconds 
72°C 2.5 minutes 
72°C 5 minutes 1 
 
PCR products were resolved using a 1% TBE-agarose gel stained with Safeview. The 
desired band was visualised using a UV luminometer and was excised using a scalpel.  The 
PCR product was purified using a QiaQuick Gel Extraction Kit. 
1 µg purified PCR product (insert) and 1 µg of pEGFP-N1 (backbone) were digested as 
follows: 
10 x NEB Buffer 4   4 µl 
NheI HF (20 U/µl)  1 µl 
NotI HF (20 U/µl)  1 µl 
BSA (1 mg/ml)   1 µl 
DNA    1 µg 
H2O    to 40 µl 
Digest reactions were incubated at 37°C for 3 hours in a thermocycler. 1µl CIP was added 
to digestion of pEGFP-N1 vectors and incubated at 37°C for a further 10 minutes.  pEGFP-
N1 digest products were resolved using a 0.8% TBE-agarose gel stained pre-run with 
Safeview.  The desired band was visualised using a UV luminometer and was excised using 
a scalpel.  The digested plasmid DNA was purified using a QiaQuick Gel Extraction Kit. 
Digested RFPturbo PCR product was purified using a QiaQuick PCR Purification Kit.  
Fragments were ligated together following the procedure described in section 2.4.8. 
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2.6.2 Confirmation of pRFPturbo assembly 
1µg plasmid DNA was digested as follows: 
10 x NEB Buffer 4   4 µl 
NheI HF (20 U/µl)  1 µl 
NotI HF (20 U/µl)  1 µl 
BSA (1 mg/ml)   1 µl 
DNA    1 µg 
H2O    to 40 µl 
Reactions were incubated at 37°C for 3 hours.  The digest products were resolved on a 1% 
TBE-agarose gel to confirm if cloning had been successful. The gel was stained prior to 
running with 2µl Safeview per 100 ml TBE buffer. Gels were imaged using a Fujifilm FLA-
5000 scanner. 
2.6.3 Construction of pRFP_SID 
The sequence of pSID4X (Cong et al., 2012) was utilised as a template to synthesise p2A-
SID. p2A-SID sequence was flanked by a 5’ BamHI and a 3’ NotI restriction site recognition 
sequences. p2A-SID synthesised sequence (in pUC57_p2A_SID) was digested and cloned 
into pRFP_TURBO to assemble pRFP_SID. Digest reactions of 2 µg pRFP_TURBO or 1 µg 
synthesised cassette were set us as follows: 
10 x NEB Buffer 4 2 µl 
BSA (1 mg/ml)  1 µl 
DNA   1 or 2 µg 
BamHI HF (20 U/µl) 0.5 µl 
NotI HF (20 U/µl) 0.5 µl 
H2O   to 20 µl 
Digest reactions were incubated in a 37°C hotblock for 3 hours. 1 µl CIP was added to 
each digest of vector backbone and incubated at 37°C for a further 10 minutes.  Digest 
products were resolved using a 0.8% TBE-agarose gel (backbones) or 2% TBE-agarose gel 
(inserts). Gels were stained with Safeview. The desired bands were visualised using a UV 
luminometer and excised using a scalpel.  The digested plasmid DNA was purified using a 
QiaQuick Gel Extraction Kit. Extracted DNA fragments were ligated following the 
procedure in section 2.4.8. 
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2.6.4 Confirmation of pRFP_SID Assembly 
2 µg plasmid DNA was digested as follows: 
10 x NEB Buffer 4 2 µl 
BSA (1 mg/ml)  1 µl 
DNA   2 µg 
NheI HF (20 U/µl) 0.5 µl 
NotI HF (20 U/µl) 0.5 µl 
H2O   to 20 µl 
Reactions were incubated in a 37°C hotblock for 3 hours and digest products were 
visualised using 1% TBE-agarose gel stained with Safeview. Gels were imaged using a 
Fujifilm FLA-5000 scanner. 
TALE N- and C- termini from the vector pCAG_T7_TALEN were cloned into pRFP_SID to 
create pRFP-TALE-SID, which is capable of participating in Golden Gate Assembly. 
2.6.5 Assembly of pRFP-TALE-SID 
A digest reaction of 1 µg pRFP_TALE-SID was set up as follows: 
10 x NEB Buffer 3 2 µl 
pRFP_TALE-SID 2 µg 
BglII (10 U/µl)  0.5 µl 
H2O   to 20 µl 
A digest reaction of 2 µg pCAG_T7 was set up as follows: 
10 x NEB Buffer 3 2 µl 
BSA (1 mg/ml)  1 µl 
pCAG_T7  2 µg 
BamHI (20 U/µl)  0.5µl 
BglII (10 U/µl)  0.5 µl 
H2O   to 20 µl 
Digest reactions were incubated in a 37°C hotblock for 3 hours. 1 µl CIP was added to 
digest of vector backbone and incubated at 37°C for a further 10 minutes. Digest products 
were resolved using 0.8% TBE-agarose gel (backbone) or 1% TBE-agarose gel (insert). Gels 
were stained with Safeview prior to running. The desired bands were visualised using a 
UV luminometer and excised using a scalpel. The digested plasmid DNA was purified using 
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a QiaQuick Gel Extraction Kit. Extracted DNA fragments were ligated following the 
procedure in Section 2.4.8. 
2.6.6 Confirmation of pRFP-TALE-SID Construction 
1 µg plasmid DNA was digested as follows: 
10 x NEB Buffer 4 2 µl 
BSA (1 mg/ml)  1 µl 
DNA   2 µg 
NheI HF (20 U/µl) 0.5 µl 
NotI HF (20 U/µl) 0.5 µl 
H2O   to 20 µl 
Digest reactions were incubated in a 37°C hotblock for 3 hours. Digest products were 
resolved using a 1% TBE-agarose gel stained with Safeview. The gel was imaged using a 
Fujifilm FLA-5000 scanner to confirm if cloning had been successful. 
2.7 Golden Gate Assembly of TALE RVDs into SID-Repressor Vectors 
2.7.1 Golden Gate TALE Repressor Assembly  
TALE RVD pTAL_A, B & C vectors (section 2.5.2) and pRFP-TALE-SID were combined with 
pLR (last RVD repeat vector) in a Golden Gate reaction to assemble all TALE RVDs 
together in SID repressor vector (section 2.6). Reactions were set up as follows: 
10 x DNA Ligase Buffer 2 µl 
pTAL_A, B & C   150 ng each 
pLR    150 ng 
pRFP-TALE-SID  75 ng 
Esp3I (10 U/µl)  1 µl 
T4 DNA Ligase (5 U/µl) 2 µl 
H2O    to 20µl 
Samples were subjected to a simultaneous digestion and ligation reaction using a 
thermocycler programmed to perform the following temperature cycles: 
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Temperature Time Number of Cycles 
37°C 5 minutes 
5 
16°C 10 minutes 
37°C 15 minutes 1 
80°C 5 minutes 1 
Golden Gate reactions were then transformed into DH5α competent cells as detailed in 
section 2.4.9. Transformation reactions were plated on LB Agar plates containing 50 
µg/ml ampicillin. Blue/white screening was performed by addition of 100 µl 20 mg/ml X-
gal and 100 µl 10mM IPTG to plates and allowing them to dry before plating bacteria. The 
plates were incubated at 37°C overnight and were then incubated at 4°C overnight to 
allow blue colour to fully develop.  
2.7.2 Confirmation of TALE Assembly in Repressor Vector 
Plasmid DNA isolated from white colonies (see section 2.4.10) was screened to confirm 
insertion of TALE RVDs into pRFP-TALE-SID vector. Restriction digest reactions were 
carried out as follows: 
10 x NEB Buffer 4   4 µl 
BamHI HF (20 U/µl)  1 µl 
StuI (10 U/µl)   1 µl 
DNA    2 µg 
H2O    to 40 µl 
Reactions were incubated in a 37°C hotblock for 3 hours.  The digest products were 
resolved on a 1% TBE-agarose gel, stained with Safeview, to confirm if cloning had been 
successful. Gels were imaged using a Fujifilm FLA-5000 scanner. 
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2.8 Construction of Advanced Nuclease Expression Vectors for TALENs 
2.8.1 Modification of pTALETF_v2 to form pTALETFΔhygro 
A portion of pTALETF_v2 had which contained an Esp3I site had to be deleted. Restriction 
digest to remove this vector sequence was carried out as follows: 
10 x NEB Buffer 1   2 µl 
BSA (1 mg/ml)   1 µl 
PmlI (20 U/µl)   0.5 µl 
DNA    2 µg 
H2O    to 20 µl 
Reactions were incubated in a 37°C hotblock for 3 hours and digest products were 
visualised using 0.8% TBE-agarose gel stained with Safeview.  The desired band was 
visualised using a UV luminometer and excised using a scalpel.  The digested plasmid DNA 
was purified using a QiaQuick Gel Extraction Kit. Extracted DNA fragment was 
recircularised using blunt ended ligation. 
2.8.2 Blunt Ended Ligation 
pTALETFΔhygro was recircularised by blunt ended ligation using the following procedure: 
10 x T4 DNA Ligase Buffer  2 µl 
pTALETFΔhygro  100 ng 
T4 DNA Ligase (5 U/µl) 1 µl 
H2O    to 20 µl 
The reaction was incubated at 23°C in a thermocycler for 2 hours. 
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2.8.3 Construction of designed TALEN N-terminus (pTALv2_NT) 
TALEN N-terminus sequence was constructed using DNA synthesis and was flanked by 
SacI and NotI restriction sites (pUC57_TALE NT). Restriction digest of 1 µg pTALETF_v2 
(backbone) and 2 µg pUC57_TALE NT (insert) were digested using the following set up: 
10 x NEB Buffer 4   2 µl 
BSA (1 mg/ml)   1 µl 
NotI HF (20 U/µl)  0.5 µl 
SacI HF (20 U/µl)  0.5 µl 
DNA    1 or 2 µg 
H2O    to 20 µl 
Reactions were incubated in a 37°C hotblock for 3 hours. Digested DNA was run on 0.8% 
(backbone) or 2% (insert) TBE-agarose gels stained with Safeview and visualised using a 
UV luminometer. Desired bands were excised using a scalpel and purified by QiaQuick Gel 
Extraction. Fragments were ligated together following the protocol outlined in section 
2.4.8. 
2.8.4 Confirmation of designed TALEN N-terminus assembly 
Insertion of designed TALE N-terminus was confirmed by performing two restriction 
enzyme digestions, as follows: 
10 x NEB Buffer 4   2 µl 
BSA (1 mg/ml)   1 µl 
NotI HF (20 U/µl)  0.5 µl 
SacI HF (20 U/µl)  0.5 µl 
DNA    1 µg 
H2O    to 20 µl 
10 x NEB Buffer 3   2 µl 
BSA (1 mg/ml)   1 µl 
NcoI (10 U/µl)   0.5 µl 
DNA    1 µg 
H2O    to 20 µl 
Reactions were incubated at 37°C in a hotblock for 3 hours and digest products were 
analysed using 1% TBE-agarose gel electrophoresis. Gels were stained with Safeview and 
imaged using a Fujifilm FLA-5000 scanner. 
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2.8.5 Construction of designed TALEN C-terminus 
Sequences encoding the TALEN C-terminus and wt or mutant codon optimised FokI, 
flanked by two BsrGI restriction sites, were constructed using DNA synthesis 
(pUC57_TALE CT WT, pUC57_TALE CT ELD-S and pUC57_TALE CT KKR-S). Restriction digest 
of 1 µg pTALv2_NT (backbone) and 2 µg C-terminus-FokI (insert) were digested using the 
following set up: 
10 x NEB Buffer 2   2 µl 
BSA (1 mg/ml)   1 µl 
BsrGI (10 U/µl)   0.5 µl 
DNA    1 or 2 µg 
H2O    to 20 µl 
Reactions were incubated in a 37°C hotblock for 3 hours. Digested DNA was run on 0.8% 
(backbone) or 1% (insert) TBE-agarose gels, stained with Safeview, and visualised using a 
UV luminometer. Desired bands were excised using a scalpel and purified by QiaQuick Gel 
Extraction. Fragments were ligated together following the protocol outlined in section 
2.4.8.  
2.8.6 Confirmation of designed TALEN C-terminus assembly 
Insertion of designed TALE C-terminus was confirmed by performing two restriction 
enzyme digestions, as follows: 
10 x NEB Buffer 3   2 µl 
BSA (1 mg/ml)   1 µl 
NcoI (10 U/µl)   0.5 µl 
DNA    1 µg 
H2O    to 20 µl 
10 x NEB Buffer 4   2 µl 
StuI (10 U/µl)    0.5 µl 
DNA    1 µg 
H2O    to 20 µl 
Reactions were incubated at 37°C in a hotblock for 3 hours and digest products were 
analysed using 1% TBE-agarose gel electrophoresis. Gels were stained with Safeview and 
imaged using a Fujifilm FLA-5000 scanner. 
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2.9 Assembly of TALE RVDs into Nuclease Expression Vectors 
2.9.1 Golden Gate TALEN Assembly (pTALEN) 
TALE RVD pTAL_A, B & C vectors (section 2.5.2) and pTALv1-FokIWT/pTALv2-
FokIWT/pTALv3-FokI ELDS or KKRS were combined with pLR (last RVD repeat vector) in a 
Golden Gate reaction to assemble all TALE RVDs together in a TALEN expression vector 
(section 2.8). Reactions were set up as follows: 
10 x DNA Ligase Buffer 2 µl 
pTAL_A, B & C   150 ng each 
pLR    150 ng 
pTALv1/v2/v3   75 ng 
Esp3I (10 U/µl)  1 µl 
T4 DNA Ligase (5 U/µl) 2 µl 
H2O    to 20µl 
Samples were subjected to a simultaneous digestion and ligation reaction using a 
thermocycler programmed to perform the following temperature cycles: 
Temperature Time Number of Cycles 
37°C 5 minutes 
5 
16°C 10 minutes 
37°C 15 minutes 1 
80°C 5 minutes 1 
Golden Gate reactions were then transformed into DH5α competent cells as detailed in 
section 2.4.9. Transformation reactions were plated on LB Agar plates containing 50 
µg/ml ampicillin, 20 mg/ml X-gal and 0.1M IPTG to perform blue/white screening of 
clones containing inserted RVDs. The plates were incubated at 37°C overnight and were 
then incubated at 4°C overnight to allow blue colour to fully develop.  
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2.9.2 Confirmation of TALE Assembly in Nuclease Vectors 
Plasmid DNA isolated from white colonies (see section 2.4.10) was screened to confirm 
insertion of TALE RVDs into pTALv1/v2/v3 vectors. Restriction digest reactions were 
carried out as follows: 
10 x NEB Buffer 4   4 µl 
BSA (1 mg/ml)   1 µl 
SacI HF (20 U/µl)  1 µl 
XhoI (20 U/µl)   1 µl 
DNA    2 µg 
H2O    to 40 µl 
Reactions were incubated in a 37°C hotblock for 3 hours.  The digest products were 
resolved on a 1% TBE-agarose gel, stained with Safeview, to confirm if cloning had been 
successful. Gels were imaged using a Fujifilm FLA-5000 scanner. 
2.10 Construction of pTRGT VEZF1 
2.10.1 PCR of hVEZF1 homology arms for pSHTLR cloning 
Homology arms were obtained by performing PCR of regions surrounding VEZF1 gene 
promoter from genomic DNA isolated from K562 cells. Primers used to amplify homology 
arms contained att sites for use in Gateway® Gene Cloning (Life Technologies). Homology 
arms were inserted into pDONR vectors by BP reaction Gateway Cloning (Grainne 
Barkess). Homology arms were PCR amplified from pDONR vectors. 
5’ Homology Arm 
PCR reaction was set up as follows: 
10 x Buffer    5 µl 
10 mM dNTPs    4 µl 
10 µM F Primer VEZF1_5’arm_H3F 1 µl 
10 µM R Primer VEZF1_5’arm_AscR 1 µl 
pDONR_VEZF1 5’arm   10 ng 
Pfu Polymerase (2.5 U/µl)  0.5 µl 
H2O     to 50 µl 
PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
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Temperature Time Number of Cycles 
95°C 2 minutes 1 
95°C 30 seconds 
33 55°C 30 seconds 
72°C 2.5 minutes 
72°C 5 minutes 1 
 
PCR products were resolved using a 1% TBE-agarose gel stained with Safeview. The 
desired band was visualised using a UV luminometer and was excised using a scalpel.  The 
PCR product was purified using a QiaQuick Gel Extraction Kit. 
3’ Homology Arm 
PCR reaction was set up as follows: 
10 x Buffer    5 µl 
DMSO     2.5 µl 
10 mM dNTPs    1 µl 
10 µM F Primer VEZF1_3’arm_H3F 1 µl 
10 µM R Primer VEZF1_3’arm_AscR 1 µl 
pDONR_VEZF1 5’arm   10 ng 
Pfu Polymerase (2.5 U/µl)  0.5 µl 
H2O     to 50 µl 
PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
 
Temperature Time Number of Cycles 
95°C 2 minutes 1 
95°C 30 seconds 
33 60°C 30 seconds 
72°C 2.5 minutes 
72°C 5 minutes 1 
 
PCR products were resolved using a 1% TBE-agarose gel stained with Safeview. The 
desired band was visualised using a UV luminometer and was excised using a scalpel.  The 
PCR product was purified using a QiaQuick Gel Extraction Kit.  
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2.10.2 Restriction digestion of hVEZF1 homology arms for pSHTLR cloning 
1 µg purified PCR product (insert) and 1 µg of either pSHTLR3 or pSHTLR5 (backbones) 
were digested as follows: 
10 x NEB Buffer 4   4 µl 
AscI (10 U/µl)   1 µl 
HindIII HF (20 U/µl)  1 µl 
DNA    1 µg 
H2O    to 40 µl 
Digest reactions were incubated at 37°C for 3 hours in a thermocycler. 1µl CIP was added 
to digestion of pSHTLR vectors and incubated at 37°C for a further 10 minutes.  pSHTLR 
digest products were resolved using a 0.8% TBE-agarose gel stained pre-run with 
Safeview.  The desired bands were visualised using a UV luminometer and was excised 
using a scalpel.  The digested plasmid DNA was purified using a QiaQuick Gel Extraction 
Kit. Digested homology arm PCRs were purified using a QiaQuick PCR Purification Kit.  
5’ VEZF1 homology arm was cloned into pSHTLR3 and 3’ VEZF1 homology arm was cloned 
into pSHTLR5. Fragments were ligated together following the procedure described in 
section 2.4.8. 
2.10.3 Confirmation of pSHTLR-Homology arm cloning 
1µg plasmid DNA was digested as follows: 
10x NEB Buffer 4   4 µl 
AscI (10 U/µl)   1 µl 
HindIII HF (20 U/µl)  1 µl 
DNA    1 µg 
H2O    to 40 µl  
Reactions were incubated at 37°C for 3 hours.  The digest products were resolved on a 1% 
TBE-agarose gel to confirm if cloning had been successful. The gel was stained prior to 
running with 2µl Safeview per 100 ml TBE buffer. Gels were imaged using a Fujifilm FLA-
5000 scanner. 
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2.10.4 Assembly of pTRGT_VEZF1 
Gateway Clonase LR reaction to combine pSHTLR5, pSHTLR3 and pSHTLRmid was set up 
as follows: 
pSHTLR_5’homology arm 10 fmol 
pSHTLR_3’homology arm 10 fmol 
pSHTLRmid   10 fmol 
pDESTR4-R3   20 fmol 
H2O    to 8 µl 
LR Clonase II   2 µl 
Reactions were incubated overnight at 25°C in a thermocycler. The clonase reaction was 
stopped by addition of 1 µl Proteinase K and incubating at 37°C for 10 minutes. 
2.10.5 Confirmation of pTRGT_VEZF1 assembly 
1µg plasmid DNA was digested as follows: 
10 x NEB Buffer 4   4 µl 
KpnI HF (20 U/µl)  1 µl 
DNA    1 µg 
H2O    to 40 µl  
Reactions were incubated at 37°C for 3 hours.  The digest products were resolved on a 1% 
TBE-agarose gel to confirm if cloning had been successful. The gel was stained prior to 
running with 2µl Safeview per 100 ml TBE buffer. Gels were imaged using a Fujifilm FLA-
5000 scanner. 
2.11 Cell Culture 
2.11.1  Culturing Cell Lines 
Cell lines were cultured with 5% CO2 at 37°C in vented flasks or dishes. 
Human Embryonic Kidney Cell Line – HEK293 T/17 Cells 
HEK293 T/17 cells were cultured in 90% DMEM-Glutamax, 10% FBS, 1% Penicillin-
Streptomycin solution.  Cultures were passaged once cell density reached ~80% at a ratio 
of 1/4 to 1/5. 
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Human Erythroleukemia Cell Line – K562 Cells 
K562 cells were cultured in 90% RPMI 1640 + GlutaMAX™, 10% FBS, 1% Penicillin-
Streptomycin solution.  Cultures were passaged three times weekly, once confluency was 
around 70-80% at a ratio of 1/5.  
2.11.2  Passaging Cell Lines 
Human Embryonic Kidney Cell Line – HEK293 T/17 Cells 
Media was removed from the flask by pipetting and the cells were rinsed with PBS.  The 
cells were dislodged from the flask by addition of trypsin and incubation at 37°C for 3 
minutes.  Trypsin was deactivated by addition of 10 volumes of fresh media and the cells 
carried over into a falcon tube by pipetting.  Cells were pelleted by centrifugation at 1100 
rpm for 5 minutes.  The supernatant was removed before the cell pellet was resuspended 
in fresh media and used to seed a new flask. 
Human Erythroleukemia Cell Line – K562 Cells 
Cells were removed from the flask by pipetting and transferred to a falcon tube.  The cells 
were collected by centrifugation at 1100 rpm for 5 minutes and the supernatant removed 
before resuspending the pellet in fresh media and using this to seed a new culture. 
2.11.3  Cell Cryopreservation 
Confluent cell cultures were collected by centrifugation at 1100 rpm for 5 minutes and 
cell pellets resuspended in 90% FBS, 10% DMSO in aliquots containing ~1x107 cells.  Cells 
were gradually frozen in CoolCell® (Biocision) chambers in -80°C freezers overnight before 
being transferred to liquid nitrogen vapour phase for long term storage.  Cells were 
thawed rapidly at 37°C and added to fresh media where they were pelleted by 
centrifugation at 1100 rpm for 5 minutes.  The pellet was then resuspended in 10 ml fresh 
media and used to seed a 25 cm2 flask. 
2.11.4 TALE Repressor Transfections 
The day before transfection, 7.5x106 HEK293 T/17 cells per well were seeded in a T75 
flask with 16ml media which did not contain antibiotics.  K562 cells to be transfected 
were counted and 7.5x106 cells seeded on the day of transfection.  Transfections were 
performed using Lipofectamine 2000 reagent.  15.6 µg plasmid DNA was combined in a 
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total volume of 2 ml in Optimem.  78 µl Lipofectamine 2000 was combined with 1872 µl 
Optimem and incubated at room temperature for 5 minutes.  The DNA/Optimem and 
Lipofectamine/Optimem mixtures were then combined and incubated at room 
temperature for 20 minutes before being added dropwise to cells.  The cells were 
incubated for three days before cell pellets were collected for analysis. 
2.11.5 ZFN & TALEN Transfections 
The day before transfection, 1x106 HEK293 T/17 cells per well were seeded in a 6 well 
plate with 2ml media which did not contain antibiotics.  K562 cells to be transfected were 
counted and 1x106 cells seeded on the day of transfection.  Transfections were performed 
using Lipofectamine 2000 reagent.  In total, 4 µg DNA was transfected: 2µg each ZFN or 
TALEN expression vector or, in the case of HDR experiments involving the targeting 
vector, a targeting vector/nuclease expression vector ratio of 30/1 was used (3874 ng 
pTRGT_VEZF1 + 63 ng each ZFN or TALEN) (Connelly et al., 2010).  Plasmid DNA was 
combined in a total volume of 250 µl in Optimem.  10 µl Lipofectamine 2000 was 
combined with 240 µl Optimem and incubated at room temperature for 5 minutes.  The 
DNA/Optimem and Lipofectamine/Optimem mixtures were treated as outlined in section 
2.11.4. 
2.11.6 FACS Analysis 
Approximately 1x106 cells were collected by centrifugation at 1000 rpm for 5 minutes.  
The cell pellet was resupened in 500µl fresh culture medium and FACS analysis was 
performed using an Attune Acoustic Focusing Cell Cytometer (Life Technologies).  
Parameters were optimised for GFP and RFP signals from HEK293 T/17 cells. 
Fluorochromes were excited by a laser at 488 nm. Voltage parameters were used as 
follows: RFP detection – FSC 2100 mV, SSC 2650 mV, BL1 1100 mV, BL2 1500 mV, BL3 
2550 mV; GFP detection – FSC 2100 mV, SSC 2650 mV, BL1 1100 mV, BL2 2200 mV, BL3 
2550 mV. Data from 20,000 cells was gathered to estimate the percentage of GFP+ cells 
within the population. The data collected was gated for analysis of live cells. Fluorescence 
intensity of GFP+ or RFP+ cells was compared to that of wild type cells using Attune 
Cytometric Software (Life Technologies). 
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2.12 Protein Isolation & Analysis 
2.12.1  Preparation of Whole Cell Extracts 
Approximately 5x107 cells were collected by centrifugation at 1000 rpm for 5 minutes.  
The supernatant was removed and the pellet washed with PBS. Cell pellets were 
resuspended in 350 µl cell lysis buffer and pellets dislodged by vortexing. The samples 
were freeze-thawed twice and then sonicated 5 x 5 seconds, until they became runny and 
clear. The samples were centrifuged at 14,000 rpm for 5.5 minutes to separate cellular 
debris from protein samples. Supernatant was removed and stored at -20°C. 
2.12.2  Protein Quantification 
Protein samples were quantified using NanoOrange Protein Quantification Kit. A standard 
curve was prepared using BSA dilutions following the protocol in the kit. Samples were 
prepared following the standard protocol and compared to the standard curve using a 
Stratagene Mx3000P thermocycler. 
2.12.3  Detection of Target Proteins using Western Blotting 
A 4 – 12 % Bis-Tris precast gel cassette (Invitrogen) was placed into a running tank and the 
tank was filled with MOPS SDS Running Buffer (1x).  The protein samples were prepared 
by addition of 4x LDS sample buffer and 10x sample reducing agent (to final concentration 
of 1x) and were heated at 70°C for 10 minutes before being loaded into the wells.  
Proteins were resolved by running the gels at 200 V for 45 minutes. 
1x Transfer Buffer was prepared as outlined in section 2.3.2. Blotting pads and filter paper 
were soaked in 1x Transfer buffer and a PVDF membrane was prepared by soaking in 
100% methanol, followed by soaking in distilled H2O and finally soaked in 1x transfer 
buffer. 
The gel was removed from the cassette after running and the wells and foot were 
removed.  The transfer stack was prepared and secured in the gel tank.  The inner 
chamber of the gel tank (containing the transfer stack) was immersed in 1x transfer 
buffer, while the outer chamber was filled with distilled H2O.  The transfer was carried out 
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at 30V for 90 minutes.  Verification of transfer was performed by Ponceau staining of the 
membrane.  The membrane was then destained by several washes in distilled H2O. 
The PVDF membrane was blocked by shaking for 2x 30 minutes at room temperature in 
1x blocking buffer.  The membrane was then incubated overnight in a sealed Kapak bag, 
rocking gently at 4°C with primary antibody, diluted 1/2000 in blocking buffer.  The 
membrane was washed four times for 15 minutes in 1xTBST whilst rocking.  The 
membrane was then incubated with secondary antibody, diluted 1/2000 in blocking 
buffer, whilst rocking, for 2 hours at room temperature and was then washed again as 
before.  SuperSignal West Dura Extended Duration Substrate (Pierce) ECL detection 
reagent was prepared by mixing the luminal enhancer and peroxide solutions in equal 
proportions.  This solution was then applied directly to the PVDF membrane to visualise 
the proteins.  The membrane was incubated for 5 minutes and the resulting 
chemiluminescent signal was detected using a CCD camera imaging system (Fuji). 
2.13 RNA Isolation & Gene Expression Analysis 
2.13.1 RNA Extraction 
Approximately 7.5 x 106 cells were harvested by centrifugation and the supernatant 
removed from the cell pellet.  The pellet was then resuspended in 1 ml Trizol and 
incubated at room temperature for 5 – 10 minutes.  100 µl BCP (1-bromo-3-
chloropropane) was added and the reactions were shaken vigorously and then incubated 
at room temperature for 15 minutes.  The reactions were then centrifuged at 12,000 g for 
15 minutes at 4°C to separate RNA, DNA and cellular proteins.   After centrifugation, the 
supernatant was transferred to a fresh tube.  500 µl of ispopropanol was added to each 
new tube and the reactions were vortexed before incubation at room temperature for 10 
minutes and then at -20°C for 20 minutes.  RNA was collected by centrifugation at 
12,000g for 15 minutes at 4°C and the supernatant was removed. The RNA pellet was 
washed using 1 ml of 75% ethanol and then pelleted again at 7,500g for 5 minutes at 
room temperature.  The supernatant was again discarded and the wash repeated as 
before.  Following the second wash, the pellet was air dried before being resuspended in 
50µl molecular grade H2O. 
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2.13.2 Assessment of RNA integrity 
RNA quality was determined by running 2 µg of each RNA preparation on 1% TBE-agarose 
gel. Gels were stained post-run using 1 µg/ml ethidium bromide and destained using TBE 
buffer. Gels were then imaged using a Fujifilm FLA-5000 scanner. 
2.13.3 cDNA Synthesis 
cDNA synthesis was carried out by combining 400 ng RNA in the following reaction: 
RNA (100 ng/µl)    4 µl 
dNTPs (10 mM)    0.5 µl 
Random Primers (50 ng/µl)   1 µl 
H2O      1 µl 
Reactions were incubated at 65°C for 5 minutes and then placed on ice for 2 minutes 
before addition of the following reagents: 
5X First Strand Synthesis (FS) Buffer  2 µl 
RNase OUT     0.5 µl 
DTT      0.5 µl 
SuperScript III Reverse Transcriptase  0.5 µl 
Reactions were subjected to the following temperature conditions in a thermocycer: 
Temperature Time 
25°C 10 minutes 
50°C 50 minutes 
85°C 5 minutes 
 
Template RNA was digested by addition of 1 µl RNase H. Reactions were incubated in a 
37°C hotblock for 20 minutes. 
2.13.4 qRT-PCR 
Gene expression analysis was performed using FastStart Universal SYBR Green. qRT-PCR 
reactions were performed in triplicate using previously validated primer sets which are 
widely used in the lab. The reactions were carried out as follows: 
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2X SYBR Green Master Mix   10 µl 
F & R Primer Mix (4 µM each primer) 4 µl 
cDNA      4 µl 
H2O      1 µl 
Real time PCR reactions were carried out on a Stratagene Mx3000P thermocycler 
programmed to perform the following temperature cycles: 
Temperature Time Number of Cycles 
95°C 10 minutes 1 
95°C 15 seconds 
40 
60°C 30 seconds 
A dissociation curve was performed upon completion of each real-time PCR in order to 
measure the dissociation temperature of PCR products between 60 ᵒC – 95 ᵒC, and thus 
detect primer dimers. 
Ct values were generated using the MxPro version 4.0 software. 
2.13.5 qRT-PCR Analysis 
Average Ct values were calculated for each sample, which was analysed in triplicate. Error 
values were expressed as a standard deviation from the mean. Expression levels of VEZF1 
were analysed by normalising to the expression of housekeeping gene, β-actin. This 
generated a ΔCt value:  
ΔCt = Ct (gene of interest) – Ct (housekeeping gene) 
Changes in gene expression were detected by calculating a ΔΔCt value using the following 
equation: 
ΔΔCt = ΔCt (treated sample) – ΔCt (WT sample) 
 Fold change in gene expression was calculated as follows: 
Fold change = N^(-∆∆Ct) 
Where ‘N’ = PCR amplification efficiency (typically = 2) 
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2.14 NHEJ Assays 
2.14.1 CelI/T7 EndonucleaseI Control Assays 
2.14.1.1 Preparation of Control Assay Substrate DNA 
PCR of Control DNA 
PCR was performed from plasmids pFOKI-EL and pFOKI-ELS. Reactions were set up as 
follows: 
10 x PCR Buffer    5 µl 
50 mM MgCl2     1.5 µl 
10 mM dNTPs     1 µl 
10 µM F Primer FokI_CelI_Cont_F  1 µl 
10 µM R Primer FokI_CelI_Cont_R  1 µl 
DNA      100 ng 
Platinum Taq (5 U/µl)    0.2 µl 
H2O      to 50 µl 
PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
 
Temperature Time Number of Cycles 
94°C 1 minute 1 
94°C 30 seconds 
30 47°C 30 seconds 
72°C 1 minute 
72°C 5 minutes 1 
 
PCR products were resolved using a 1% TBE-agarose gel stained with Safeview. Desired 
bands were visualised using a UV luminometer and excised using a scalpel.  The digested 
plasmid DNA was purified using a QiaQuick Gel Extraction Kit. 
Denature & re-annealing of control DNA 
Purified PCR products from pFOKI-EL and pFOKI-ELS were mixed in predefined ratios to 
create mismatched DNA. This was added to the following reagents: 
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10 x Maximase Polymerase Buffer 5 µl 
25 mM MgSO4    4 µl 
10 mM dNTPs    1 µl 
DNA     2 µg 
H2O     to 50 µl 
Reactions were incubated in a thermocycler programmed to perform the following 
temperature cycles: 
Temperature Time 
90°C 3 minutes 
65°C 10 minutes 
37°C 10 minutes 
22°C 10 minutes 
 
2.14.1.2 Digestion of control DNA with CelI 
Re-annealed DNA was digested in the following reaction: 
10 x Maximase Polymerase Buffer 2.5 µl 
150 mM MgCl2   1.25 µl 
Enhancer    1 µl 
DNA     up to 400 ng 
CelI     1 µl 
H2O     to 25 µl 
Digest reactions were incubated in a thermocycler at 42°C and 2.5 µl Stop Solution was 
added to each sample following incubation. Results of control assay were analysed 
immediately by agarose gel electrophoresis of the samples using 2% TBE-agarose gels 
stained with Safeview. Gels were then imaged using a Fujifilm FLA-5000 scanner. 
2.14.1.3 Digestion of control DNA with T7 EndonucleaseI 
Re-annealed DNA was digested in the following reaction: 
10 x NEB Buffer 2   2.5 µl 
BSA (1 mg/ml)    1 µl 
DNA     up to 400 ng 
T7EI (10 U/µl)    1 µl 
H2O     to 25 µl 
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Digest reactions were incubated in a thermocycler at 37°C and 2.5 µl 250 mM EDTA was 
added to each sample following incubation. Results of control assay were analysed 
immediately by agarose gel electrophoresis of the samples using 2% TBE-agarose gels 
stained with Safeview. Gels were then imaged using a Fujifilm FLA-5000 scanner. 
2.14.2 RFLP Assays 
Genomic DNA was isolated from HEK 293 and K562 cells which had been transfected with 
vectors expressing TALENs. DNA extraction was performed using the standard protocol 
from the DNeasy Blood & Tissue Kit. 
A 1310 bp region of the VEZF1 promoter was PCR amplified using the following set up: 
5 x GC Buffer     10 µl 
GC Enhancer     5 µl 
10 mM dNTPs     1 µl 
10 µM F Primer hVEZF1pro-374F  2 µl 
10 µM R Primer hVEZF1pro+895R  2 µl 
DNA      100 ng 
One Taq (20 U/µl)    0.25 µl 
H2O      to 50 µl 
PCR reactions were incubated in a thermocycler programmed to perform the following 
temperature cycles: 
Temperature Time Number of Cycles 
94°C 30 seconds 1 
94°C 30 seconds 
30 56°C 30 seconds 
68°C 1.5 minutes 
68°C 5 minutes 1 
 
An aliquot of each PCR reaction was visualised using 1% TBE-agarose gel stained with 
Safeview and imaged using a Fujifilm FLA-5000 scanner. The remainder of the PCR 
reaction was purified using the standard protocol of the MinElute PCR purification kit. 
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2.14.2.1 RFLP Assay 1 Digestion 
Purified PCR product was subject to restriction digest as follows: 
10 x NEB Buffer 4   1 µl 
BSA (1 mg/ml)    0.5 µl 
DNA     250 ng 
BsrBI (10 U/µl)   0.5 µl 
BstEII HF (20 U/µl)   0.5 µl 
H2O     to 10 µl 
Digest reactions were incubated in a thermocycler at 37°C for 3 hours and the enzymes 
were heat inactivated by incubation at 80°C for 20 minutes. 
2.14.2.2 RFLP Assay 2 Digestion 
Purified PCR product was subject to restriction digest as follows: 
10 x NEB Buffer 4   1 µl 
BSA (1 mg/ml)    0.5 µl 
DNA     250 ng 
BstEII HF (20 U/µl)   0.5 µl 
RsaI (10 U/µl)    0.5 µl 
H2O     to 10 µl 
Digest reactions were incubated in a thermocycler at 37°C for 3 hours and the enzymes 
were heat inactivated by incubation at 80°C for 20 minutes. 
2.14.2.3 RFLP Assay 3 Digestion 
Purified PCR product was subject to restriction digest as follows: 
10 x NEB Buffer 4   1 µl 
BSA (1 mg/ml)    0.5 µl 
DNA     250 ng 
MspI (20 U/µl)    0.5 µl 
SacI HF (20 U/µl)   0.5 µl 
H2O     to 10 µl 
Digest reactions were incubated in a thermocycler at 37°C for 3 hours and the enzymes 
were heat inactivated by incubation at 80°C for 20 minutes. 
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2.14.2.4 DNA Bioanalyser analysis of RFLP fragments 
DNA bioanalyser analysis was carried out using a DNA-1000 kit for the Agilent 2100 
Bioanalyser by Julie Galbraith, Glasgow Polyomics. 
2.14.2.5 Agarose gel electrophoresis analysis of RFLP fragments 
Digested DNA samples were analysed by agarose gel electrophoresis. Half of each RFLP 
digest (5 µl) was run on TBE-agarose gels. RFLP assays 1, 2 and 3 were analysed on 2%, 
1.5% and 2.5% agarose gels respectively.  Samples were loaded in an equal volume (5 µl) 
gel loading buffer to prevent sample loss. Gels were stained post-run with 1 µg/ml 
ethidium bromide and destained using TBE buffer. Gels were then imaged using a Fujifilm 
FLA-5000 scanner. 
2.15 Sequence Analysis of TALEN-treated DNA 
2.15.1 PCR Amplification of TALEN-treated DNA 
Genomic DNA from both WT HEK 293 cells and HEK 293 treated with TALEN 15/16 v2 was 
PCR amplified using the following protocol: 
5 x GC Buffer     10 µl 
GC Enhancer     5 µl 
10 mM dNTPs     1 µl 
10 µM F Primer hVEZF1pro-374F  2 µl 
10 µM R Primer hVEZF1pro+895R  2 µl 
DNA      100 ng 
One Taq (20 U/µl)    0.25 µl 
H2O      to 50 µl 
PCR reactions were incubated in a thermocycler programmed to perform the following 
temperature cycles: 
 
Temperature Time Number of Cycles 
94°C 30 seconds 1 
94°C 30 seconds 
30 56°C 30 seconds 
68°C 1.5 minutes 
68°C 5 minutes 1 
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An aliquot of each PCR reaction was visualised using 1% TBE-agarose gel stained with 
Safeview and imaged using a Fujifilm FLA-5000 scanner. The remainder of the PCR 
reaction was purified using the standard protocol of the MinElute PCR purification kit. 
2.15.2 A-tailing of PCR products 
A-tailing reactions were set up as detailed below: 
10 x ThermoPol Buffer  1 µl 
50 mM MgCl2    1 µl 
10 mM dATP    1 µl 
DNA     218 ng 
NEB Taq Polymerase (5 U/µl)  1 µl 
H2O     to 10 µl 
Reactions were incubated in a hotblock at 70°C for 30 minutes. Amount of PCR product 
DNA required for ligation was calculated using the equation in section 2.4.8 and DNA was 
used directly from this reaction. Ligation reactions were set up as detailed in section 
2.4.8. 
2.15.3 Confirmation of insertion of TALEN-treated DNA into pGEM-T Easy 
Ligations were transformed as detailed in section 2.4.9 and transformation reactions 
were plated on LB Agar plates containing 50 µg/ml ampicillin. Blue/white screening was 
performed by addition of 100 µl 20 mg/ml X-gal and 100 µl 10mM IPTG to plates and 
allowing them to dry before plating bacteria. The plates were incubated at 37°C overnight 
and were then incubated at 4°C overnight to allow blue colour to fully develop. 
Several white colonies were analysed for the presence of inserted TALEN-treated DNA by 
colony PCR. Individual colonies were responded in 50 µl H2O and a 5 µl aliquot was taken 
into the following PCR reaction: 
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10 x ThermoPol Buffer  2.5 µl 
10 mM dNTPs    1 µl 
10 µM F Primer M13F   0.5 µl 
10 µM R Primer M13R  0.5 µl 
Colony suspension   5 µl 
NEB Taq Polymerase (5 U/µl)  0.2 µl 
H2O     to 25 µl 
PCR was performed using a thermocycler programmed to perform the following 
temperature cycles: 
Temperature Time Number of Cycles 
94°C 2 minutes 1 
94°C 30 seconds 
34 55°C 30 seconds 
72°C 1 minute 
72°C 10 minutes 1 
 
PCR products were resolved using a 1% TBE-agarose gel stained with Safeview. Gels were 
imaged using a Fujifilm FLA-5000 scanner. Amplification of inserted genomic PCR product 
was difficult due to the GC rich and complex nature of the inserted genomic DNA 
sequence. Therefore, clones which did not result in production of a PCR amplicon were 
further screened by restriction enzyme digest of plasmid DNA.  
Colony suspensions from potentially correct clones were cultured overnight by 
inoculating the remaining suspension into 2 ml LB containing 50 µg/ml ampicillin and 
shaking at 37°C for 16 hours. Plasmid DNA was isolated following the procedure outlined 
in section 2.4.10. 
Plasmid DNA of potentially positive clones was screened by restriction enzyme digest as 
detailed below: 
10 x NEB CutSmart Buffer  2.5 µl 
DNA     800 ng 
NotI HF (20 U/µl)    0.5 µl 
RsaI (10 U/µl)    1 µl 
H2O     to 25 µl 
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Digest reactions were incubated in a hotblock at 37°C for 3 hours. Digest products were 
analysed using 1% TBE-agarose gel electrophoresis. Gels were stained with Safeview and 
imaged using a Fujifilm FLA-5000 scanner. 
2.15.4 Sequence Analysis of TALEN-treated DNA 
Plasmid DNA samples were sequenced by Source Bioscience using M13F and M13R 
primers. Five clones containing WT HEK 293 DNA were analysed and compared to 
generate a consensus WT sequence with which to compare TALEN-treated DNA samples. 
Sequencing of clones containing TALEN-treated DNA was performed in duplicate and each 
run analysed comparatively to create a consensus sequence for that sample. Sequence 
analyses from all TALEN-treated clones were compared to WT consensus and mutations 
identified by alignments using MultAlin online software 
(http://multalin.toulouse.inra.fr/multalin/).  
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3 Chapter 3 
Zinc Finger Nucleases to Modify the VEZF1 Gene Promoter 
3.1 Introduction 
VEZF1 is a highly conserved vertebrate transcription factor that is essential in mice and is 
reported to have roles in vascular and haematopoietic development (Kuhnert et al., 2005, 
Zou et al., 2010). Recent ChIP-seq analyses in human cells have found that VEZF1 is bound 
at the promoters of most transcriptionally active genes in addition to many cell type-
specific enhancer elements (Low, 2013). RNA interference has been used to knockdown 
VEZF1 expression as an approach to studying VEZF1 function. However, this approach 
only leads to modest reductions in VEZF1 binding in vivo (Strogantsev, 2009). It is 
therefore desirable to knock out the VEZF1 gene in human somatic cells to study VEZF1’s 
gene regulatory functions. 
Gene targeting in somatic cell types is a very inefficient process. The creation of a double 
stranded DNA break (DSB) at a target locus promotes gene targeting via the homology 
directed DSB repair pathway (Brenneman et al., 1996, Choulika et al., 1995, Sargent et al., 
1997). Zinc finger nucleases (ZFNs) are engineered chimeric proteins that fuse zinc finger 
DNA binding domains with an endonuclease domain. The choice of pre-characterised zinc 
fingers of known DNA sequence specificity allows for the creation of endonucleases that 
can target a chosen genetic locus. In this chapter, I describe the design and assembly of 
custom zinc finger nucleases (ZFNs) that target the human VEZF1 gene promoter region 
and exon 1. Designed ZFNs were assembled using the Modular Assembly Kit (Wright et 
al., 2006), which was available at the time of starting this project. Purchasing an assembly 
kit was considered more cost effective, as it allowed us to construct multiple ZFN pairs 
and provided the option to create reagents for other genes of interest in our lab. The cost 
of purchasing a pair of pre-assembled and validated ZFNs is now around £4500 
(http://www.sigmaaldrich.com/catalog/product/sigma/cstzfnd?lang=en&region=GB) but 
this price was much higher when beginning this study. Assembled ZFNs will be 
subsequently used to promote gene targeting (Chapters 5 & 6). 
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3.2 Aims of this chapter 
 Design custom ZFNs that target the VEZF1 promoter 
 Construct ZFNs using the Zinc Finger Consortium Modular Assembly Kit 
 Develop expression vectors that produce obligate heterodimer ZFNs with 
enhanced cleavage properties 
3.3 Design of Custom Zinc Finger Nucleases  
3.3.1 Zinc Finger Nuclease Design using Zinc Finger Targeter (ZiFiT) 
ZiFiT is a web based tool (www.zifit.partners.org/ZiFiT_v3.3) which enables users to 
identify characterised zinc finger modules that can be used in ZFN designs for any given 
target sequence (Sander et al., 2007).  Created in collaboration with the Zinc Finger 
Consortium (www.zincfingers.org), it includes a database of the properties of the modular 
assembly zinc fingers (Wright et al., 2006).  ZiFiT searches can be restricted to suggest zinc 
finger proteins (ZFPs) from only one or all three module sets.  
A 400 bp DNA sequence covering 200 bp either side of the transcription start site of the 
human VEZF1 gene was searched using ZiFiT (Sander et al., 2007) to design two pairs of 
three-fingered ZFNs. I decided to utilise Sangamo modules that recognise GNN triplets, as 
these were the most well-characterised for use at the ends of, and within, zinc finger 
arrays (Section 1.3.3.1.2, (Liu et al., 2002)). During the construction of these ZF arrays, a 
study identified a number of zinc finger modules that consistently performed well in ZFNs 
(Section 1.3.3.1.4, (Kim et al., 2009)). A pair of four-fingered ZFNs was designed from this 
recommended module set.  ZFN design details are outlined in Table 3.1.  The VEZF1 
promoter is largely uncharacterised and promoter regulatory elements have not yet been 
identified. The three ZFN pairs described above were chosen as they recognise different 
locations around the transcription start site and 5’ untranslated region (UTR) of the VEZF1 
gene. Different target locations were chosen to account for differences in sequence 
accessibility. The ZFN pairs were chosen as they bind the VEZF1 promoter between two 
well positioned nucleosomes in a nucleosome depleted region (NDR, Figure 3.1). 
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Design 
name 
ZF module 
numbers 
DNA recognition 
residues 
DNA recognition 
sequence 
DNA binding configuration 
ZFN_35 
ZFN_36 
07-23-42 
06-30-50 
RDDR-RDDR-RDDR 
EGTR-DSAR-QSAR 
GCG-GCG-GCG 
GCC-GTC-GTT 
        3  2  1 
   CGCCGCCGCCGCTTTGTTGTCGCC 
   GCGGCGGCGGCGAAACAACAGCGG 
    1  2  3 
ZFN_37 
ZFN_38 
11-26-42 
11-23-36 
RDHR-DSHR-RDDR 
RDHR-RDDR-QGNR 
GGG-GGC-GCG 
GGG-GCG-GAA 
                   3  2  1 
   CCCGCCCGCCCCGGCGAAGCGGGG 
   GGGCGGGCGGGGCCGCTTCGCCCC 
    1  2  3 
ZFN_43 
ZFN_44 
098-091-132-078 
108-139-108-108 
HGHE-RDNE-RDHT-SADR 
DSCR-VSTR-DSCR-DSCR 
CGC-CAG-YGG-ACA 
GCC-GCT-GCC-GCC 
             4  3  2  1 
GCGCTGCCATGTTGAGGAGCCGCCGCTGCC 
CGCGACGGTACAACTCCTCGGCGGCGACGG 
 1  2  3  4 
Table 3.1 Zinc Finger Nuclease Designs 
ZFN designs using ZiFiT. The module reference numbers for the modular assembly kit are 
indicated for each ZF array (Wright et al., 2006). The amino acids at α-helix positions -1, 2, 4 & 
6 that recognise DNA bases are shown for each ZF module. The left ZFN recognises the bottom 
DNA strand and the right binds to the top strand.  ZF modules are numbered with the first 
finger being furthest away from the cleavage domain.  The DNA recognition sequence and 
binding configuration of each finger module to its target site are also shown. 
 
Figure 3.1 ZFN sites locate within a nucleosome depleted region of the VEZF1 promoter 
UCSC Genome browser view of Human hg19 chr17:56063000-56067000. The Refseq 
annotation of the VEZF1 gene is shown in blue, with Exon 1 depicted as a wide bar, preceded 
by a 5’UTR. Intron 1 is depicted by a line with chevrons indicating the direction of the gene. A 
1221 bp CpG island is depicted by a green bar. CAGE-seq data from K562 cells 
(FANTOM5:DRR008730) indicates that VEZF1 is a unidirectional promoter, with the K562 TSS 
located within the annotated 5’UTR. ENCODE ChIP-seq analysis of H3K27ac 
(wgEncodeEH000043), H3K4me3 (wgEncodeEH000048) and H2A.Z (wgEncodeEH001038) 
indicate that highly positioned nucleosomes enriched for these modifications flank a ~560 bp 
nucleosome depleted region (NDR, red bar). The cleavage profile and individual cuts of DNAse I 
(wgEncodeEH000480) are shown beneath, indicating that DNAse I cuts either side of the 
positioned nucleosomes. The locations of the ZFN recognition sites are shown above (black 
bars). 
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3.4 Construction of Designed Zinc Finger Expression Sequences 
3.4.1 Modular Assembly of Designed Zinc Fingers 
Complete zinc finger expression sequences were constructed via modular assembly 
(Wright et al., 2006). Each zinc finger module is joined onto an array individually, starting 
with the addition of ZF2 onto ZF1, followed by the addition of ZF3 and ZF4 (Figure 3.2). 
Each ZF module plasmid is flanked by a common set of restriction enzyme recognition 
sequences that permit the sub-cloning of ZF modules in a manner that retains the open 
reading frame of a ZF array. The receiving plasmid, for ZF1 for example, is opened using 
AgeI and BamHI. The donating insert, ZF2 for example, is excised using XmaI and BamHI. 
The compatible CCGG 5’ overhangs of AgeI and XmaI permit ligation of ZF2 onto ZF1. The 
insert fragment carries an AgeI recognition site, which is used in repeat rounds to add 
ZF3, ZF4 and so on. The addition of each zinc finger module adds 96 bp to the receiving 
vector. Analysis of the XbaI – BamHI fragment size is used to confirm the inclusion of each 
ZF module after each assembly step. Plasmids containing 1, 2, 3 or 4 ZF modules yield a 
96, 192, 288 or 384 bp XbaI – BamHI fragment, respectively (Figure 3.3). The completed 
zinc finger arrays 35, 36, 37, 38, 43 and 44 (Table 3.1) were checked by Sanger sequencing 
(Appendix II) prior to sub-cloning into ZFN expression vectors, as described below. 
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Figure 3.2 Construction of Zinc Finger Arrays by Modular Assembly 
Schematic showing the stepwise assembly of four finger array plasmid. Receiving plasmids are 
opening using AgeI and BamHI. Donating fragments are excised using XmaI and BamHI. 
Compatible AgeI and XmaI overhangs allow for assembly. The carry over of a new AgeI 
recognition site with each insert allows for repeated round of assembly. XbaI and BamHI are 
used to excise the whole ZF array for size analysis by agarose gel electrophoresis. 
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Figure 3.3 Cloning of Zinc Finger Arrays 
Agarose gel electrophoresis of XbaI – BamHI restriction fragments from ZF array plasmids. 
Plasmids containing 1 (lane 5), 2 (lane 4), 3 (lane 9) or 4 (lane 11) ZF modules yield a 96, 192, 
288 or 384 bp  XbaI – BamHI fragment, respectively. Single digest controls with BamHI and 
XbaI individually (Lanes 2 & 3) confirm each enzyme’s activity by linearising the plasmid. 
3.5 Construction of Designed Zinc Finger Nucleases 
3.5.1 FokI domain mutagenesis 
ZFNs utilise the cleavage domain of the Type II restriction enzyme FokI, which has no DNA 
sequence specificity of its own (Li et al., 1992). FokI functions as a homodimer when 
mediating endonuclease activity (Bitinaite et al., 1998). A number of groups have 
undertaken mutagenesis of FokI such that it only functions as an obligate heterodimer 
(Section 1.3.4.1.2). Obligate heterodimer ZFNs have been found to have greatly reduced 
off-target cleavage compared to their wild type FokI counterparts (Miller et al., 2007). 
FokI expression plasmids pMLM290 (Addgene 21872) and pMLM292 (Addgene 21873) 
which encode the “KK” (E490K, I538K) and “EL” (Q486E and I499L) heterodimers mutants 
were acquired. The KK ZFN is employed on the left and the EL ZFN is employed to the 
right of the target cleavage site. The EL/KK heterodimer mutations have been shown to 
reduce FokI cleavage activity by three fold (Miller et al., 2007). One study described FokI 
cleavage domain mutations that increased endonuclease activity without any observed 
increase in cytotoxicity (Guo et al., 2010). This and subsequent studies have shown that 
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these “Sharkey” mutations (S418P and K441E) can be used to increase the performance 
of heterodimer FokI mutant ZFNs (Doyon et al., 2011, Perez-Pinera et al., 2012). 
I decided to combine the Sharkey mutations with both the EL and KK FokI mutants to 
allow the study of whether these mutations can result in better ZFN performance. The 
inclusion of the Sharkey mutations required two single base pair changes at codon 418, 
TCC -> CCC, (S418P) and at codon 441, AAA -> GAA (K441E) (Figure 3.4). Codons 418 and 
441 lie within a 274 bp HindIII restriction fragment, so the Sharkey mutant fragment was 
therefore generated via DNA synthesis. The Sharkey fragment was sub-cloned into the EL 
and KK FokI plasmids using the HindIII restriction sites. The resulting constructions were 
checked for the correct orientation of the Sharkey fragment using BamHI and AgeI 
digestion (Figure 3.5). The KK-S and EL-S encoding plasmids (Table 3.2) were checked by 
Sanger sequencing (Appendix II) prior to the creation of ZFN expression vectors, as 
described below. 
 
 
Figure 3.4 Modification of the FokI coding sequences to incorporate Sharkey mutations 
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Figure 3.5 Construction of plasmids encoding Sharkey FokI heterodimer mutants 
A) Scale plasmid map of pFOKI_KK-S.  The KK obligate heterodimer (E490K, I538K) and Sharkey 
(S418P, K441E) FokI mutations are indicated. B) Agarose gel electrophoresis of pFOKI_KK-S 
plasmid clones digested with AgeI and BamHI. Sharkey fragments correctly oriented between 
the HindIII sites result in 654 bp AgeI - BamHI fragment (Lanes 5, 8, 10 – 12). Single digest 
controls with AgeI and BamHI individually (Lanes 13 & 14) confirm each enzyme’s activity by 
linearising the plasmid. The control is the parent plasmid pFOKI_KK. 
Plasmid Name Source FokI Mutation 
pFOKI_KK pMLM290 (Addgene 21872) E490K, I538K 
pFOKI_EL pMLM292 (Addgene 21873) Q486E, I499L 
pFOKI_KK-S Modification of pMLM290 E490K, I538K, S418P, K441E 
pFOKI_EL-S Modification of pMLM292 Q486E, I499L, S418P, K441E 
Table 3.2 Plasmids encoding mutant FokI domains 
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3.5.2 Construction of Zinc Finger Nuclease Expression Vectors using Assembled ZF 
Domains 
The three pairs of ZF arrays were subcloned into the pFOKI vectors via the XbaI and 
BamHI restriction sites. The insertion of the ZF arrays into the resulting pZFN vectors was 
checked by restriction analysis with NheI and EcoRI (Figure 3.6).  The ZFN expression 
vectors created are summarised in Table 3.3. The pFOKI vectors, which are derived from 
pMLM290/292, already contain a CMV promoter, SV40 enhancer and polyA elements. 
The pZFN vectors are therefore ready for the expression of ZFNs in mammalian cells. 
 
 
Figure 3.6 Construction of zinc finger nuclease expression vectors 
A) Scale map of pZFN44-FokIKK. The location of the sequences encoding the zinc fingers 108, 
139, 108 and 108 and the FokI expression cassette. B) Agarose gel electrophoresis of pZFN44-
FokIKK plasmid clones digested with EcoRI and NheI. Plasmids containing the four finger ZF44 
contain a 590 bp fragment (lanes 2-5). The parental pFOKI-KK plasmid contains a 206 bp 
fragment (lane 6). Single digest controls with EcoRI or NheI alone (Lanes 7 and 8) confirm each 
enzyme’s activity by linearising the plasmid. 
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Plasmid Name FokI Mutation DNA binding configuration 
pZFN35-FokI-KK E490K, I538K         3  2  1 
   CGCCGCCGCCGCTTTGTTGTCGCC 
   GCGGCGGCGGCGAAACAACAGCGG 
    1  2  3 pZFN36-FokI-EL Q486E, I499L 
pZFN37-FokI-KK E490K, I538K                    3  2  1 
   CCCGCCCGCCCCGGCGAAGCGGGG 
   GGGCGGGCGGGGCCGCTTCGCCCC 
    1  2  3 pZFN38-FokI-EL Q486E, I499L 
pZFN43-FokI-KK E490K, I538K  
 
 
                   4  3  2  1 
GCGCTGCCATGTTGAGGAGCCGCCGCTGCC 
CGCGACGGTACAACTCCTCGGCGGCGACGG 
1  2  3  4 
pZFN44-FokI-EL Q486E, I499L 
pZFN43-FokI-KKS E490K, I538K, S418P, K441E 
pZFN44-FokI-ELS Q486E, I499L, S418P, K441E 
Table 3.3 Mammalian expression plasmids encoding ZFNs assembled in this study 
 
3.6 Discussion 
This chapter has described the design and construction of mammalian expression 
plasmids that encode zinc finger nucleases that target the human VEZF1 promoter. The 
ZiFiT design tool was straightforward to use and enabled the design of ZFNs that use 
specific sets of zinc finger modules that are reported to function in the context of ZFNs in 
mammalian cells. Standardised plasmid libraries and protocols were utilised to assemble 
zinc finger arrays from individual modules selected in the design process.  Custom zinc 
finger arrays were cloned into obligate heterodimer FokI nuclease expression vectors, and 
one pair was assembled into an advanced FokI nuclease architecture that should improve 
cleavage activity. These ZFNs are later used in experiments to modify the VEZF1 gene 
promoter via HDR and NHEJ (Chapters 5 & 6). 
While straightforward, modular assembly is a laborious and time consuming method of 
constructing zinc finger arrays as each finger must be added in sequence. The repetitive 
nature of the zinc finger array sequences can be prone to recombination during the 
cloning stages, especially when the array is longer than three ZF modules. In fact, greater 
difficulties were faced as lytic phage contamination accompanied our use of the zinc 
finger consortium plasmid library. The contamination prevented successful plasmid 
culture through the West laboratory for over four months until new methods for 
decontamination and waste control, together with physical separation of three areas for 
media preparation, inoculation and plasmid preparation were established in the 
99 
 
laboratory. Great care must be taken when receiving plasmids and bacterial stocks from 
outside laboratories. 
Since the advent of this project, there have been major advances in assembling zinc finger 
arrays. Construction methods such as OPEN (Maeder et al., 2009) and CoDA (Sander et 
al., 2011b) greatly accelerate assembly, regardless of whether low throughput in an 
academic group or high throughput in a facility are required. Furthermore, the falling cost 
of DNA synthesis enables individual groups to create ZFN expression constructs more 
readily. 
More importantly, a new technology arose during the course of this work, where DNA-
binding domains from the TALE transcription factors have been fused to FokI domain to 
create TALE nucleases (TALENs). TALENs have been found to be more reliable than ZFNs 
and the proteins have a simple DNA-recognition code, simplifying the construction 
process. The development and application of TALE proteins that target the human VEZF1 
promoter is described in the following chapters. 
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4 Chapter 4 
Development of TALE proteins that target the VEZF1 gene 
4.1 Introduction 
Transcription activator like effectors (TALEs) are a class of DNA-binding proteins from 
Xanthomonas spp. which permit fusion with a variety of protein domains to direct site-
specific DNA cleavage or gene regulatory functions (Section 1.4). TALE proteins contain 
tandem arrays of ~34 amino acid repeats, where each repeat interacts with a single DNA 
base pair. Two amino acids in each repeat, called the repeat variable diresidue (RVD), 
mediate base interactions. The TALE repeats are modular, such that TALE proteins can be 
designed to target any sequence of choice. TALE protein fusions with the catalytic domain 
of the FokI endonuclease, known as TALE nucleases (TALENs), have been shown to be 
efficient at directing specific targeted genetic mutations in a wide variety of species 
including mammals (Section 1.4.2). The simplicity of the TALE DNA recognition code, 
where only 4 repeats are required, coupled with the high reliability of TALE proteins are 
major advantages compared to zinc fingers. Furthermore, the ability to assemble long 
TALE proteins with over 20 bp of specificity greatly reduces confounding off-target effects 
(Miller et al., 2011, Beumer et al., 2013, Mussolino et al., 2011). 
A number of molecular cloning strategies have been devised to allow the rapid assembly 
of repetitive TALE protein expression constructs, whether for low throughput individual 
groups or for high throughput facilities (Section 1.4.6). In this chapter, the use of one of 
these strategies to create TALE proteins that target the human VEZF1 promoter is 
described. I developed expression vectors that allow the creation of TALE-repressor 
proteins that are designed to give a readout of TALE binding performance at the VEZF1 
promoter in human cells. Functional TALE-repressors will also be a useful resource for the 
knockdown of VEZF1 expression. Functional TALE domains could be subsequently 
transferred into TALE-nuclease expression vectors for use in VEZF1 gene knockout 
strategies. 
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4.2 Aims of this chapter 
 Design and construct custom TALE DNA-binding domains that target the human 
VEZF1 gene promoter 
 Develop expression vectors for the creation of TALE-repressor proteins 
 Determine the performance of TALE-repressor proteins in human cells 
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4.3 Design of TALE DNA-binding domains 
Previous studies have indicated that there are some target DNA sequence constraints, 
particularly at the start of a TALE repeat, which should be considered to increase the 
chance of obtaining high affinity TALE proteins (Boch et al., 2009, Moscou and 
Bogdanove, 2009, Cermak et al., 2011). TALE protein recognition sites tend to start with a 
T then the first two RVD domains should be not T and not A, respectively. Furthermore, 
the most functional TALEs tend not have recognition sites that end with a G (Cermak et 
al., 2011). Given that the end goal was to create functional TALENs, the TALE DNA-binding 
proteins were designed so they could function both individually in TALE repressors, and as 
in pairs in TALENs. A number of studies published at the time recommended that TALE 
domains be 15 - 20 RVDs long and suggested various spacer sizes ranging from 15 - 31 bp 
in size (Cermak et al., 2011, Miller et al., 2011, Mussolino et al., 2011, Li et al., 2011b). 
The TALE-NT webtool (www.tale-nt.cac.cornell.edu) was used to design TALENs using 
these guidelines within a 400 bp region of the human VEZF1 promoter (200 bp either side 
of the TSS) (Doyle et al., 2012) to generate a design output of all possible TALE domains 
that could target this region.   
I chose to develop TALE proteins of 16 - 29 repeats in length, to investigate whether 
longer TALEs result in better performance, either by increased affinity or specificity for 
the target sequence. Furthermore, I selected to test TALEN designs where the DNA spacer 
between the left and right TALEN targets was either 15 or 30 bp in length. While a 15 bp 
spacer had been reported by various groups as being the optimal distance for FokI 
dimerisation between two TALEs (Cermak et al., 2011, Miller et al., 2011), larger spacers 
of up to 30 bp had also been demonstrated to be advantageous (Li et al., 2011b). Ten 
TALE protein designs were chosen, which can be combined into six TALEN pairs (Table 
4.1).  The TALE designs were selected as they bind in the nucleosome depleted region of 
the VEZF1 promoter (Figure 4.1). In total, the selected TALENs are design to cleave at 
three different locations within the VEZF1 promoter and incorporate different TALE 
lengths and TALEN spacers (Figure 4.2). TALE pair 15/16 straddles the predicted TSS of 
VEZF1 and the remaining five TALE pairs bind at in the 5’ untranslated region (UTR).  All of 
these TALENs are compatible with the gene targeting strategy to knockout VEZF1 
described in Chapter 5.
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Design RVD Sequence DNA Recognition Sequence Configuration 
Left-X-Right 
TALE_13 NN NG HD NN HD HD NG HD HD NG HD HD NN NN HD 
NG 
          TALE 13 
       |||||||||||||||| 
GTCGCCTCCTCCGGCT---AGTGGGGAGGAGGGGGGTCGGCCGCCGC 
CAGCGGAGGAGGCCGA---TCACCCCTCCTCCCCCCAGCCGGCGGCG 
                   |||||||||||||||||||||||||||| 
                     TALE 14 
 
16-30-28 TALE_14 NN HD NN NN HD NN NN HD HD NN NI HD HD HD HD 
HD HD NG HD HD NG HD HD HD HD NI HD NG 
TALE_15 HD NN HD HD NN HD HD NN HD NN NN NG NN NN NG 
NN HD NN NG 
             TALE 15 
        ||||||||||||||||||| 
CGCCGCCGCGGTGGTGCGT---AAGTGGCCGCGCTCGGCGCTGCC 
GCGGCGGCGCCACCACGCA---TTCACCGGCGCGAGCCGCGACGG 
                      ||||||||||||||||||||||| 
                     TALE 16 
 
19-15-23 TALE_16 NN NN HD NI NN HD NN HD HD NN NI NN HD NN HD 
NN NN HD HD NI HD NG NG 
TALE_17/19 NN HD HD NN HD HD NN HD HD NN HD HD NN HD HD 
NN HD HD NN HD NG NG NG NN NG NG NN NG 
 
         TALE 17/19 
|||||||||||||||||||||||||||| 
GCCGCCGCCGCCGCCGCCGCTTTGTTGT---AGGAGGCTCCCCGAGCGGGGGGAGTGGGG 
CGGCGGCGGCGGCGGCGGCGAAACAACA---TCCTCCGAGGGGCTCGCCCCCCTCACCCC 
                               ||||||||||||||||||||||||||||| 
                                    TALE 18       TALE 20 
 
28-15-22 TALE_18 HD HD HD HD HD HD NN HD NG HD NN NN NN NN NI 
NN HD HD NG HD HD NG 
TALE_20 HD HD HD HD NI HD NG HD HD HD HD HD HD NN HD 
NG HD NN NN NN NN NI NN HD HD NG HD HD NG 28-15-29 
TALE_21/23 NN NG NG NN NG HD NN HD HD NG HD HD NG HD HD 
NN NN HD NG 
 
        TALE 21/23 
     ||||||||||||||||||| 
GTTGTCGCCTCCTCCGGCT---AGGAGGGGGGTCGGCCGCCGCAGCCATGG 
CAACAGCGGAGGAGGCCGA---TCCTCCCCCCAGCCGGCGGCGTCGGTACC 
                      ||||||||||||||||||||||||||||| 
                    TALE 22        TALE 24 
 
19-30-25 TALE_22 NN NN HD NG NN HD NN NN HD NN NN HD HD NN NI 
HD HD HD HD HD HD NG HD HD NG 
TALE_24 HD HD NI NG NN NN HD NG NN HD NN NN HD NN NN 
HD HD NN NI HD HD HD HD HD HD NG HD HD NG 19-30-29 
Table 4.1 Designs for TALENs that target the human VEZF1 gene promoter
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Figure 4.1 TALEN sites locate within a nucleosome depleted region of the VEZF1 promoter 
UCSC Genome browser view of Human hg19 chr17:56063000-56067000. The Refseq 
annotation of the VEZF1 gene is shown in blue, with Exon 1 depicted as a wide bar, preceded 
by a 5’UTR. Intron 1 is depicted by a line with chevrons indicating the direction of the gene. A 
1221 bp CpG island is depicted by a green bar. CAGE-seq data from K562 cells 
(FANTOM5:DRR008730) indicates that VEZF1 is a unidirectional promoter, with the K562 TSS 
located within the annotated 5’UTR. ENCODE ChIP-seq analysis of H3K27ac 
(wgEncodeEH000043), H3K4me3 (wgEncodeEH000048) and H2A.Z (wgEncodeEH001038) 
indicate that highly positioned nucleosomes enriched for these modifications flank a ~560 bp 
nucleosome depleted region (NDR, red bar). The cleavage profile and individual cuts of DNAse I 
(wgEncodeEH000480) are shown beneath, indicating that DNAse I cuts either side of the 
positioned nucleosomes. The locations of the TALEN recognition sites are shown above (black 
bars). 
 
Figure 4.2 TALE target sites at the human VEZF1 gene promoter 
Cartoon demonstrating the location of TALEs within the VEZF1 gene.  Designed TALEs can be 
used individually as TALE repressors or as pairs (as indicated by colour coding) when co-
expressed as TALENs. 
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4.4 Assembly of Designed TALEs 
The Golden Gate (GG) assembly method, developed by the Voytas group, was chosen to 
enable the straightforward assembly of TALE repeats into the TALE protein PthXoI 
(Cermak et al., 2011). This system assembles up to ten repeats at a time in a single GG 
reaction. Up to three sets of arrays are joined with a last repeat and the rest of the TALE 
encoding sequences in a second GG reaction to create TALE proteins up to 31 repeats in 
length. This GG assembly system utilises the type IIS restriction enzymes BsaI or Esp3I, 
which cleave a number of bases away from their recognition site. Both enzymes generate 
4 base overhangs of any sequence. The overhang sequences can therefore be used to 
direct the ordered ligation of a mixed reaction (Figure 4.3). Another favourable property 
of these two enzymes is that they are active in T4 DNA ligase buffer, which allows rounds 
of sequential digestion and ligation reactions to be performed in the same tube. The 
assembly vectors are designed in a way that the BsaI or Esp3I recognition sequences are 
not retained upon assembly, so the GG reaction can only proceed in the desired direction.  
 
Figure 4.3 Golden Gate Assembly 
Golden Gate (GG) assembly employs type IIS restriction enzymes, which cleave outside of their 
recognition sites. The vectors in the GG kit are designed such that digest with Esp3I creates 
complementary overhangs which will assemble the TALE repeats in the correct order. The first 
10 RVDs are assembled into TAL-A, the next 10 are assembled into TAL-B and any additional 
RVDs in TALEs more than 20 RVDs long are assembled into TAL-C. TAL-A/B/C vectors are then 
digested and RVDs are combined with pRFP-TALE-SID to create full length TALEs in pTALEREP 
expression vector (adapted from Cermak et al., 2011). 
The Voytas GG system consists of plasmids encoding the four TALE modules NI, HD, NN 
and NG (which recognise A, C, G and T, respectively) with flanking overhang sequences 
that direct assembly into positions 1 to 10 of an array (40 plasmids). There are also array, 
last repeat and expression vector plasmids (Figure 4.4). The assemblies of the first, 
second and an optional third set of TALE repeats were named TAL-A, TAL-B and TAL-C. In 
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order to prevent errors at the bench, the output from the TALE-NT website was used to 
create a spreadsheet file that summarised the picking of plasmids to be added into the 
GG reactions (Figure 4.5). 
 
Figure 4.4 Golden Gate array, last repeat and backbone plasmids 
Schematic of plasmid vectors in the GG kit for assembly of TALEs. To assemble TALEs of fewer 
than 20 RVDs, the first 10 RVDs are assembled in pFUS_A and the remainder are assembled in 
a pFUS_B vector. Assembly of TALEs containing more than 20 RVDs in total is carried out by 
inserting the first 10 RVDs into pFUS_A30A. RVDs 11-20 of long TALE domains are assembled 
into pFUS_A30B and the remainder are constructed in a pFUS_B vector. The choice of pFUS_B 
depends on the number of RVDs in the assembly (e.g. to assemble 5 RVDs use pFUS_B5). pFUS 
assemblies are carried out by digest with BsaI, sequences of overhangs created are in blue. The 
pFUS RVD assemblies can be combined, with pLR (last repeat) into pTAL vectors by digest with 
Esp3I, sequences of overhangs created are in green (Cermak et al., 2011). 
GG assembly reactions were performed on a thermocycler (10 cycles of 37°C/5minutes, 
16°C/10minutes) and then transformed into competent cells and transformants selected 
via blue/white screening.  White colonies were selected and subjected to screening by 
colony PCR to determine the number of RVD domains contained within the vector (Figure 
4.6 A).  Colony PCR of TALE repeat assemblies with Taq polymerase results in a laddered 
banding pattern due to termination of the PCR product as a result of the repetitive nature 
of the sequence.  Nevertheless, the main product represented the expected length for 
each TALE repeat for the majority of clones. The only exceptions are plasmid clones from 
failed assemblies, which appear as re-ligated empty pTAL vector (e.g. Figure 4.6 A, lanes 6 
and 7).  One plasmid clone for each assembly was checked for the correct insert length by 
restriction digestion (Figure 4.6 B). This confirmed the integrity of the TALE repeats and 
that aborted elongation was responsible for the laddered colony PCR products. In total, 
27 pTAL plasmids containing the TALE repeats were constructed and these were next 
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combined in the final stage of GG assembly to create full length TALEs in expression 
vectors. The identity of each repeat in the assembly was confirmed by Sanger sequencing 
(Figure 4.7). 
 
Figure 4.5 Plasmid Pick Sheet for Golden Gate Assembly of TALEREP plasmids 
Example of a plasmid pick sheet used to set up Golden Gate reactions.  Plasmids containing 
each RVD in the desired position in the final TALE array are combined in a tube with pTAL_A, 
pTAL_B or final expression plasmid with restriction enzyme BsaI and T4 DNA ligase to undergo 
a Golden Gate reaction.  The pick sheet format above allows for quick and easy setup.
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Figure 4.6 Golden Gate assembly of TALE repeats 
(A) Agarose gel electrophoresis of TALE repeat length after GG assembly. Colony PCR using the 
primers pCR8_F1 and pcR8_R1 from three transformants resulting from three pTAL-B GG 
assembly reactions are shown. Colony PCR from cells containing empty pFUS-B vector yield a 
250 bp product, as found in lanes 6 and 7. Successful GG assembly adds 100 bp per TALE 
repeat. The expected PCR product sizes for 7-mer (lanes 2-4) 8-mer (lane 5) and 5-mer (lanes 
8-10) repeats are 950, 1050 and 750 bp, respectively. Aborted PCR products of 100 bp 
decreasing sizes are likely to be due to the repetitive nature of the TALE repeat template. (B) 
Agarose gel electrophoresis of pTAL-B/C plasmids prepared from colonies analysed in part A. 
pTAL-B/C plasmids containing 7 (lane 18 (lane 2) or 5 (lane 3) TALE repeats were digested with 
AflII and XbaI to excise760 860 and 560 bp repeat fragments, respectively.  
 
Figure 4.7 Sequence analysis of TALE assemblies 
An example Sanger sequencing analysis of a pTAL plasmid resulting from GG assembly of TALE 
repeats. pTAL-A-13, a plasmid consisting of the first set of 10 repeats for the TALE 13 protein 
assembled into pFUS_A, was sequenced using the primers pCR8_F1 and pCR8_R1. The 
expected RVD composition is listed at the top.  Bases highlighted in yellow have been assigned 
following inspection of the chromatogram data. 
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4.5 Development of a TALE transcriptional repressor expression vector 
While the Voytas Golden Gate system allows for the rapid assembly of TALE repeats, it 
lacks a mammalian expression vector that the repeats can be assembled into to form 
functional TALE effector proteins. Rather than employ bacterial or yeast one hybrid and 
related assays to score for the DNA-binding activity of TALE proteins, I preferred to assess 
the performance of TALE proteins at their intended targets in human cells. I decided to 
construct a TALE repressor expression vector that is compatible with the Voytas GG 
assembly system.  This ability of TALE-repressor expression to mediate the repression of 
VEZF1 would both confirm the ability of TALE proteins to bind at their intended target and 
offer another tool for VEZF1 knockdown. 
Szurek et al. (2002) demonstrated that the TALE protein AvrBs3 with a truncated version 
of the N-terminus (Δ152) was fully capable of reaching its intended DNA binding site and 
so the amino acids deleted in this truncation were dispensable for DNA binding activities 
of TALEs.  Miller et al. (2011) employed this truncation to develop highly active TALEN 
nuclease architectures.  This study also demonstrated that the truncation of the C-
terminus of TALE protein AvrBs3 to 63 amino acid residues in length (+63 truncation) 
resulted in TALENs with a higher DNA-binding activity than full length TALE proteins 
(Miller et al., 2011). I sought to incorporate these truncations into our TALE repressor 
vectors. 
Cong et al. (2012) recently tested the performance of several transcription repression 
domains when fused to TALE proteins in HEK293 cells. The SIN Interaction Domain (SID) 
was reported to mediate the strongest repression of the target gene. The SID domain is a 
fragment of the Mad1 transcription factor, which mediates the recruitment of the 
SIN3A/B co-repressor complex (Ayer et al., 1996). The SIN3 proteins act as a scaffold to 
bring together many co-repressor proteins that mediate histone modification and 
chromatin remodelling. The repression activities include histone deacetylation 
(HDAC1/2), histone H3K4 demethylation (KDM5A), H3K9 methylation (SUV39H1, ESET) 
(van Oevelen et al., 2008, Yang et al., 2003). I therefore decided to develop an expression 
vector that encodes TALE-SID proteins following the TALE repressor architecture 
described by Cong et al. In order to track TALE-repressor expression by flow cytometry, I 
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decided to express turboRFP and the TALE-SID proteins from the same transcript, using an 
intervening 2A self-cleavage peptide sequence (Figure 4.8). 
 
Figure 4.8 TALE repressor expression cassette 
Schematic representation of the proteins encoded by pTALEREP vectors. Abbreviations: turbo 
RFP – red fluorescent protein, p2A – porcine 2A self cleaving peptide, TAL NT – TALE Δ152 N-
terminus, RVD – repeat variable diresidue, TAL CT – TALE +63 C-terminus, SID – SIN interaction 
domain. 
Three rounds of DNA sub-cloning were required to produce the pRFP-TALE-SID vector to 
be used in GG assembly reactions. Firstly, the sequences encoding turboRFP were PCR 
amplified from the lentiviral vector pTRIPZ (Thermo) using the primers RFP5_Nhe_Age 
and RFP3_Bam_Not, which were then sub-cloned into pEGFP-N1 using NheI and NotI. This 
creates pRFPturbo, which offers CMV-driven RFP expression (Figure 4.9 and Figure 4.10). 
In the second step, a 180 bp fragment encoding a P2A peptide and the SID domain 
flanked by restriction sites was synthesised (Figure 4.11 A). This fragment was inserted 
into pRFPturbo using BamHI and NotI to create pRFP-SID (Figure 4.11 B and Figure 4.12 
A). Lastly, a 1027 bp BglII-BamHI encoding TALE N- and C-termini with an internal lacZ 
fragment was sub-cloned from pCAG_T7_TALEN (Addgene 37184) into the single BglII site 
of pRFP-SID to form pRFP-TALE-SID (Figure 4.13). Restriction digestion and Sanger 
sequencing was used to check each stage of sub-cloning (Figure 4.12 B, not shown). 
 
Figure 4.9 Construction of pRFPturbo 
Agarose gel electrophoresis of restriction digested plasmid DNA from transformants gained 
following ligation of RFPturbo into pEGFP-N1 to create pRFPturbo.  Digest of pRFPturbo with 
NheI & NotI results in 722 bp band (lanes 2 – 5).  Digest of pEGFP-N1 with NheI & NotI results 
in 814 bp band (lanes 2 – 5).   
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Figure 4.10 Plasmid map of pRFPturbo 
Scale map of pRFPturbo. Sequences encoding turboRFP (derived from pTRIPZ, Thermo) are 
located in between the NheI and NotI sites. TurboRFP is expressed from the CMV promoter 
(green) using a downstream SV40 enhancer (red). 
A 
>P2A_SID 
GGATCCGGCGCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACGTGGAGGAGAACCCCGG
CCCCAGATCTATGAACATCCAGATGCTGCTGGAGGCCGCCGACTACCTGGAGCGCCGCGAGC
GCGAGGCCGAGCACGGCTACGCCAGCATGCTGCCCTGAATCGATGCGGCCGCGATC 
B 
 
Figure 4.11 Plasmid map of pRFP-SID 
A) Synthetic DNA fragment encoding a P2A peptide (brown, derived from (Kim et al., 2011)) 
and the SID domain (blue, derived from Cong et al. (2012)). BamHI (orange), BglII (green), ClaI 
(red) and NotI (purple) restriction sites used for sub-cloning are shown. B) Scale map of pRFP-
SID. Sequences encoding the P2A-SID peptide are located in between the BamHI and NotI 
sites. 
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Figure 4.12 Restriction analysis of plasmid constructs  
(A) Agarose gel electrophoresis of restriction digested plasmid DNA from transformants gained 
following ligation of P2A_SID into pRFPturbo to create pRFP-SID.  Digest of pRFPturbo with 
NheI & NotI results in 722 bp band (lane 2).  Addition of P2A_SID adds 159 bp, therefore 
positive clones result in 881bp product (lane 3). (B) Agarose gel electrophoresis of restriction 
digested plasmid DNA from transformants gained following ligation of TALE N- and C-termini 
to create pRFP-TALE-SID, which adds 1027 bp. Digest of pRFP-TALE-SID with NheI & NotI 
results in 1908 bp band (lane 2). 
 
Figure 4.13 Plasmid map of pRFP-TALE-SID 
Scale map of pRFP-TALE-SID. Sequences encoding the N- and C-termini of the PthXo1 TALE 
protein (derived from pCAG_T7_TALEN) are located between the P2A and SID coding 
sequences. A lacZ gene for blue white selection is located within the TALE domain. The Esp3I 
sites are compatible with the Voytas GG assembly of TALE repeats (Cermak et al., 2011), which 
would remove the lacZ gene. 
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4.6 Assembly of TALE repressor expression vectors 
The production of TALE effector expression plasmids requires the GG assembly of TALE 
repeats from pTAL vectors (Section 4.4) into an expression plasmid, in this case pRFP-
TALE-SID (Section 4.5). The Voytas GG assembly is arranged such that cleavage of the 
vectors with the type IIS restriction enzyme Esp3I generates cohesive ends that facilitate 
the ordered unidirectional assembly of TALE domains into the pRFP-TALE-SID vector. A 
plasmid pick sheet just as was designed for use in construction of the pTAL_A/B/C 
plasmids (Figure 4.5) was devised to aid in the reaction set up for the final step GG 
assembly of TALE repressors (Figure 4.14). The resulting pTALEREP vectors encode a fully 
assembled TALE-SID protein, which is co-expressed with turboRFP from a shared CMV 
promoter (Figure 4.15). Plasmid DNA was prepared from white colonies resulting from 
transformation of GG assembly reactions. These pTALEREP plasmids were checked for the 
correct assembly of TALE repeats by restriction digestion with StuI and BamHI (Figure 
4.16). 
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Figure 4.14 Plasmid pick sheet for the assembly of pTALEREP TALE repressor expression plasmids 
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Figure 4.15 Plasmid map of pTALEREP-13 
Scale map of pTALEREP-S-13 as an example of pTALEREP vectors. pTALEREP vectors encode a 
fully assembled TALE-SID protein that is co-expressed with turboRFP from a shared CMV 
promoter. StuI and BamHI sites used to confirm TALE assembly are shown.  TALE 13 contains 
16 RVD TALE repeats (red triangles). 
 
Figure 4.16 Restriction analysis of pTALEREP plasmids 
Agarose gel electrophoresis of pTALEREP plasmids digested with StuI and BamHI. Digestion 
cleaves the plasmid backbone into 3450 bp and 350 bp (not shown) fragments and drops out 
the full length TALE repressor coding sequences (sizes indicated below lanes). Each of the 
vectors shown contains the expected size of dropout fragment. 
116 
 
4.7 TALE repressor-mediated silencing of the human VEZF1 gene 
HEK293 cells were transfected with individual pTALEREP plasmids. Two independent 
bioreplicates of TALE repressor transfection were performed. The level of turbo RFP 
expression three days post-transfection was monitored by flow cytometry. Approximately 
40-50% of cells have high levels of RFP expression at this time (Table 4.2), although a 
further 30-40% have low levels of RFP expression (Figure 4.17). Cells were harvested and 
RNA and protein were isolated to investigate the effect of TALE repressor activity on 
VEZF1 expression.  
 
Figure 4.17 Analysis of RFP fluorescence in cells transfected with pTALEREP plasmids 
An example flow cytometry analysis of RFP fluorescence in HEK293 cells. Forward scatter (FSC) 
and side scatter (SSC) plot is shown on the left and fluorescence analysis on the right. Healthy 
cells are gated in the FSC/SSC plot to exclude debris. Fluorescence plots of HEK293 cells are 
shown before (yellow) and after transfection with pTALEREP plasmid (black). This example is 3 
days after transfection of pTALEREP-13, first replicate. In this example, 69% of events had 
more fluorescence than non-transfected HEK293 cells. 
Sample % RFP + 
Run 1 Run 2 
WT <1 <1 
TALEREP 13 69 44 
TALEREP 14 58 30 
TALEREP 15 54 22 
TALEREP 16 63 30 
TALEREP 17/19 71 23 
TALEREP 18 62 50 
TALEREP 20 58 59 
TALEREP 21/23 66 59 
TALEREP 22 69 48 
TALEREP 24 59 50 
Table 4.2 Quantification of RFP expression in cells transfected with pTALEREP plasmids 
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Quantitative RT-PCR analyses revealed that the expression of six of the ten TALE 
repressors resulted in reduced VEZF1 RNA expression levels (Figure 4.18). The expression 
of TALEREP 13 or TALEREP 21/23 resulted in substantial VEZF1 silencing, to averages of 
17.5 and 23.5% of wild type levels, respectively. The expression of TALEREP 15 or 
TALEREP 22 resulted in moderate VEZF1 repression, to averages of 74.5 and 86.5% of wild 
type levels, respectively. The expression of TALEREP 16 or TALEREP 18 resulted in 
silencing of VEZF1 to as much as 59 and 55% of wild type, but this repression was not 
consistent between replicates. The expression of TALEREPs 14, 17/19, 20 or 24 had no 
effect on VEZF1 mRNA levels. 
 
Figure 4.18 Analysis of TALE repressor action on VEZF1 gene expression  
Quantitative RT-PCR analysis of VEZF1 mRNA expression levels in HEK293 cells. The expression 
of VEZF1 in each cell line is normalised against ACTB expression and then adjusted to the level 
of VEZF1 expression in untransfected HEK293 cells. RNA levels were quantified three days after 
transfection of individual TALEREP plasmids.  The results from two independent bioreplicate 
transfections are shown (runs 1 and 2). Statistical analyses haven not been carried out on this 
data as the experiments were performed in duplicate. Dotted line shows level of VEZF1 
expression level of WT cells.  Error bars represent the standard deviation between three 
technical qRT-PCR replicates. 
It is possible that while TALE repressors can result in silencing of VEZF1 transcription, 
post-transcriptional regulatory mechanisms may maintain VEZF1 protein levels. Western 
blotting analysis was therefore used to confirm that the expression of TALE repressors 
does indeed knock down VEZF1 protein levels within three days after transfection. 
Protein levels from Run 1 were quantified relative to the Ponceau stain (Figure 4.19 A), 
however, this is not a validated method of protein quantification. Samples from Run 2 
(Figure 4.19 B) were not quantified due to the high level of background staining in the 
Ponceau. The expression of TALEREP 13 and TALEREP 21/23 both resulted in substantial 
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knock down of VEZF1 protein levels (Figure 4.19), which is consistent with the RNA 
analyses.  
However, the moderate level of VEZF1 silencing at the RNA level following the expression 
of TALEREPs 15, 16 or 18 did not significantly impact VEZF1 protein levels (Figure 4.19). 
The inconsistencies between VEZF1 RNA and protein levels are likely to be due to 
different modes of action of each TALEREP in some cases and delayed effects of RNA 
knock down on VEZF1 protein levels in other cases (see Discussion). 
 
Figure 4.19 TALE repressor expression reduces VEZF1 protein levels 
Western blot analysis of HEK293 cell extracts three days after transfection of pTALEREP 
plasmids. Ponceau staining of the membrane after transfer is a loading control.  The analyses 
of two bioreplicates (A and B) are shown. Sample set A were quantified and levels compared to 
WT, using the intense band at the bottom of the Ponceau stain to normalise for loading 
(please note that the use of Ponceau as a loading control is not a validated method of protein 
quantification). 
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4.8 Discussion 
This chapter has described the design and construction of ten TALE DNA-binding proteins 
that specifically target VEZF1 gene promoter sequences of 16 to 29 bp in length. An 
expression vector was created that allows the production of TALE repressor proteins. The 
expression of TALE repressor proteins in a human cell line was found to rapidly silence 
VEZF1 RNA and protein levels. The TALE repressors were found to be a simple approach 
to determine the performance of TALE domains in a chromatin context. Two of the TALE 
repressors are powerful tools to knock down VEZF1 expression in future studies. 
A Golden Gate assembly system was used to assemble TALE repeats. The system proved 
to be simple and reliable and relatively time efficient given the number of constructs 
assembled. Importantly, no evidence of unwanted recombinants of the TALE repeats was 
observed at any stage. There are more rapid methods of TALE construction available to 
the academic community, but these systems require liquid handling robots as they rely on 
larger vector libraries and/or work on solid phase supports (Reyon et al., 2012b) The 
other GG assembly system of interest to individual research groups is one developed by 
the Zhang group, which relies on a library of PCR primers rather than plasmids, as 
components for assembly reactions (Zhang et al., 2011). I opted against this system as 
sub-optimal PCR could reduce the performance of the system and/or introduce error. 
Another key advantage of stepwise GG assembly systems is that pre-assembled TALE 
DNA-binding domains can be quickly inserted into different expression vectors to produce 
TALE effector proteins such transcription activators and repressors or site-specific 
nucleases for example. At the time of release of Voytas GG assembly system there was no 
mammalian-based vector platform for creating TAL effectors or nucleases. I developed a 
mammalian expression vector to produce TALE repressor proteins using this system. Six 
of the ten TALE repressor proteins produced in this study were found to direct repression 
of VEZF1. The TALEREP 13 and TALEREP 21/23 proteins were more potent repressors than 
the other TALEREPs.  Interestingly, these two proteins target the same genomic site at the 
VEZF1 promoter, with TALEREP 21/23 recognising an additional 3 bp target (Figure 4.2). 
The superior performance of these two TALEREPs not only indicates that their target 
sequence is accessible, but that TALEREP binding may interfere with the binding of a key 
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transcription factor at the VEZF1 promoter. Alternatively, this position is optimal for SIN3-
mediated repression of the VEZF1 promoter.  
The TALEREPs 15, 16, 18 and 22 resulted in moderate repression of VEZF1. The degree of 
knockdown of VEZF1 RNA and protein levels varied between the TALEREPs. This is 
probably due to the fact that RNA and proteins samples were both collected three days 
after transfection. If a TALEREP has slow kinetics of repression due to low target site 
accessibility, RNA levels may be just beginning to reduce at day 3. Protein levels may be 
unaffected at this time. SIN3 acts as a scaffold to recruit co-repressors that both remove 
histone modifications that are favourable to transcription (H3/H4 acetylation and H3K4 
methylation) and add marks that are repressive to transcription (H3K9 methylation and 
possibly DNA methylation) (van Oevelen et al., 2008, Yang et al., 2003). It is possible that 
analyses of VEZF1 expression after longer periods of exposure to TALEREPs will reveal 
greater degrees of repression with more of the TALEREPs. Nevertheless, the aim of this 
study was to identify TALE domains that can access their sequence readily after transient 
transfection. This information can be taken into consideration when developing TALE 
nuclease strategies using these TALE proteins. 
Interestingly, there appears to be a correlation between level of VEZF1 knockdown 
mediated by a TALE Repressor and TALE domain length.  The longest TALEs, found in 
TALEREPs 14, 17/19, 20 and 24, recognise the longest sites at 28 or 29 bp, but had little 
effect on VEZF1 expression. TALEREPs 16 and 18, which recognise 22 and 23 bp sites, 
provided moderate levels of VEZF1 repression. TALEREP 15, which binds a 19 bp site, 
performed consistently to mediate a moderate knockdown.  The greatest level of VEZF1 
repression was observed using the shortest TALE domains.  TALEREPs 13 and 21/23 
recognise 16 and 19 bp sites, respectively. The correlation between decreasing TALE 
length and increasing repression performance may be a coincidence, and the results may 
differ if the effects of TALEREPs are studied for longer periods, given the inconsistencies 
observed between biological replicates (e.g. TALEREP 16) and in the disagreeing levels of 
repression in RNA versus protein expression (e.g. TALEREP 22, run 2). However, it is 
possible that the reduced, or slower, performance of TALEREPs with increasing binding 
site length may be due to competition for binding with endogenous transcription factors. 
Further studies are required to address this possibility. Researchers may need to balance 
the improved site specificity of longer TALE proteins with reduced DNA accessibility. A 
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comparison of in vitro DNA-binding affinity of each TALE protein with their in vivo 
performance would be helpful to address this possibility. 
From this work, it has been demonstrated that at least six of the ten TALEs designed and 
constructed are functional at their intended chromosomal targets after a short period of 
expression.  These TALE DNA-binding domains should be useful in strategies to create 
TALE nucleases that can direct genetic alteration of the VEZF1 gene to create a knockout 
of VEZF1 expression in somatic human cells, which is described in Chapters 5 and 6.  
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5 Chapter 5 
Production of TALENs to Modify the VEZF1 Gene Promoter 
5.1 Introduction 
Transcription activator like effectors (TALEs) are a class of DNA binding proteins from the 
plant pathogen Xanthomonas Spp. (Boch et al., 2009). Unlike other DNA-binding domains, 
the RVD domains of TALE proteins recognise a single DNA base, which allows the modular 
assembly of engineered proteins of designed DNA sequence specificity. I have designed 
and assembled 10 TALE domains to target DNA sequences of the VEZF1 gene promoter 
(Chapter 5). Following the successful validation of VEZF1 promoter targeting, the next aim 
is to fuse TALE domains to the catalytic domain of the FokI endonuclease to create TALE 
nucleases (TALENs) that can be employed to mutate the promoter of VEZF1. 
The ability to knockout the VEZF1 gene would greatly assist the study of VEZF1 function. 
VEZF1 is broadly expressed across many cell types and is known to bind at the promoters 
of many genes (Section 1.5) VEZF1 has been demonstrated to be essential in embryonic 
vascular development (Kuhnert et al., 2005, Zou et al., 2010) and also in the regulation of 
the angiogenic and lymphangiogenic phases in wound healing in adults (Gerald et al., 
2013). Its mechanism of action is unknown due to the difficulties faced in generating a 
sufficient level of VEZF1 knockdown using RNAi. Previous efforts to generate VEZF1 
knockdown lines have resulted in reduction of VEZF1 expression by up to 80% but this 
resulted in only partial depletion of VEZF1 binding at its target sites in vivo (Strogantsev, 
2009). 
Murine Vezf1 is essential for cell survival and a recent study by a colleague has revealed 
that human VEZF1 is bound at the promoters of the majority of transcribing genes (Low, 
2013), there is a possibility that human VEZF1 promoter mutation may impact upon 
normal cell growth. The straightforward delivery of either ZFNs or TALENS into cells would 
result in a variety of uncontrolled VEZF1 mutations as a result of double stranded break 
repair by non-homologous end joining (NHEJ). NHEJ results in mutations that are usually 
small insertions or deletions (Durai et al., 2005). It may be challenging to isolate VEZF1 
null cells from a population of heterozygous and silent mutations, particularly if VEZF1 
null cells have a reduced growth phenotype. 
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It is therefore more desirable to undertake a gene targeting approach where homology-
directed repair (HDR) of a DSB using a designed targeting vector is used to create desired 
mutations that can be readily selected for. This strategy will require the assembly of a 
targeting vector that contains a selectable transgene cassette flanked by regions of 
sequence homology to sequences surrounding the VEZF1 promoter.  HDR-mediated 
insertion of this transgene cassette would result in complete loss of the VEZF1 promoter 
and first exon on targeted alleles. This approach can be used to create and screen for 
VEZF1 null cells and/or create inducible VEZF1 null cells. 
A number of different TALEN architectures have been described, where truncations of the 
TALE domain or mutations of the FokI nuclease domains have been developed to improve 
DNA-binding activity or target specificity (Section 1.3.4.1.2). There were no vectors 
developed for the mammalian expression of TALENs using the Voytas Golden Gate 
assembly system as the time of starting this study. I therefore needed to develop 
expression vectors that were compatible with this system and incorporated the latest 
developments in TALEN architecture. 
5.2 Aims of this chapter 
 Design and construct mammalian expression vectors that assemble validated TALE 
domains into TALE Nucleases (TALENs) 
 Devise a strategy for performing homology directed repair (HDR) at the VEZF1 
promoter using a targeting vector 
 Develop ZFN/TALEN-stimulated HDR based targeting as an approach to generating 
designed VEZF1 gene mutations 
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5.3 Development of TALE Nuclease Expression Vectors 
A Golden Gate assembly system was utilised to assemble TALE domains that were then 
validated to target the VEZF1 promoter in cultured human cells in the context of 
monomeric TALE repressor proteins (Chapter 4). Destination vectors for the Voytas 
Golden Gate (GG) Assembly system that enable mammalian expression of TALENs were 
not available at the time of completing this study (Cermak et al., 2011). I considered that 
the following requirements should be met in order to maximise the performance of 
TALENs: 
1. A strong mammalian promoter should be used 
2. The TALE domain should contain the Miller truncations N∆152 and C+63 for 
maximal nuclease activity in mammalian cells (Szurek et al., 2002, Miller et al., 
2011) 
3. Epitope tags should be added for Western blotting analysis of TALEN expression, if 
required 
4. The cloning vector should be compatible with the Voytas GG TALE assembly 
system, with a selection marker for correct cloning events 
5. Mutations should be incorporated into the FokI nuclease domain to allow for 
obligate heterodimer function and enhanced cleavage 
6. The TALEN coding sequences should be optimised for human codons 
In order to meet these requirements, new TALEN expression vectors had to be 
assembled. It was clear that the coding sequences for the N- and C-termini of the TALE 
protein needed to be generated by DNA synthesis in order to meet our requirements. I 
decided that the TALE transcription activator plasmid, pTALETF_v2 would be the best 
starting point as it contained a strong CMV promoter, SV40 polyA and enhancer for 
mammalian expression and a central ccdB negative selection marker that can be used to 
screen for GG insertions (Sanjana et al., 2012).  Firstly, I needed to delete a portion of the 
pTALETF_v2 plasmid which contained an Esp3I site, as this is the restriction site that is 
used in the Voytas GG TALE assembly system (Figure 5.1). A 1,032 bp fragment containing 
an unnecessary hygromycin resistance gene was excised using PmlI and the plasmid was 
re-circularised by blunt ended ligation (pTALETFΔhygro). 
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Figure 5.1 Plasmid Map of pTALETF_v2 
Scaled map of pTALETF_v2 showing CMV promoter and CAG/T7 enhancer from where 
transcription of inserted TALEs initiates, TAL N- & C-termini and SV40 NLS.  Hygromycin 
resistance gene (hygroB) containing an Esp3I site, and Esp3I site used in Golden Gate Assembly 
are also indicated.  PmlI restriction sites shown were used to remove this region. 
5.3.1 Creation of a designed TALE N-terminus 
In order to obtain a TALE Δ152 N-terminus coding sequence that i) has an additional 3x 
FLAG-tag, ii) is human codon optimised and iii) has an Esp3I site compatible with the 
Voytas GG system, I had to replace the TALE N-terminus sequences already present 
between the SacI and NotI restriction sites in pTALETF_v2 with a designed fragment 
(Figure 5.2) to create the vector pTALv2_NT (Figure 5.3). The insertion of the SacI - NcoI 
TALv2_NT fragment was confirmed by restriction digestion of pTALv2_NT plasmid DNA 
with SacI & NotI (Figure 5.4, Lanes 2 – 7) and by digest with NcoI (Figure 5.4, Lanes 8 – 
13). 
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A 
  
B 
>TALv2NT SacI-NotI CMVpro T7 Kozak FLAGx3 NLS TALΔ152 SapI AgeI 
vector Esp3I-CUT 
GAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGG
GGCCACCATGGACTATAAGGATCATGACGGCGACTACAAGGACCACGACATCGACTACAAGGACGACG
ACGACAAGATGGCCCCCAAGAAGAAGCGCAAGGTGGGCATCCACGGCGTGCCCGCCGCCGTGGACCTG
CGCACCCTGGGCTACAGCCAGCAGCAGCAGGAGAAGATCAAGCCCAAGGTGCGCAGCACTGTCGCCCA
GCACCACGAGGCCCTGGTGGGCCACGGCTTCACCCACGCCCACATCGTGGCCCTGAGCCAGCACCCCG
CTGCACTGGGCACCGTGGCCGTGAAGTACCAGGACATGATCGCCGCTCTTCCGGAAGCCACCCACGAG
GCCATCGTGGGCGTGGGCAAGCAGTGGAGCGGCGCCCGCGCCCTGGAGGCCCTGCTGACCGTGGCCGG
CGAGCTGCGCGGCCCCCCCCTGCAGCTGGACACCGGCCAGCTGCTGAAGATCGCCAAGCGCGGCGGCG
TGACCGCCGTGGAGGCCGTGCACGCCTGGCGCAACGCCCTGACCGGTGCCCCCCTGGAGACGctgaca
gagaccGCGGCCGC 
Figure 5.2 Design of the synthesised TALE v2 N-terminus fragment TALv2NT 
A) Cartoon of the designed TALE N-terminus. B) Sequence of the synthesised SacI-NotI 
TALv2NT fragment. The humanised AvrBs3 TALE coding sequence matched that of TALE 
effector vectors developed by the Zhang lab (Sanjana et al., 2012).  The 5’ end of the TALv2_NT 
fragment contained the remainder of the CMV promoter (green) after the SacI cloning site 
(light blue) followed by i) a T7 promoter (brown) for future in vitro transcription work, ii) a 
Kozak translation initiation site (red), iii) a 3x FLAG-tag epitope (mid blue) to monitor TALE 
protein expression and iv) a nuclear localisation signal (NLS, grey).  The 3’ end of the TALv2NT 
fragment ends with an Esp3I site that creates the same CCCT overhang utilised in the Voytas 
GG system (underlined). 
 
Figure 5.3 Plasmid Map of pTALv2_NT 
Scaled map of pTALv2_NT showing the modified TALv2 N-terminus inserted using restriction 
sites SacI & NotI.  Insertion of the N-terminus expression cassette was confirmed using NcoI, 
which is also annotated.  TAL C terminus and EGFP were subsequently replaced with the 
modified TALv2 C-terminus using BsrGI (section 5.3.2). 
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Figure 5.4 Restriction analysis of pTALv2_NT clones 
Agarose gel electrophoresis of restriction digested plasmid DNA from transformants gained 
following ligation of the TALv2_NT into pTALETF_v2.  Correct insertion of the TALv2NT 
fragment results in the excision of a 619 bp fragment with SacI & NotI, whereas the original 
vector would yield an 811 bp fragment. All six clones analysed had the expected insert for 
TALv2NT (lanes 2-7). Insertion of the TALv2NT fragment introduces an additional NcoI site. All 
six clones resulted in the excision of 1167 & 277 bp fragments expected for pTALv2_NT (lanes 
8 – 13). 
5.3.2 Creation of designed TALEN C-termini 
In order to create a TALEN C-terminus that i) encoded the TALE +63 C-terminus fused to 
the wild type FokI nuclease domain, ii) is human codon optimised and iii) is has an Esp3I 
site compatible with the Voytas Golden Gate Assembly system, the incompatible TALE C-
terminus and EGFP sequences already present between the two BsrGI restriction sites in 
pTALv2NT (Figure 5.3) had to be replaced with a designed TALv2CT-FokIWT fragment 
(Figure 5.5) to create the vector pTALv2-FokIWT (Figure 5.6). 
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A 
 
B 
>TALv2CT-FokWT    BsrGI ccdB Esp3I TAL_CT FokIWT XhoI BsaI 
TGTACAGAGTGATATTATTGACACGCCCGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTG
TCAGATAAAGTCTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATGACCA
CCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTGGCTGATCTCAGCCACCGCGAAAATGA
CATCAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCTCCCTTATACACAGCCAGTCT
GCAGGTCGACCGTCTCCAACGACCACCTGGTGGCCCTGGCCTGCCTGGGCGGACGCCCtGCtCTGGACGC
CGTGAAGAAGGGCCTGCCCCACGCCCCCGCCCTGATCAAGCGCACCAACCGCCGCATCCCCGAGCGCACC
AGCCACCGCGTGGCCGGCAGCCAGCTGGTGAAGAGtGAaCTGGAGGAGAAGAAGAGCGAGCTGCGCCACA
AGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGCAACAGCACCCAGGACCGCAT
CCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACCGCGGCAAGCACCTGGGCGGCTCG
AGAAAGCCCGACGGCGCCATCTACACCGTGGGCAGCCCCATCGACTACGGCGTGATCGTGGACACCAAGG
CCTACAGCGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAGATGCAGCGCTACGTGGAGGAGAACCA
GACCCGCAACAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCCAGCAGCGTGACCGAGTTCAAG
TTCCTGTTCGTGAGCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCCGCCTGAACCACATCACCA
ACTGCAACGGCGCCGTGCTGAGCGTGGAGGAGCTGCTGATCGGCGGCGAGATGATCAAGGCCGGCACCCT
GACCCTGGAGGAGGTGCGCCGCAAGTTCAACAACGGCGAGATCAACTTCTAATGTACA 
Figure 5.5 Design of the synthesised TALEN C-terminus fragment TALv2CT-FokIWT 
A) Cartoon of the designed TALEN C-terminus. B) Sequence of the synthesised BsrGI TALv2CT-
FokIWT fragment. The humanised AvrBs3 TALE coding sequence matched that of TALE effector 
vectors developed by the Zhang lab (Sanjana et al., 2012).  The 5’ end of the TALv2CT-FokIWT 
fragment contained the remainder of the ccdB selection marker (blue) BsrGI cloning site 
(purple) followed by i) an Esp3I site that creates the same AACG overhang utilised in the 
Voytas Golden Gate system, ii) the humanised AvrBs3 TALE +63 C-terminus coding sequence 
(orange) as used previously (Sanjana et al., 2012), iii) a humanised coding sequence for the 
wild type FokI cleavage domain (green). Silent mutations in the FokI domain were included to 
create a XhoI restriction site (dark green) that could be used to exchange FokI domain 
mutation in future studies. 
 
Figure 5.6 Plasmid Map of pTALv2-FokIWT 
Scaled map of pTALv2-FokIWT showing the previously modified TALE N-terminus and the 
present insertion of the TALEN C-terminus at BsrGI.  Insertion of the C-terminus was confirmed 
using NcoI & StuI, which are also annotated. 
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The correct insertion of the TALv2CT-FokIWT fragment into pTALv2-FokIWT was 
confirmed by restriction digestion of the plasmid with NcoI, which excises the inserted 
TALEN C-terminus sequence from the plasmid backbone (Figure 5.7, Lanes 2 – 9). The 
correct orientation of the cloned TALEN C-terminus had to be determined as the cloning 
strategy involved a pair of compatible BsrGI sites. Restriction digestion with StuI, which 
has a recognition sequence present once in the cloned TALEN C-terminus and once in the 
plasmid backbone identified that 4 of the 8 clones analysed had the TALEN C-terminus 
cloned in the desired orientation (Figure 5.7, Lanes 10 – 17).  Clones in the correct 
orientation can be seen in lanes 10, 14, 15 & 17. 
 
Figure 5.7 Restriction analysis of pTALv2-Fok1WT clones  
Agarose gel electrophoresis of restriction digested pTALv2-FokIWT plasmid DNA clones 
resulting from ligation of the TALv2CT-FokIWT fragment into pTALv2_NT.  Digestion with NcoI 
confirmed that all eight clones contained the TALv2CT-FokIWT fragment as each had the 
expected pattern of 3326, 2001, 1167 and 277 bp digestion products (lanes 2 – 9).  Digestion 
with StuI identified that only four of the clones contained the TALv2CT-FokIWT fragment in the 
desired orientation, where a 911 bp product is excised (lanes 10, 14, 15 & 17). 
Two further versions of the TALEN C-terminus were created that incorporate previously 
characterised mutations of FokI that i) cause it to function as an obligate heterodimer and 
ii) increase cleavage activity. This obligate heterodimer mutations are the same as those 
employed in ZFN construction (Chapter 3), namely Q486E and I499L (“EL”) in the right 
hand monomer and E490K, I538K (“KK”) in the left hand monomer. However, I have also 
included the N496D and H537R mutations to create “ELD” and “KKR”. The D/R mutations 
used in addition to EL/KK mutations have been shown to have greater cleavage activity 
than either WT or EL/KK versions of FokI (Doyon et al., 2011).  In addition, I have added 
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the so-called Sharkey mutations S418P and K441E to both ELD and KKR as the Sharkey 
mutations have been reported to result in improved cleavage activity of FokI heterodimer 
mutants (Guo et al., 2010). The resulting heterodimer TALENs ELD-S and KKR-S are 
hereafter referred to as version 3 (v3) TALENs. 
A 
 
B 
>TALv2CT-FokELD-S (Q486E,I499L,N496D - S418P,K441E) 
BsrGI ccdB Esp3I TAL_CT FokI XhoI BsaI  
TGTACAGAGTGATATTATTGACACGCCCGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGC
TGTCAGATAAAGTCTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATG
ACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTGGCTGATCTCAGCCACCGCGA
AAATGACATCAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCTCCCTTATACACA
GCCAGTCTGCAGGTCGACCGTCTCCAACGACCACCTGGTGGCCCTGGCCTGCCTGGGCGGACGCCCtG
CtCTGGACGCCGTGAAGAAGGGCCTGCCCCACGCCCCCGCCCTGATCAAGCGCACCAACCGCCGCATC
CCCGAGCGCACCAGCCACCGCGTGGCCGGCAGCCAGCTGGTGAAGAGtGAaCTGGAGGAGAAGAAGAG
CGAGCTGCGCCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGCAACC
CCACCCAGGACCGCATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACCGCGGC
GAGCACCTGGGCGGCTCGAGAAAGCCCGACGGCGCCATCTACACCGTGGGCAGCCCCATCGACTACGG
CGTGATCGTGGACACCAAGGCCTACAGCGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAGATGG
AGCGCTACGTGGAGGAGAACCAGACCCGCGACAAGCACCTGAACCCCAACGAGTGGTGGAAGGTGTAC
CCCAGCAGCGTGACCGAGTTCAAGTTCCTGTTCGTGAGCGGCCACTTCAAGGGCAACTACAAGGCCCA
GCTGACCCGCCTGAACCACATCACCAACTGCAACGGCGCCGTGCTGAGCGTGGAGGAGCTGCTGATCG
GCGGCGAGATGATCAAGGCCGGCACCCTGACCCTGGAGGAGGTGCGCCGCAAGTTCAACAACGGCGAG
ATCAACTTCTAATGTACA 
 
>TALv2CT-FokKKR-S (E490K,I538K,H537R - S418P,K441E) 
BsrGI ccdB Esp3I TAL_CT FokI XhoI BsaI   
TGTACAGAGTGATATTATTGACACGCCCGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGC
TGTCAGATAAAGTCTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATG
ACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTGGCTGATCTCAGCCACCGCGA
AAATGACATCAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCTCCCTTATACACA
GCCAGTCTGCAGGTCGACCGTCTCCAACGACCACCTGGTGGCCCTGGCCTGCCTGGGCGGACGCCCtG
CtCTGGACGCCGTGAAGAAGGGCCTGCCCCACGCCCCCGCCCTGATCAAGCGCACCAACCGCCGCATC
CCCGAGCGCACCAGCCACCGCGTGGCCGGCAGCCAGCTGGTGAAGAGtGAaCTGGAGGAGAAGAAGAG
CGAGCTGCGCCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCCGCAACC
CCACCCAGGACCGCATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACCGCGGC
GAGCACCTGGGCGGCTCGAGAAAGCCCGACGGCGCCATCTACACCGTGGGCAGCCCCATCGACTACGG
CGTGATCGTGGACACCAAGGCCTACAGCGGCGGCTACAACCTGCCCATCGGCCAGGCCGACGAGATGC
AGCGCTACGTGAAGGAGAACCAGACCCGCAACAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTAC
CCCAGCAGCGTGACCGAGTTCAAGTTCCTGTTCGTGAGCGGCCACTTCAAGGGCAACTACAAGGCCCA
GCTGACCCGCCTGAACCGCAAGACCAACTGCAACGGCGCCGTGCTGAGCGTGGAGGAGCTGCTGATCG
GCGGCGAGATGATCAAGGCCGGCACCCTGACCCTGGAGGAGGTGCGCCGCAAGTTCAACAACGGCGAG
ATCAACTTCTAATGTACA 
Figure 5.8 Design of the synthesised heterodimer TALEN C-terminus fragments 
A) Cartoon of the designed TALEN C-termini. B) Sequence of the synthesised BsrGI TALv2CT-
FokELD-S and TALv2CT-FokKKR-S fragments. The composition of the fragments is as described 
for TALv2CT-FokIWT in Figure 5.5, except that the indicated mutations are present in the FokI 
coding sequence. 
The ELD-S and KKR-S forms of FokI were created by DNA synthesis of the TALEN C-
terminus fragments TALv2CT_FokELD-S and TALv2CT_FokKKR-S (Figure 5.8). These were 
cloned into the BsrGI restriction sites of pTALv2NT as described for TALv2CT-FokIWT 
above (not shown) to create the vectors pTALv3-FokIELD-S and pTALv3-FokIKKR-S. During 
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the course of this work, an additional destination vector for the Voytas GG system that 
creates a wild type FokI TALEN for mammalian expression called pCAG-T7-TALEN became 
available (Addgene.org, plasmid 37184). I acquired this vector as other groups have 
begun to use it to produce functional TALENs, and refer to pCAG-T7-TALEN as pTALv1-
FokIWT (Table 1.1).  
 
Name FokI Human codon 
optimised 
References 
pTALv1-FokIWT Wild type No Pelczar (Unpublished) 
pTALv2-FokIWT Wild type Yes (Miller et al., 2011, Sanjana et 
al., 2012) 
pTALv3-FokI-ELDS S418P, K441E, Q486E, 
N496D and I499L 
Yes (Miller et al., 2007, Guo et al., 
2010, Doyon et al., 2011) 
pTALv3-FokI-KKRS S418P, K441E, E490K, 
H537R and I538K 
Yes (Miller et al., 2007, Guo et al., 
2010, Doyon et al., 2011) 
Table 5.1 Destination vectors for mammalian TALEN expression 
All of these vectors create TALEN assemblies with Δ152 TALE N-termini and +63 C-termini.  
5.3.3 Assembly of Designed TALE RVD Domains into Nuclease Expression Vectors 
All ten of the TALE domains that target the human VEZF1 gene promoter were assembled 
into pTALv1, pTALv2 or pTALv3 vectors as described in Table 5.2. A plasmid pick sheet was 
used to set up Golden Gate assembly reactions (similar to that shown in Figure 4.14) of 
pTAL A, B and C constructs of TAL RVDs and the desired FokI expression vector to 
assemble pTALEN vectors. An example TALEN vector is shown in Figure 5.9.  The correct 
assembly of TALE RVDs into pTAL plasmids was confirmed by SacI – XhoI digestion of the 
resulting pTALEN plasmids. An example is shown in Figure 5.10. The pTALEN plasmids can 
be combined in transfection experiments to produce 18 TALEN pairs. These TALEN pairs 
are subsequently referred to by their original TALE names followed by the TALEN version, 
for example TALEN 13/14_v1 or 13/14_v2 etc.  
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v1 TALEN 
(standard homodimer) 
v2 TALEN 
(optimised homodimer) 
v3 TALEN 
(optimised heterodimer) 
Configuration 
(L-Space-R) 
DNA Recognition Sequence 
TALE13–WT-L 
+ TALE14-WT-R 
TALE13–WT*-L 
+ TALE14-WT*-R 
TALE13–ELDS*-L 
+ TALE14-KKRS*-R 
16-30-28 
             TALE 13 
GTCGCCTCCTCCGGCT---AGTGGGGAGGAGGGGGGTCGGCCGCCGC 
CAGCGGAGGAGGCCGA---TCACCCCTCCTCCCCCCAGCCGGCGGCG 
                  TALE 14 
TALE15-WT-L 
+ TALE16-WT-R 
TALE15-WT*-L 
+ TALE16-WT-R 
TALE15-ELDS*-L 
+ TALE16-KKRS*-R 
19-15-23 
               TALE 15 
CGCCGCCGCGGTGGTGCGT---AAGTGGCCGCGCTCGGCGCTGCC 
GCGGCGGCGCCACCACGCA---TTCACCGGCGCGAGCCGCGACGG 
                     TALE 16 
TALE17/19-WT-L 
+ TALE18-WT-R 
TALE17/19-WT*-L 
+ TALE18-WT*-R 
TALE17/19-ELDS*-L 
+ TALE18-KKRS*-R 
 
28-15-22 
           TALE 17/19 
GCCGCCGCCGCCGCCGCCGCTTTGTTGT---AGGAGGCTCCCCGAGCGGGGGGAGTGGGG 
CGGCGGCGGCGGCGGCGGCGAAACAACA---TCCTCCGAGGGGCTCGCCCCCCTCACCCC 
                                       TALE 18       TALE 20 
TALE17/19-WT-L 
+ TALE20-WT-R 
TALE17/19-WT*-L 
+ TALE20-WT*-R 
TALE17/19-ELDS*-L 
+ TALE20-KKRS*-R 
28-15-29 
TALE21/23-WT-L 
+ TALE22-WT-R 
TALE21/23-WT*-L 
+ TALE22-WT*-R 
TALE21/23-ELDS*-L 
+ TALE22-KKRS*-R 
19-30-25            TALE 21/23 
GTTGTCGCCTCCTCCGGCT---AGGAGGGGGGTCGGCCGCCGCAGCCATGG 
CAACAGCGGAGGAGGCCGA---TCCTCCCCCCAGCCGGCGGCGTCGGTACC 
                               TALE 22        TALE 24 
TALE21/23-WT-L 
+TALE24-WT-R 
TALE21/23-WT*-L 
+TALE24-WT*-R 
TALE21/23-ELDS*-L 
+TALE24-KKRS*-R 
19-30-29 
Table 5.2 TALEN assemblies that target the human VEZF1 gene promoter 
The TALE domains characterised in Chapter 4 (Table 4.1) were assembled into pTALv1-FokIWT (v1), pTALv2-FokIWT (v2) or pTALv3-FokI-ELDS/KKRS (v3) using the 
Voytas Golden Gate system. The different versions of TALENs are v1 = wild type FokI, non-optimised (“WT”), v2 = wild type FokI, human codon optimised (“WT*”) 
and v3 = heterodimer ELDS/KKRS FokI, human codon optimised (“ELDS*/KKRS*”). All of the TALENs share the same Δ152N/+63C TALE architecture. 
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Figure 5.9 Plasmid map of pTALEN_13_v2 
Scaled map showing pTALEN_13_v2, which was produced from the assembly of TAL-A13 and 
TAL-B13 into pTALv2-FokIWT. Restriction sites SacI and XhoI were used to confirm the correct 
assembly of TALE RVDs. 
 
Figure 5.10  Restriction analysis of pTALEN vector assemblies 
Agarose gel electrophoresis of restriction digested plasmid DNA from five different TALE 
assemblies into pTALv2-FokIWT. Plasmid DNA from three clones of each pTALEN assembly was 
digested with SacI and XhoI.  Digestion of pTALv2-FokIWT excises a 2413 bp fragment (lane 
17).  Digestion of pTALEN vectors yields a fragment of 823 +100 bp per TALE RVD domain. The 
expected dropout sizes and number of TALE RVD domains in each clone is indicated below the 
gel. 
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5.4 Design of human VEZF1 gene targeting vector 
In order to allow for designed gene and promoter mutations, conditional gene knockout 
and knockout of a potentially essential gene like VEZF1, it is desirable to undertake gene 
targeting via homology directed repair (HDR). HDR occurs with very low efficiency in 
almost all somatic human cells, but this can be stimulated up to 50,000 fold by inducing a 
double strand DNA break (Jasin, 1996, Elliott et al., 1998). Our first targeting strategy 
involved a test to see whether ZFN- or TALEN-mediated cleavage can stimulate the 
targeted insertion of an EGFP transgene at the human VEZF1 gene promoter. The EGFP 
transgene needs to be flanked by VEZF1 gene sequences, known as homology arms. 
Homology arms are recommended to be around 750 bp -- 1 kb in length and to be within 
200 bp of double strand break (Davis and Stokoe, 2010, Davis and Pruett-Miller, 2010, 
Urnov et al., 2010). 
I designed an EGFP targeting vector for the VEZF1 promoter, which includes a puromycin 
resistance cassette to allow for the selection of targeted cells (Figure 5.11).  The 5’ 
homology arm consists of a 725 bp portion of the upstream VEZF1 promoter and the 3’ 
arm consists of a 744 bp portion of intron 1. The arms flank the core promoter, 5’UTR and 
the short exon 1. The proximal ends of each arm are between 70 and 230 bp from the 
various ZFN and TALEN cleavage sites. HDR using these homology arms should replace the 
VEZF1 core promoter, TSS, ATG and exon 1 with an EGFP-PURO transgene (Figure 5.13). 
HDR-mediated insertion of the EGFP-PURO transgene at the VEZF1 target locus will result 
in the removal of the ZFN and TALEN binding sites, so further cleavage after targeting is 
not possible. This is with the exception of ZFN pair 37/38, which does have a cleavage site 
in the homology arms. This ZFN pair were designed and constructed prior to the design of 
the targeting strategy, and this ZFN pair is the only one which is designed to cleave in 
sequences downstream of exon 1 in VEZF1. 
The homology arms were cloned into a transgene system created by Ms. Ileana Guerrini 
in the West group (data not shown). This SHuTtle-LEFT-RIGHT (SHTLR) system employs 
multisite Gateway cloning to quickly assemble 5′ and 3′ homology arm sequences onto 
different transgenes to facilitate gene targeting and other applications (Figure 5.11). The 
5′ VEZF1 homology arm was obtained by genomic PCR using the primers 
VEZF1_5’arm_H3F and VEZF1_5’arm_AscR and cloned into pSHTLR3 via HindIII and AscI to 
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form pSHTLR3_VEZF1_R5'arm. The 3’ VEZF1 homology arm was obtained using the 
primers VEZF1_3’arm_H3F and VEZF1_3’arm_AscR and cloned into pSHTLR5 via HindIII 
and AscI to form pSHTLR5_VEZF1_R3'arm. An LR Gateway reaction between the pSHTLR 
plasmids, the pDestR4-R3 destination vector and a pSHTLRmid plasmid containing a CMV-
driven EGFP-puro transgene was performed to form pTRGT_VEZF1 (Ileana Guerrini, Figure 
5.12). 
 
Figure 5.11  SHTLR cloning of gene targeting vectors 
Schematic representation of targeting vector assembly by multisite Gateway cloning. 
Homology arms towards the target locus are conventionally cloned into multiple cloning sites 
locate in the pSHTLR5/3 plasmids. The locations of AscI and HindII restriction sites used for the 
insertion of VEZF1 homology arms in a reverse orientation are shown. The transgene located in 
pSHTLRmid for this study encodes both EGFP and a puromycin resistance gene separate by a 
T2A self-cleavage peptide (Kim et al., 2011). LR clonase-mediated assembly results in the 
formation of pTRGT_VEZF1, where the GFP transgene is in the reverse orientation between 
the VEZF1 homology arms. The locations of recognition sequences for flp (FRT) and cre (loxP) 
recombinases are shown. 
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Figure 5.12 Plasmid Map of pTRGT_VEZF1 
Scaled Map of pTRGT_VEZF1 showing VEZF1 homology arms flanking EFGP/puromycin 
transgene cassette expressed via CMV promoter.  Also annotated are recognition sequences 
for flp (FRT) and cre (loxP) recombinases.   
The VEZF1 GFP targeting vector was designed such that the EGFP-PURO transgene would 
become integrated in the reverse orientation to the VEZF1 gene body, so that transgene 
transcription does not read through into the remaining VEZF1 sequences (Figure 5.13).  
The transgene cassette also contains recognition sites for the site-specific recombinases 
Cre and Flp which enable the subsequent removal or exchange of the transgene. Cre-
mediated recombination between the two loxP sites will remove the intervening EGFP-
PURO transgene. Alternatively, Flp-mediated recombination at the FRTwt and FRTR3 sites 
will facilitate cassette exchange with a donor plasmid containing the same sites. The 
presence of these recombination sites will be key to future strategies to modify the VEZF1 
locus in a controlled manner, including conditional homozygous deletion of VEZF1. 
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Figure 5.13 VEZF1 Targeting Strategy 
(A) Schematic cartoon depicting the pTRGT_VEZF1 vector construct which includes a CMV-
driven EGFP-puro transgene flanked by recombination sites and VEZF1 homology arms  (B) 
Scale diagram of a 1900 bp region at the 5′ end of the VEZF1 gene promoter region based on 
UCSC Genome Browser alignments (hg19, chr17:56064601-56066500). The VEZF1 gene is 
shown in blue, which transcribes from right to left. The 5’UTR, codons of exon1, followed by 
intron 1 are all indicated. The extent of the CpG Island (green) and the location of the TSS 
(orange) are indicated below the gene. The locations of the ZFN and TALEN recognition 
sequences used in this study are depicted by black boxes above the gene. Above that are the 
locations of the sequences included as VEZF1 homology arms in pTRGT_VEZF1. 
5.5 HDR-Based Targeting to Knockout the VEZF1 gene Promoter 
Circular ZFN or TALEN expression vectors were transfected into HEK293 cells with the 
circular targeting vector pTRGT_VEZF1 to determine whether the expression of the 
designed nucleases can stimulate transgene insertion at the VEZF1 target locus. EGFP 
expression was measured by flow cytometry as an indicator of intracellular plasmid 
concentration three days post-transfection (Figure 5.14, left column). It was apparent 
that the transfection efficiency was greater than 75 % in all of the experiments 
performed. The transiently transfected cells were passaged once prior to commencing 
puromycin selection seven days post-transfection. The aim of selection is to enrich for 
cells that contain stably integrated transgenes following the dilution of non-integrated 
plasmids. As a control, cells which had been transfected with pTRGT_VEZF1 only were 
also subjected to selection to ensure that any plasmid integration was a consequence of 
ZFN/TALEN cleavage. 
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Figure 5.14 Transgene expression with and without ZFNs / TALENs  
Flow cytometry analysis of EGFP fluorescence in HEK293 cells transfected with 
pTRGT_VEZF1 alone (top row) or pTRGT_VEZF1 with ZFN/TALEN expression vectors (lower 
rows). Analyses were completed 3 days post transfection (no selection), 14 days (7 days 
without then 7 days with selection) or 18 days (11 days of selection). The green region in 
each plot indicates EGFP expressing cells as the fluorescence intensity is greater than non-
transfected control cells (purple). 
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Non-transfected HEK293 control cells were rapidly killed by puromycin selection (not 
shown). Unexpectedly, cells transfected with pTRGT_VEZF1 alone retained EGFP 
expression and grew rapidly under puromycin selection (Figure 5.14, top row). This 
finding indicates a substantial degree of off-target transgene integration in the conditions 
used. Cells that were co-transfected with nuclease expression vectors retain a similar 
level of EGFP expression as the pTRGT_VEZF1 only control following selection (Figure 
5.14). The level of off-target integration is clearly too high to warrant further analysis of 
the effects of nuclease-mediated targeting in these conditions. 
The control experiment where the circular pTRGT_VEZF1 plasmid is transfected alone, 
followed by puromycin selection, was repeated to determine whether the timing of 
selection is key to minimising off-target integration. The transfected cells were passaged 
once, two days before commencing drug selection. Five days post-transfection, the 
culture was divided into two populations. One culture was subjected to puromycin 
selection and the parallel culture was monitored for the loss of transiently transfected 
pTRGT_VEZF1 without selection.  Flow cytometry analyses revealed that cells transfected 
with pTRGT_VEZF1 alone retained substantial levels of GFP expression seven days post-
transfection without selection (Figure 5.15, black plots, top row). EGFP fluorescence levels 
only returned to non-transfected control levels between days 9 and 12 post-transfection. 
pTRGT_VEZF1 transfected cells subjected to puromycin selection retained high levels of 
EGFP expression, even after the non-selected cells had returned to WT fluorescence 
levels (Figure 5.15, blue plots). 
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Figure 5.15 Efficient random integration of pTRGT_VEZF1 following selection 
Flow cytometry analysis of EGFP fluorescence in HEK293 cells 3, 7, 9, 12 & 14 days following 
transfection with pTRGT_VEZF1.  Parallel cultures with puromycin selection after day 5 (blue 
plots), or without selection (black plots), were compared to non-transfected controls (red 
plots). 
It is clear that generation of a VEZF1 knockout via HDR using our targeting vector is not as 
straightforward as initially envisaged.  The issue of high level random integration that is 
retained following puromycin selection must be resolved before proceeding. The control 
experiment above demonstrated that a substantial level of pTRGT_VEZF1 plasmid is 
present in cells when selection was initiated 5 to 7 days post-transfection. Initiation of 
selection at around 10 days post-transfection may result in lower levels of random 
integration as any transiently transfected plasmid is lost from the population.  However, a 
similar experiment to address this issue did not significantly reduce the level of selection 
for random integration of an EGFP transgene (Ileana Guerrini, data not shown). 
Furthermore, if the targeting of VEZF1 results in any growth disadvantage, long periods of 
recovery between transfection and selection may result in the loss of targeted cells. I 
therefore decided that it best to take an alternative approach to studying the 
performance of the ZFNs and TALENs produced in this study, described in Chapter 6, until 
an improved strategy for gene targeting is available. 
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5.6 Discussion 
This chapter has described the development of advanced TALEN expression vectors which 
were used to create three versions of TALENs that are designed to target the human 
VEZF1 promoter. A gene targeting strategy was developed and experiments were 
performed to determine whether the TALENs and the ZFNs developed in this study can 
promote VEZF1 gene targeting.   
Two expression vectors were created that produce two new versions of TALENs, called v2 
and v3, using the Voytas Golden Gate assembly system. These two new versions encode 
TALEN sequences that are codon optimised throughout, whose performance can be 
compared to the non-codon optimised expression vector, v1. Like v1, the v2 vector 
encodes a TALEN that has a wild type FokI cleavage domain, whereas v3 vectors encode a 
number of FokI mutations that have been reported to increase cleavage and restrict 
TALENs to function as heterodimers. The use of obligate heterodimer TALENs would be 
the safest way to generate VEZF1 mutations while minimising confounding off-target 
effects. The assembled TALEN mammalian expression plasmids allow for the comparison 
of (i) differences in TALEN activity at different target sequences, (ii) differences in TALEN 
activity between different target sequence spacers, (iii) the effect of human codon 
optimisation on TALEN activity and (iv) the impact of FokI mutations on TALEN activity. 
The gene targeting vector pTRGT_VEZF1 was also designed and assembled, to assess the 
ability of ZFNs and TALENs to stimulate homology-directed double strand break repair. 
However, initial gene targeting experiments revealed that off-target integration of 
pTRGT_VEZF1 is prevalent under standard conditions and that substantial optimisations 
are required (Section 5.5). Delaying the point at which antibiotic selection is initiated 
should allow for the depletion non-integrated vector and reduce the chance of selecting 
for off-target integration, but poses another potential issue of population outgrowth of 
targeted cells. Initial investigation suggests that this optimisation alone is insufficient in 
abolishing random integrants (Ileana Guerrini, data not shown). Transfection of a smaller 
plasmid load to reduce the number of plasmid copies per cell may lessen random 
integration. 
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It is possible that off-target integration cannot be completely prevented, so it was 
decided to add an HSV thymidine kinase (TK) gene into the backbone of the pTRGT vector. 
TK expressing cells will rapidly convert the deoxy-guanosine analogue ganciclovir to 
ganciclovir triphosphate, which inhibits DNA replication. Cells with randomly integrated 
pTRGT-TK plasmids can be selected against using ganciclovir. Cells containing GFP 
transgenes that have integrated via HDR would lack the pTRGT-TK plasmid backbone and 
should survive selection. Colleagues in the West group are determining the optimal 
conditions for selection of cells using this method. 
Once the issue of off-target integration of the targeting vector has been resolved or 
mitigated, a number of gene targeting steps could be undertaken to create VEZF1 null 
and heterozygous cells even, if VEZF1 is essential for growth. In the first approach, 
ZFN/TALEN and pTRGT_VEZF1 vectors will be transfected into cells. After a quick check 
that cells express GFP, clonal cell lines would be generated using puromycin selection. 
VEZF1 gene integrity and VEZF1 expression would be analysed to determine whether 
there are lines in which targeting has been successful.  At this point, it may be possible to 
identify lines in which homozygous VEZF1 gene targeting has occurred, should such lines 
survive. These lines could be characterised at length and future rounds of re-targeting 
may not be required.  
If it is found that all of the correctly targeted cells express VEZF1 because they are only 
targeted on one allele, then it is likely that VEZF1 is essential for growth. Further steps will 
be required to create conditional VEZF1 homozygous null cells. The following steps rely 
on cells where only one VEZF1 allele is faithfully targeted with the GFP-puro transgene. 
This transgene is flanked by loxP and FRT recognition sequences for the cre and flp 
recombinases, respectively, which will be used for cassette exchange or removal. The 
second allele must ideally be wild type and must retain the ZFN/TALEN target site and 
VEZF1 expression. The following three steps to create a conditional VEZF1 null cell line are 
envisaged: 
1. Exchange the integrated GFP-puro transgene to restore the VEZF1 promoter and 
exon 1 sequence, but leaving the flanking loxP sites. Sequences encoding RFP and a 
T2A self-cleavage peptide will be added immediately prior to the VEZF1 coding 
sequences to enable the visualisation of VEZF1 null cells in the final stage. Sequences 
encoding a triple FLAG epitope tag will also added to the VEZF1 N-terminus. The 
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ZFN/TALEN recognition sequences will be mutated. The cassette exchange will be 
performed by transfection of FLP recombinase expression and targeting plasmids into 
cells. Clonal cell lines that lack GFP expression will be selected following limiting 
dilution. Western blotting will be used to confirm the presence of FLAG-tagged 
VEZF1. This tagged allele should retain VEZF1 function in cells, but can be 
subsequently deleted using cre recombinase. It will no longer be a ZFN/TALEN target. 
2. ZFN/TALEN and pTRGT_VEZF1 vectors will be transfected into cells selected in step 1. 
GFP expressing cell lines will be selected using puromycin as described above. VEZF1 
gene integrity and VEZF1 expression would be analysed to identify the lines where 
wild type VEZF1 has been lost and only RFP-FLAG-VEZF1 remains. These 
heterozygotes can be studied for any phenotype. 
3. The remaining RFP-FLAG-VEZF1 allele will be deleted using cre recombinase. The 
transfection of a cre expression plasmid should result in loss of the VEZF1 promoter 
and exon 1. The effect of VEZF1 deletion on cell growth and VEZF1 target gene 
regulation can be studied in the cells that lack RFP expression. 
Given that the generation of a VEZF1 knockout via nuclease-directed gene targeting 
requires further technical development and time was limiting, I decided to focus on 
examining whether the assembled nucleases are capable of inducing mutations at the 
VEZF1 promoter via error-prone non-homologous end joining (NHEJ) DNA repair.  I wish 
to determine which of the ZFNs and TALENs are most efficient. These experiments, 
described in Chapter 6, will feedback to future efforts to undertake precise HDR-mediated 
gene targeting of the VEZF1 gene. 
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6 Chapter 6 
Using Designer Nucleases to Modify the VEZF1 Gene Promoter 
6.1 Introduction 
ZFNs and TALENs have been used to efficiently create gene mutations without the need 
for gene targeting vector strategies (Perez et al., 2008, Li et al., 2011c, Holt et al., 2010). 
This is because the dominant form of double strand break repair in most somatic cells is 
error-prone non-homologous end joining (NHEJ). The presence or absence of short 
insertions and deletions at the ZFN/TALEN target sites can be used to assess the 
performance of the designed nucleases in cells. The assay of nuclease-mediated 
mutations following ZFN/TALEN transfection provides information about performance in 
endogenous mammalian chromatin contexts, which is more relevant than exogenous 
bacterial or yeast reporter assays (Maeder et al., 2008, Ramirez et al., 2008). This 
approach will be used to compare nuclease target location, TALEN dimer spacing, TALEN 
architecture and the effect of codon optimisation. The most efficient nucleases can then 
be used in conjunction with an updated targeting vector to generate an HDR-mediated 
VEZF1 knockout in subsequent studies (as described in Chapter 5). Given that the ZFN and 
TALEN targets sites lie within the VEZF1 core promoter, it may be discovered NHEJ 
mutations that are sufficient to reduce or remove VEZF1 expression. 
In order to accurately compare our assembled nucleases, I need to design an assay 
system to quantify nuclease-mediated mutations. Mutations associated with NHEJ are 
typically small insertions and deletions (indels) resulting from an error-prone resection 
and filling repair process. These mutations can be easily scored using restriction fragment 
length polymorphism (RFLP) assays, where the presence or absence of a restriction 
enzyme recognition sequence at the nuclease target site is studied (Huang et al., 2011). 
RFLP assays are simple to perform and interpret, but different assays must be developed 
for each individual target site. 
A more generic assay for indels at nuclease target sites involves the use of the 
endonucleases CelI or T7 EndonucleaseI, which cleave mismatched DNA structures 
(Kulinski et al., 2000, Babon et al., 2003, Oleykowski et al., 1998). Genomic PCR products 
of nuclease target regions that contain a mixture of wild type and mutant sequences can 
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be melted and reannealed to create mismatched molecules that can be visualised 
following cleavage by these enzymes. I intend to develop and optimise such assays to 
analyse the performance of ZFNs and TALENs in somatic cells.   
6.2 Aims of this chapter 
 Develop a reliable and quantitative assay system to test for the presence of 
mutations likely to be created by nucleases 
 Deliver TALENs & ZFNs to cultured human cells and test their abilities to create 
targeted mutations at the VEZF1 gene promoter 
 Determine the nature of nuclease-mediated mutations and how they affect VEZF1 
expression 
6.3 Development of an Assay to Detect NHEJ Events 
6.3.1 CelI & T7EI Assays 
The non-sequence specific endonucleases CelI (Surveyor) and T7 endonucleaseI (T7EI) can 
be used to detect mismatches created following erroneous DSB repair by NHEJ (Kulinski 
et al., 2000, Babon et al., 2003, Oleykowski et al., 1998).  The enzymes detect “bulges” in 
DNA molecules and digest DNA at these points.  The “bulges” are created by the 
annealing of two strands of DNA that harbour small base pair mismatches to each other, 
such as the changes created following DNA repair via NHEJ.  When visualised on an 
agarose gel, these digest products can be detected as compared to an undigested parent 
band which is composed of non-mismatched (WT) DNA. 
6.3.1.1 Designing a Control Assay for CelI & T7EI 
To allow for direct comparison and optimisation of the CelI and T7EI assays for NHEJ, I 
decided to develop a universal control assay.  The Surveyor kit provides a control in the 
form of two plasmids named C and G, which differ from each other at only one base pair.  
The plasmids are individually packaged and mixed with primers for amplification of the 
region containing the C or G base to be used as a mismatch.  The PCR products from 
plasmids G and C can be mixed in known ratios and the amplicons are denatured and re-
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annealed to create DNA fragments containing a predicted percentage of mismatched 
DNA which differs at only one base pair.  This mismatched DNA can then be treated with 
CelI nuclease and analysed on an agarose gel.  However, each Surveyor kit only provides 
enough control DNA for 10 experimental runs which, given all of the suggested 
optimisations, would not be adequate to thoroughly assess and compare both CelI and 
T7EI.  I have therefore devised a similar control using plasmids that are available in the 
lab. 
Plasmids encoding the FokI domains for zinc finger nuclease expression have been 
modified to express the Sharkey FokI variant (pFOKI-EL-S, Chapter 3).  This mutation is 
two base pair changes from the original FokI plasmid (pFOKI-EL; see Figure 3.6).  Primers 
(NHEJ CONTROL F & R) were designed to amplify the region containing these two base 
pair changes (Figure 6.1).  By performing PCR from pFOKI-EL and pFOKI-EL-S, the 
amplicons generated differ from each other by only two bases.  These PCR products can 
then be mixed in known ratios and denatured and re-annealed, as in the protocol for the 
CelI Control Assay, to create DNA samples with two single base pair mismatches in a 
predicted percentage of the sample.  This can be treated with both nucleases, testing a 
variety of conditions, and analysed on an agarose gel with the aim to determine the 
optimal conditions and best performing nuclease to assess ZFN and TALEN activity. 
 
Figure 6.1 Plasmid Map of pFOKI_v2L 
Scaled map of pFOKI_v2L showing the FokI gene with amino acid variations encoding obligate 
heterodimer (E490K & I538K) and Sharkey mutations (S418P& K441E).  Binding sites of primers 
NHEJ control F & R used for PCR amplification to create a DNA sample containing a mismatch 
to be used as a control for NHEJ assays. 
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6.3.1.2 Determining Optimal Conditions for CelI & T7EI 
Optimisations suggested in the manual for CelI nuclease were performed using both CelI 
and T7EI.  Initially, variation in the amount of DNA and the amount of enzyme were 
tested using a variety of percentage mismatches in the sample, 0%, 2% and 10%.  The 
testing of 0% mismatched DNA permits the observation of any non-specific activity of the 
enzyme used and may allow the determination of a false positive reporting rate.  The 
FokI-EL and FokI-EL-S PCR products were purified via gel extraction, quantified, mixed in 
buffer and melted for 3 minutes at 90°C prior to annealing at  65°C, 37°C and then 22°C 
for 10 minutes at each temperature. PCR products were then diluted to required 
concentrations for digest.  The suggested maximum amount of DNA to digest with CelI is 
400 ng and so I digested this amount, 270 ng (2/3) and 135 ng (1/3) with 5 or 10 units of 
each enzyme for two hours, as this is the recommended digest time for CelI nuclease.  
It was found that both the CelI and T7EI unexpectedly digest 0% mismatch control DNA 
(Figure 6.2, compare lanes 2-7 with lane 20 in parts A and B). The cleavage appears to be 
non-specific, as the cleavage products are of random size, resulting in a smear. The 2% 
and 10% mismatch experiments resulted in a similar digestion profile to the 0% control 
(Figure 6.2, lanes 9-19 in parts A and B). The parent PCR product of 901 bp is expected to 
be digested into three fragments of 643 bp, 190 bp and 68bp based on the location of the 
mismatches in the DNA sample. It therefore appears that no mismatch-specific products 
are revealed by CelI or T7EI endonucleases due to the high background of non-specific 
cleavage. 
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 Figure 6.2 Two hour CelI & T7EI digestion of control DNA 
Agarose gel electrophoresis of FokI control DNA treated with either CelI (A) or T7EI (B).  
Varying amounts of PCR product DNA containing a ratio of 0, 2 or 10% mismatches after 
annealing were incubated with nucleases for 2 hours. The 901 bp PCR product is expected to 
cleave into products of 643, 190 and 68 bp when mismatches are present.  Lane 20 on both 
gels illustrates the band intensity expected from undigested samples. 
The high level of non-specific cleavage by CelI and T7EI may have been due to the length 
of time the reaction was incubated.  A timecourse experiment was carried out to 
determine if less time would lower the non-specific cleavage activity observed.  Digestion 
reactions were set up as before, except for shorter incubation periods of 30, 45 or 60 
minutes. Non-mismatched DNA was used to determine the time at which non-specific 
digest did not occur. However, prevalent non-specific cleavage was observed, despite the 
shorter incubation times (Figure 6.3).  
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Figure 6.3 CelI & T7EI digestion of 0% mismatched control DNA for 30 to 60 minutes 
Agarose gel electrophoresis of FokI control DNA following digestion with CelI or T7EI. The amount of control DNA and incubation periods used are indicated above 
the gel images. The 901 bp PCR product is expected to cleave into products of 643, 190 and 68 bp when mismatches are present. Lanes 2, 17 and 34 demonstrate 
the band intensity of annealed PCR products, loaded neat on the gel. Lanes 3, 10, 18, 27, 35 and 43 illustrate the band intensity expected from undigested 
samples. 
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The apparent non-specific cleavage by CelI and T7EI may still be due to excessive 
incubation times.  I therefore reduced the incubation times to 5 or 15 minutes with CelI 
Figure 6.4or T7E1 to try and find a condition where 0% mismatch control DNA was not 
digested. Control DNA containing 0 or 30% mismatched sample was incubated with or 
without enzyme for 5 or 15 minutes. It was found that incubation with CelI for 5 or 15 
minutes resulted in little or no digestion of 0% mismatch negative control DNA (Figure 6.4 
compare lanes 2, 3 with lanes 6, 7). However, none of the expected digestion products 
were observed in the 30% mismatch positive control DNA (Figure 6.4, compare lanes 8, 9 
with lanes 4, 5). It is apparent that CelI is unable to detect mismatches with desired 
efficiency with the control DNA and conditions used. 
Figure 6.4 Five and fifteen minute digestion of control DNA with CelI 
Agarose gel electrophoresis of FokI control DNA following CelI digestion for (A) 5 or (B) 15 
minutes.  The 901 bp PCR product is expected to cleave into products of 643, 190 and 68 bp 
when mismatches are present.  Mock experiments with no enzyme are shown in lanes 2-5. 
Unlike CelI, T7EI exhibited substantial non-specific cleavage activity with 15 minutes of 
incubation (Figure 6.5 B, lanes 6-9). This activity was minimal in 5 minute incubations 
(Figure 6.5 A, lanes 6-9). However, none of the expected digestion products were 
observed in the 30% mismatch positive control DNA (Figure 6.5 A, B, lanes 8, 9). It is 
apparent that like CelI, T7EI is unable to detect mismatches with desired efficiency with 
the control DNA and conditions used. 
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Figure 6.5 Five and fifteen minute digestion of control DNA with T7EI 
Agarose gel electrophoresis of FokI control DNA following T7EI digestion for (A) 5 or (B) 15 
minutes.  The 901 bp PCR product is expected to cleave into products of 643, 190 and 68 bp 
when mismatches are present.  Mock experiments with no enzyme are shown in lanes 2-5. 
Prevalent non-specific cleavage of 0% mismatch PCR product DNA was observed with 
both the CelI and T7EI endonucleases. Reduction of incubation times to 15 minutes for 
CelI and 5 minutes for T7EI removed the non-specific cleavage to acceptable levels. 
However, none of the expected digestion products were observed in the mismatch 
positive control experiments. It is possible that the mismatches for this particular control 
sequence are not suitable substrates for CelI or T7EI, or that there are problems with the 
melting and re-annealing step of the assay (see Discussion). In the interests of time, I 
decided to discontinue using these assays as a means of assessing the level of NHEJ repair 
resulting from ZFN and TALEN activity.  This has driven the need to design a customised 
assay based around the specific sequences of the ZFN and TALEN binding locations at the 
VEZF1 promoter. 
6.3.2 Restriction Fragment Length Polymorphism (RFLP) Analysis of TALEN-mediated 
mutations 
I decided to employ an assay that did not rely on the melting and accurate re-annealing of 
PCR product DNA. Restriction fragment length polymorphism (RFLP) analysis is a simple 
assay where restriction digestion determines whether NHEJ has resulted in the loss of a 
restriction enzyme recognition sequence. The key to this assay is the identification of 
restriction sites that overlap the point of cleavage by the TALEN being studied. Working 
on the principle that TALEN-mediated DSBs repaired by NHEJ is erroneous, a restriction 
site present in a TALEN spacer would become mutated upon repair (Figure 6.6).  Digesting 
TALEN-treated DNA with this restriction enzyme would result in a differential digest band 
pattern than would be observed from WT DNA.  The ratio of the polymorphism would 
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directly relate to the cleavage activity of the TALEN.  I designed RFLP assays to analyse 
NHEJ events occurring following TALEN treatment of DNA.  I attempted to design similar 
assays for ZFN-treated samples but the restriction sites present in the spacer between our 
ZFN pairs were found to be highly frequent, which prevented the development of a 
diagnostic RFLP for these sequences (data not shown).   
 
Figure 6.6 RFLP Assay Overview 
Cartoon depicting the general principle of RFLP analysis.  Genomic DNA is bound and cleaved 
by TALENs across a restriction enzyme recognition sequence; the example shown here is BstEII.  
Repair of the TALEN-mediated DSB by NHEJ will result in mutation of the restriction enzyme 
recognition sequence.  When incubated with the restriction enzyme, mutant DNA will not be 
digested and will generate an RFLP when compared to WT DNA. 
The six TALEN pairs that target the human VEZF1 promoter, described in Chapter 5, target 
three cleavage points. Three different RFLP assays were designed to test for TALEN 
activity at these target sites (Figure 6.7).  Assay 1 was designed to test TALENs 13/14, 
21/22 and 23/24.  Assay 2 was designed for TALEN pair 15/16, and assay 3 tested TALENs 
17/18 and 19/20.   
153 
 
 
Figure 6.7 VEZF1 Promoter Regions in RFLP Assay 
Schematic overview of TALEN target sites demonstrating the requirement for three RFLP assay 
designs to encompass the different TALEN target regions.  Restriction sites located in the 
spacers were selected for RFLP analyses.   
6.3.2.1 RFLP analysis of VEZF1 promoter mutagenesis directed by TALEN pairs 13/14, 
21/22 & 23/24 
It is desirable to have a sensitive and quantitative assay for polymorphisms so that direct 
comparisons can be made between efficient and inefficient TALEN designs. It was 
considered that the use of a DNA Bioanalyser (Agilent) would generate the most accurate 
data for the RFLP assay. The Bioanalyser resolves DNA molecules via electrophoresis 
through a matrix with high precision and quantifies different sized species to produce a 
quantitative electropherogram. RFLP assay 1 is designed to analyse the mutations 
directed by TALEN pairs 13/14, 21/22 & 23/24. The cleavage site located in the centre of 
the recognition sequence for these TALEN pairs overlaps a BsrBI restriction enzyme 
recognition sequence (Figure 6.8).  PCR primers were designed to generate a 1310 bp 
genomic PCR product for this region.  This PCR product was purified and subjected to 
restriction digestion with the enzymes BsrBI and BstEII, which cleave wild type DNA into 
634, 390, 172 and 114 bp fragments. TALEN-directed loss of a BsrBI site would result in a 
mutant 286 bp cleavage product (Figure 6.8). 
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Figure 6.8 The design of RFLP Assay 1 
The sequences recognised by TALEN pairs 13/14 (beige), 21/22 & 23/24 (red) are indicated by 
filled arrows over the DNA sequence. A BsrBI restriction site overlaps the central spacer of 
these TALEN pairs.  Above: A scale diagram depicting the cleavage pattern of a 1310 bp PCR 
product with BsrBI and BstEII.  
HEK293 cells were transfected with 2 µg of each pair of expression plasmids for TALEN 
pairs 13/14, 21/22 and 23/24 in v1, v2 and v3 formats (9 transfections). A parallel 
transfection with an EGFP expression vector was monitored by FACS after 24 hours to 
confirm that transfection efficiency was greater than 90% (not shown). Genomic DNA was 
prepared from wild type and TALEN-transfected cells 72 hours after transfection. PCR was 
performed on the genomic DNAs using primers hVEZF1pro-374_F and hVEZF1pro+895_R. 
The 1310 bp PCR product was purified using a column and digested with BsrBI and BstEII. 
The product from wild type cells cleaved into the expected 634, 390, 172 and 114 bp 
fragments (Figure 6.9, WT). Importantly, there was no peak representing a 286 bp 
fragment in the WT sample, indicating complete cleavage at the BsrBI site studied in the 
RFLP assay. 
TALEN-directed mutagenesis is expected to mutate this BsrBI site, which results in 286 bp 
fragment in the assay as BsrBI would no longer be able to cleave this into 172 and 114 bp 
fragments. RFLP analysis of DNA from cells transfected with TALEN_23/24 FokI_v3 reveals 
the presence of a band matching 286 bp (Figure 6.9, bottom right). The presence of a 634 
bp fragment in this same assay, and the absence of a 920 bp fragment (634 + 286) 
indicates that BsrBI digestion was complete in this assay. Quantification of the fluorescent 
units (FU) indicates that the VEZF1 promoter is mutated in at least 15% of alleles in cells 
transfected with TALEN_23/24 FokI_v3. The RFLP assay did not detect mutations with any 
of the other TALENs in this experiment (Figure 6.9). 
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Figure 6.9 Bioanalyser RFLP analysis of VEZF1 promoter mutagenesis directed by three 
versions of TALEN pairs 13/14, 21/22 & 23/24 
Electropherogram plots of DNA fragments resulting from digestion of a 1310 bp PCR of the 
VEZF1 promoter with BsrBI and BstEII. Digests were performed on PCRs of HEK293 genomic 
DNA from wild type (WT) cells and cells transfected with three versions of the TALEN pairs 
13/14, 21/22 & 23/24. Fragment sizes are annotated on each plot, which are determined by 
the Bioanalyser software based on the 15 bp and 1500 bp markers (black).  Unexpected 
peaks are indicated by red asterisks.  A candidate 286 bp RFLP peak observed in 
TALEN_23/24_v3 is indicated by a red box. 
Three DNA fragments of unexpected size were identified on the Bioanalyser from RFLP 
assay 1 (Figure 6.9, asterisks). These peaks were visible in all of the samples and tended to 
vary in intensity between replicates (not shown). It is possible that these are non-specific 
PCR products. The presence of these unexpected peaks makes it more difficult to infer 
the presence of TALEN-directed mutations. Before deciding on whether to optimise the 
PCR product purity further, the same PCR product digests were analysed by agarose gel 
electrophoresis for a second opinion. 
Agarose gel electrophoresis also reveals the presence of an RFLP of expected size in PCRs 
from TALEN transfected cells, but there are key differences from the Bioanalyser data. A 
clear band consistent with the expected 286 bp RFLP fragment is found in DNA from cells 
transfected with TALEN_13/14 FokI_v2 and TALEN_21/22 FokI_v1 (Figure 6.10,  lanes 3 
and 5). This RFLP band appears to be present in DNA from the other TALEN experiments, 
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but this often smeared and cannot be called with confidence (Figure 6.10). It is to be 
expected that indels will vary in size, and thus result in smeared rather than distinct 
bands. The expected disappearance of the 172 and 114 bp fragments in DNA from TALEN 
transfected cells is another means of calling an RFLP. These bands are clearly reduced 
compared to WT DNA in DNA from cells transfected with TALEN_13/14 FokI_v1 and v2, 
TALEN_23/24 FokI_v3 (Figure 6.10, lanes 2, 3 and 10). The fact that the disappearance of 
the 172 and 114 bp bands and appearance of the 286 bp RFLP fragment are not entirely 
concordant may reflect variable NHEJ insertion/deletions (indels) between experiments. 
Variable indel sizes might also explain why the Bioanalyser profiles reported less 
polymorphism rates than agarose gel electrophoresis.  
Figure 6.10 RFLP analysis of VEZF1 promoter mutagenesis directed by three versions of 
TALEN pairs 13/14, 21/22 & 23/24 
Agarose gel electrophoresis of DNA from cells transfected with TALEN pairs 13/14, 21/22 & 
23/24 compared to wild type DNA digested with BsrBI and BstEII.  Wild type DNA is digested 
into 634, 390, 172 and 114 bp fragments as indicated.  Mutagenesis of a BsrBI site results in 
the loss of the 172 and 114 bp fragments and gain of a 286 bp, or similar, fragment. Non-
specific PCR products are indicated by an asterisk. 
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6.3.2.2 RFLP analysis of VEZF1 promoter mutagenesis directed by TALEN pair 15/16 
A BstEII restriction enzyme recognition site was found to overlap the cleavage site of the 
TALEN pair 15/16. An RFLP assay involving digestion of the 1310 bp PCR product 
described above with BstEII and RsaI will result in 732, 390 and 188 bp fragments (Figure 
6.11). TALEN-directed mutagenesis of the BstEII site will result in a loss of the 390 and 188 
bp fragments and gain of a 578 bp fragment. It is possible that the products of 
mutagenesis may result in RFLP fragments that vary from 578 bp due to the variable 
nature of NHEJ-mediated indels, as discussed above. 
 
Figure 6.11 The design of RFLP Assay 2 
The sequence recognised by TALEN pair 15/16 is indicated by filled grey arrows over the DNA 
sequence. A BstEII restriction site overlaps the central spacer of these TALEN pairs.  Above: A 
scale diagram depicting the cleavage pattern of a 1310 bp PCR product with RsaI and BstEII.  
HEK293 cells were transfected pairs of plasmid vectors that encode the three versions of 
the TALEN pair 15/16. PCR DNA digested with RsaI and BstEII was profiled on the Agilent 
Bioanalyser. DNA from wild type cells was found to digest into the expected 732, 390 and 
188 bp fragments (Figure 6.12, WT). Similar background peaks described above were also 
present in RFLP assay 2, increasing the likelihood that these were non-specific PCR 
products (Figure 6.12, asterisks). A very well defined peak approximating 578 bp is 
apparent in DNA from cells transfected with TALEN_15/16 FokI_v2 and v3 (Figure 6.12). 
This size matches that expected for TALEN-directed mutations which result in loss of the 
BstEII site. In the case of TALEN_15/16 FokI_v1, however, no such mutant peak can be 
identified.  This demonstrates that, despite the presence of non-specific background 
peaks, the RFLP assay can identify mutations at the anticipated site. 
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Figure 6.12 Bioanalyser RFLP analysis of VEZF1 promoter mutagenesis directed by three 
versions of TALEN pair 15/16 
Electropherogram plots of DNA fragments resulting from digestion of a 1310 bp PCR of the 
VEZF1 promoter with RsaI and BstEII. Digests were performed on PCRs of HEK293 genomic 
DNA from wild type (WT) cells and cells transfected with three versions of the TALEN pair 
15/16. Fragment sizes are annotated on each plot, which are determined by the Bioanalyser 
software based on the 15 bp and 1500 bp markers (black).  Unexpected peaks are indicated by 
red asterisks.  A candidate 578 bp RFLP peak observed in TALEN 15/16 v2 and v3 cells is 
marked by a red box. 
The presence of TALEN 15/16-directed mutagenesis at the human VEZF1 promoter was 
confirmed by agarose gel electrophoresis. The same RsaI / BstEII digested PCR products 
shown above were analysed again. A band approximating 578 bp is observed from the 
DNA of all cells transfected with the TALEN pair 15/16 (Figure 6.13, lanes 2-4). It should 
be noted that the 578 bp band appears to be a collection of similar sized species. The 
different resolution properties of agarose and the Bioanalyser matrix may explain the 
different levels of mutagenesis reported by the two assays from the same DNA. The 
presence of the ~578 bp band on agarose gels is mirrored by the reduction of the 390 and 
188 bp bands (Figure 6.13, lanes 2-4). Quantification of the 188 bp band indicates that 
43% and 46% of alleles are mutant within three days of transfection with the v2 and v3 
15/16 TALEN pair, respectively. Analysis of the 188 band in the samples transfected with 
v1 of TALEN 15/16 did not reveal a significant level of mutations. This indicates that 
codon optimisation of TALENs offers a major advance in TALEN performance, probably 
due to increased TALEN protein levels. The mutation of FokI to produce obligate 
heterodimers results in some loss of performance, but this is minimal for the 15/16 
TALEN pair. This result is consistent with recent reports of combining the ELD, KKR and 
Sharkey mutations. 
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Given the high efficiency of the 15/16 v2 TALEN pair in HEK293 cells, I investigated 
whether this TALEN could be used to generate VEZF1 promoter mutations in erythroid 
K562 cells. K562 cells are much more difficult to transfect but are an experimentally 
important model for studying erythroid gene regulation. A control transfection with an 
EGFP expression plasmid monitored by flow cytometry indicated that the transfection 
efficiency for K562 cells was 38 % for this experiment. Despite only a fraction of K562 cells 
having TALEN expression, a 578 bp RFLP band is clearly observed from the DNA of all cells 
transfected with the v2 TALEN pair 15/16 (Figure 6.13, lane 6). The 15/16 TALEN pair is 
therefore very efficient at directing VEZF1 promoter mutagenesis in different cell types 
and should be useful in difficult to transfect cells like primary and stem cells. 
Figure 6.13 RFLP analysis of VEZF1 promoter mutagenesis directed by three versions of the 
TALEN pair 15/16 
Agarose gel electrophoresis of DNA from cells transfected with versions of the TALEN pair 
15/16 compared to wild type DNA digested with RsaI and BstEII.  Wild type DNA is digested 
into 732, 390 and 188 bp fragments as indicated.  Mutagenesis of a BstEII site results in the 
loss of the 390 and 188 bp fragments and gain of a 578 bp, or similar, fragment. Non-specific 
PCR products are indicated by an asterisk.  
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6.3.2.3 RFLP analysis of VEZF1 promoter mutagenesis directed by the TALEN pairs 
17/18 and 19/20 
An MspI restriction enzyme recognition site was found to overlap the cleavage site of the 
TALEN pairs 17/18 and 19/20. An RFLP assay involving digestion of the 1310 bp PCR 
product described above with MspI and SacI, results in 23 fragments (Figure 6.14). The 
majority of these digest products are smaller than 50 bp in size. I expect to be able to 
distinguish the larger 340, 125, 109 and 88 bp fragments from the smaller fragments in 
both the Bioanalyser and gel electrophoresis assays. TALEN-directed mutagenesis of the 
MspI site present in the TALEN spacer should result in the loss of the 109 and 88 bp 
fragments and gain of a 197 bp fragment (Figure 6.14). It is possible that the products of 
mutagenesis may result in RFLP fragments that vary from 197 bp due to the variable 
nature of NHEJ-mediated indels, as discussed above. 
 
Figure 6.14 The design of RFLP Assay 3 
The sequences recognised by the TALEN pairs 17/18 and 19/20 are indicated by filled green 
arrows over the DNA sequence. An MspI restriction site overlaps the central spacer of these 
TALEN pairs.  Above: A scale diagram depicting the cleavage pattern of a 1310 bp PCR product 
with MspI and SacI (unlabelled sites are MspI). 
HEK293 cells were transfected with pairs of plasmid vectors that encode the three 
versions of the TALEN pairs 17/18 and 19/20. PCR DNA digested with MspI and SacI was 
profiled on the Agilent Bioanalyser. DNA from wild type cells was found to digest into the 
expected 340, 125, 109, 88 bp and smaller fragments (Figure 6.15, WT). However, the 
electropherograms did not identify any peaks approximating 197 bp in DNA from cells 
transfected with the TALEN pairs 17/18 and 19/20 (Figure 6.15). 
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Figure 6.15 Bioanalyser RFLP analysis of VEZF1 promoter mutagenesis directed by three 
versions of the TALEN pairs 17/18 and 19/20 
Electropherogram plots of DNA fragments resulting from digestion of a 1310 bp PCR of the 
VEZF1 promoter with MspI and SacI. Digests were performed on PCRs of HEK293 genomic DNA 
from wild type (WT) cells and cells transfected with three versions of the TALEN pairs 17/18 
and 19/20. Fragment sizes are annotated on each plot, which are determined by the 
Bioanalyser software based on the 15 bp and 1500 bp markers (black). 
Given that the Bioanalyser approach reported less mutagenesis in the RFLP assays 
described above, the same MspI / SacI digested PCR products shown above were 
analysed by agarose gel electrophoresis. A diffuse band approximating 197 bp was 
detected from the DNA of cells transfected with TALEN_17/18 FokI_v2 (Figure 6.16, lane 
3). Faint smeared bands of the same size may be present in the DNA from cells 
transfected with the other TALENs, but mutagenesis cannot be called with any confidence 
in these other experiments due to background on the gel (Figure 6.16). It is not possible 
to accurately quantify either the 109 or 88 bp band that may be lost following 
mutagenesis as the gel is too crowded. It appears that the TALEN pair 17/18 results in a 
low degree of VEZF1 promoter mutagenesis, but the TALEN pair 19/20 is not sufficiently 
active for clear detection with the RFLP assay described here. Faint banding of 
approximately the correct size is visible, but is not easily distinguished from background 
(Figure 6.16, lanes 5 – 7). The use of high percentage gels with either specialist high 
resolution grade agarose or polyacrylamide may be useful for future analyses with RFLP 
assay 3. 
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Figure 6.16 RFLP analysis of VEZF1 promoter mutagenesis directed by three versions of the 
TALEN pairs 17/18 and 19/20 
Agarose gel electrophoresis of DNA from cells transfected with versions of the TALEN pairs 
17/18 and 19/20 compared to wild type DNA digested with MspI and SacI.  Wild type DNA is 
digested into 340, 125, 109, 88 bp and smaller fragments as indicated.  Mutagenesis of a MspI 
site results in the loss of the 109 and 88 bp fragments and gain of a 197 bp, or similar, 
fragment. 
6.4  Analysis of TALEN-directed mutations at the VEZF1 promoter 
6.4.1 Analysis of the Effect of NHEJ-induced Mutations on VEZF1 Expression 
Given that v2 and v3 of TALEN pair 15/16 directed 43 and 46% mutation of the VEZF1 
promoter, there is a possibility that these mutations alone are sufficient to result in a loss 
of VEZF1 expression in HEK293 cells. This TALEN pair was originally designed to stimulate 
HDR-mediated removal of the VEZF1 promoter and first exon by gene targeting (Chapter 
5). However, because this TALEN pair overlaps the only annotated TSS of the VEZF1 gene 
(Figure 6.11), there is a good chance that TALEN 15/16-directed mutations will reduce 
VEZF1 transcription levels. Total RNA was collected from HEK293 cells seven days after 
transfection with plasmids encoding the v2 and v3 of TALEN pair 15/16. This was the 
same transfection studied by RFLP assays above. RT-PCR analysis of VEZF1 transcript 
levels were not reduced in these cells despite the high levels of VEZF1 promoter mutation 
(Figure 6.17 A). Furthermore, western blotting analyses found no change in VEZF1 protein 
levels (Figure 6.17 B). It appears that in a polyclonal mixture of cells, the mutations of the 
VEZF1 promoter are not sufficient to significantly reduce transcription. Alternatively, if 
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loss of VEZF1 expression impacts cell growth and survival, the mutant cells that were 
identified at day 3 may have been lost from culture by day 7 post-transfection. 
 
Figure 6.17 VEZF1 Expression in HEK293 Cells following TALEN 15/16 mutagenesis 
(A) Quantitative RT-PCR analysis of VEZF1 expression levels in HEK293 cells seven days after 
transfection of TALEN 15/16.  Expression levels are normalised relative to ACTB expression and 
VEZF1 expression in WT cells assigned a value of 1.  Error bars represent standard deviation 
between three technical replicates. This data is from one biological sample set (no replicates) 
and so no statistical analyses have been performed.  (B) Western blot analysis of VEZF1 protein 
levels in TALEN treated HEK293 cells as compared to Ponceau loading control. 
6.4.2 Determining the Nature of TALEN-directed VEZF1 promoter mutagenesis  
RFLP analysis by agarose gel electrophoresis indicated that the VEZF1 promoter was 
mutated on 43% of alleles in HEK293 cells three days after transfection of TALEN 15/16 
expression plasmids (Figure 6.13). However, gene expression analyses after an additional 
four days of culture failed to reveal any change in VEZF1 expression (Figure 6.17). The lack 
of any change in VEZF1 expression is unexpected and may be a consequence of studying a 
polyclonal mixture of mutant and wild type cells. It is possible to generate monoclonal cell 
lines following TALEN treatment, which could be screened by RFLP and RT-PCR analyses.  
This is a laborious undertaking, so it would be useful to know what kinds of mutations 
arise from TALEN-directed mutagenesis. The DNA from HEK293 cells three days after 
transfection of TALEN 15/16 v2 (that was previously subject to RFLP assays) was then 
subjected to Sanger sequencing analysis. The 1310 bp PCR product described above was 
inserted into the plasmid vector pGEM-T Easy via TA cloning (Figure 6.18).  
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Figure 6.18 TA cloning of TALEN treated VEZF1 promoter DNA 
Scaled map of pGEM-T Easy PCR containing a 1310 bp PCR product of the VEZF1 promoter 
from HEK293 cells three days after TALEN 15/16 treatment. Shown on the map are the TALEN 
binding location and the m13 F & R primer sites used to screen clones for correct ligation of 
PCR product by colony PCR.  Also shown are restriction sites NotI & RsaI employed to screen 
potentially positive clones by restriction digest. 
Each E.coli transformant clone arises from a single plasmid, which represents a single 
allele from any given cell in the polyclonal population transfected with TALEN 15/16 v2. 
Plasmid DNA was prepared from 28 transformant clones derived from TALEN treated DNA 
and a total of 9 clones derived from wild type DNA (only 2 shown), which were screened 
for the presence of the cloned PCR fragment by restriction digestion (Figure 6.19). 
Digestion of the parent pGEM-T Easy vector with RsaI and NotI yields 1813 and 1168 bp 
fragments (e.g. Figure 6.19, lanes 3, 4). Plasmids containing the VEZF1 promoter PCR 
product yield additional 749 and 595bp fragments (e.g. Figure 6.19, lane 10). 24 of the 
plasmid clones contained TALEN treated DNA inserts. Some of these had different 
fragment lengths compared to wild type DNA, indicative of NHEJ indels (Figure 6.19, 
compare WT lane 9 with TALEN DNA in lanes 7, 18, 21 and 22). 
Five clones containing WT DNA and fifteen clones containing TALEN treated DNA were 
sequenced using M13 primers, whose sites flank the cloned PCR product (Figure 6.18).  
Clones from TALEN treated DNA which generated unexpected digest patterns when 
screened by restriction enzyme digest were selected preferentially over those which 
resulted in predicted digest products (Figure 6.19, sequencing clone IDs detailed below 
each clone). 
165 
 
 
 
Figure 6.19 Cloning of TALEN treated VEZF1 promoter DNA  
Agarose gel electrophoresis of plasmid DNA from transformants resulting from ligation of VEZF1 promoter PCR product into pGEM-T Easy Vector by TA-cloning.  
Digest of empty pGEM-T Easy vector with NotI & RsaI generates 1813 and 1168 bp fragments and digestion of pGEM-T Easy plasmids that contain PCR product 
inserts results in additional products of 749 and 595 bp.  Note some clones have produced unexpected digest products (lanes 2, 6, 14 & 21), these clones were 
preferentially picked for sequencing as they may demonstrate large insertions or deletions following TALEN-mediated DSB repair.  Clones picked for sequencing 
were allocated a sequencing ID as denoted below each relevant lane.  Lane 15 demonstrates digest of empty pGEM-T Easy vector, arising from failed ligation of 
TALEN –treated DNA. 
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The sequences from wild type clones were aligned to produce a consensus sequence for 
the HEK293 cells used in the West group (Figure 6.20 A, top).  Five of the clones derived 
from TALEN treated DNA had wild type sequence, and ten were mutant. This gives a 
mutation rate of 66% (10 out of 15) for the clones studied, compared to the RFLP analysis 
value of 43% (Figure 6.13). Eight of the clones derived from TALEN treated DNA have 
short deletions of 5 to 62 bp, with occasional substitutions that localise to the TALEN 
15/16 recognition sites (Figure 6.20 A). These mutations are characteristic of DSB repair 
events by NHEJ (Bibikova et al., 2002, Lloyd et al., 2005). Two of the clones of TALEN-
exposed DNA exhibited more substantial deletions of 320 and 758 bp (Figure 6.20 B). 
These larger deletions both produced unexpected digest patterns when analysed by 
restriction digest (Figure 6.19, lanes 2 and 14). Furthermore, they are indicative of the 
types of deletions which would result in VEZF1 knockout by NHEJ DSB repair, as in both 
clones the TSS and entire exon 1 of VEZF1 are deleted. TALEN pair 15/16 can therefore be 
used in either the v2 or v3 formats to generate mutations of VEZF1 that should result in 
the loss of expression without the need for gene targeting. 
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Figure 6.20 Sequence analysis of TALEN-directed VEZF1 promoter mutagenesis  
Sequencing data demonstrating the range of mutations observed at the VEZF1 promoter three 
days after transfection of TALEN 15/16 v2.  (A) Sequence in the region of the VEZF1 TSS in 8 
clones from TALEN treated DNA compared to wild type. Insertions (blue), substitution (red) 
and deletions observed (dashes).  The binding sites of TALEN 15/16 are highlighted in yellow. 
(B) Scaled diagram showing larger deletions identified in clones 1 & 4.  Purple boxes represent 
retained sequences and red lines represent deleted sequences.  The TALEN 15/16 binding site 
is illustrated by beige boxes.  The size of the deletion is indicated below the deleted region. 
The location of the TSS and ATG are represented by blue and green lines, respectively. Exon 1, 
illustrated by a darker purple box, was deleted in both clones. 
6.5 Discussion 
This chapter has described the development of reliable RFLP assays to test for ZFN and 
TALEN-directed mutations of the VEZF1 gene promoter. The assays reveal that human 
codon optimisation considerably improves the performance of TALENs. The assays also 
indicate that the addition of “Sharkey” enhanced cleavage mutations allowed obligate 
heterodimer TALENs to perform to at a comparable level to TALENs that contain wild type 
FokI cleavage domains. Finally, TALEN-directed mutations of the VEZF1 gene promoter 
were sequenced and the effect of such mutations on VEZF1 expression was studied. 
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The generic mismatch cleavage assays using the CelI or T7EI endonucleases were found to 
be challenging to optimise, with prevalent non-specific cleavage (section 6.3.1.2). 
Plasmids of known sequence differences were used as controls for CelI and T7EI assays. 
The use of these controls relies upon the ability of these enzymes to cleave single base 
pair mismatches. Both CelI and T7EI have been reported to cleave single base pair 
mismatches previously (Oleykowski et al., 1998, Kulinski et al., 2000, Tsuji and Niida, 
2008) and this principle is the basis of the commercial control samples for the Surveyor 
assay that uses CelI (Transgenomic). I was not able to define an incubation condition 
where single base matches could be identified over background non-specific cleavage by 
either CelI or T7EI. It is possible that sequence context may be important when studying 
such small mismatches.  
The higher than expected degree of non-specific cleavage of reannealed control DNA, 
irrespective of the degree of mismatch, suggests that mis-annealing may be the 
predominant flaw in this assay. I compared two different annealing protocols that involve 
either gradual or step-wise decreases in annealing temperatures after melting. Both 
approaches resulted in annealed products of the expected size on agarose gels, with a 
tighter banding observed for the stepwise procedure (data not shown), which I selected 
for the assays shown in this chapter. It is possible that the quality of the purified PCR 
product following gel extraction is not good enough for mismatch assays. Contaminants 
such as guanidium isothiocyanate, agarose fines or ethanol carryover from the agarose 
gel extraction of genomic PCR products may result in mis-annealed products that are 
legitimate endonuclease substrates. Future studies should avoid gel extraction 
completely. This approach would rely on optimised genomic PCR conditions that produce 
unique products that can be used directly in mismatch analyses. Mismatch analyses offer 
a generic solution to study the effects of ZFNs and TALENs, so further efforts to resolve 
the problems I have observed are worthwhile. 
RFLP assays were developed to enable the analysis of TALEN-directed mutagenesis.  
Unfortunately, it was not possible to develop an RFLP assay for the ZFNs prepared in this 
study due to the paucity of suitable restriction sites in the spacers of our ZFN designs. The 
presence of restriction sites should be considered when designing any nuclease strategy 
in future. Despite the straightforward principle of RFLP assays, and careful attempts to 
design and perform RFLP assays, I found that it can be sometimes difficult to interpret the 
169 
 
digestion profiles from these assays. Low degrees of mutation in mixed populations of 
cells, non-specific/background PCR products and the variable size and intensity of the 
digestion products from mutant DNA all present challenges that need to be considered in 
future TALEN designs. 
Primer design is obviously key in NHEJ assay design. Mispriming can lead to the 
production of non-specific PCR products, which interfere with interpretation. While I 
recommend TALEN designs be selected based on restriction enzymes present in their 
spacers, I recommend primers for RFLP assays be designed with expected digest patterns, 
from both WT and mutant samples, in mind. Inadequate primer design can result in digest 
patterns which can be problematic to resolve and can obscure interpretation. Primer 
design therefore must be carefully considered to ensure primers are specific and 
appropriate for RFLP patterns. 
One TALEN pair was found to be very efficient at directing mutagenesis of the VEZF1 gene 
promoter. Transfection of TALEN 15/16, which is designed to cleave at the transcription 
start site of the VEZF1 gene promoter, resulted in up to 46% mutagenesis when the RFLP 
products were visualised on agarose gels. All of the TALEN pairs have demonstrated some 
activity in RFLP assays, although none can be said to have performed as well as TALEN 
15/16. TALENs 17/18, 13/14 and 21/22 have all demonstrated clear activity in RFLP 
analysis visualised on agarose gels (Figure 6.16, lane 3 & Figure 6.10, lanes 3 & 5, 
respectively). The high activity of TALEN 15/16 could be down to genomic location, as 
TALEN 15/16 is the only TALEN pair to be positioned separately from the others (Figure 
4.2). However, TALE domains which target the downstream genomic site have 
demonstrated binding as TALE Repressors (Chapter 4). The results of TALE performance 
are summarised in (Table 6.1). 
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TALE 
Domain 
Length 
Location 
(bp from 
TSS) 
VEZF1 
Repression 
Spacer 
Total TALEN 
Length 
(domains + 
spacer) 
TALEN performance 
Run 1 Run 2 v1 v2 v3 
13 16 +77 0.12 0.23 
30 74 + ++ + 
14 28 +123 1.18 1.04 
15 19 -31 0.78 0.71 
15 57 ++ +++ +++ 
16 23 +3 1.26 0.59 
17/19 28 +51 0.31 1.11 
15 65 +/- ++ +/- 
18 22 +94 0.20 0.93 
17/19 28 +51 0.31 1.11 
15 72 +/- + + 
20 29 +94 0.41 1.42 
21/23 19 +74 0.50 0.29 
30 74 ++ + + 
22 25 +123 0.93 0.80 
21/23 19 +74 0.50 0.29 
30 78 + + + 
24 29 +123 1.39 0.89 
Table 6.1 Summary of TALE performance 
Performance as TALE Repressors does not necessarily translate directly into performance 
as TALENs, but can serve as some indication as to how TALEN pairs will perform. Take for 
example TALENs 21/22 and 23/24, both of these TALENs demonstrated modest activity 
levels, TALEN 21/22 showed a slightly improved performance over 23/24 (Figure 6.10, 
lane 5). When taking into account the repression mediated by TALE 22 compared to TALE 
24, TALE 22 performed slightly better (Figure 4.18) and may be reflected in the 
performance of TALEN 21/22 versus 23/24. However, the use of TALE Repressor as 
predictors of TALEN activity does not hold in the case of TALEs 15 and 16, which were the 
greatest performing TALENs (Figure 6.13) but demonstrated only modest levels of 
repression (Figure 4.18). 
 The difficulties in using TALE Repressors as a predictor tool for TALEN activity may be due 
to unpredictable issues faced with reliance on both members of the TALEN pairs binding 
together in-situ, such as accessibility of both target sites simultaneously and ability of 
each partner to interact with the other in context. Experiments involving TALE Repressors 
do not serve to address either of these issues but can only provide information about 
each individual TALE domain binding in isolation and relies upon a different effector 
domain to report functionality. To assess the accessibility of each TALE binding site, 
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transcription factor ChIP data was obtained from the UCSC Genome Browser and 
locations of transcription factor binding was compared to TALE and ZFN recognition sites 
(Figure 6.21). Interestingly, the location where TALEN pair 15/16 binds has less 
transcription factors binding in this region, which may have enabled this TALEN pair to 
access its target site and resulted in the higher levels of DNA cleavage observed. 
Transcription factor binding at the recognition site of TALEs when used as TALE 
Repressors may also have inhibited Repressor functionality. However, levels of 
transcription factor binding at the recognition sites for TALEREP 13 and TALEREP 21/23 
was similar to that at the recognition sites of other TALE Repressors used in this study. 
The VEZF1 promoter remains largely uncharacterised and binding of regulatory elements 
has not been tested in functional assays. The true composite of transcription factors 
binding at this region remains to be determined and transcription factor data available 
from the ENCODE project is by no means an exhaustive list. However, levels of 
transcription factor binding at intended DNA target sites may be a parameter worth some 
consideration during the design process but from this data, it does not offer a definitive 
prediction of the functionality of one TALE domain over another.  
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Figure 6.21 Transcription Factor Binding at the VEZF1 Promoter 
Scale diagram of a 770 bp region of at the 5’ end of the VEZF1 gene promoter region based on 
UCSC Genome Browser alignments (hg19, chr17:56065164-56065933). Locations of ZFN, 
TALEN and TALEREP recognition sequences in the VEZF1 gene are depicted by black boxes 
above VEZF1 gene, shown in blue, which transcribes from right to left. Locations of ENCODE 
transcription factor binding, as measured by ChIP in K562 and HEK293 cells, in this region of 
the VEZF1 promoter are also shown. 
One interesting parallel has been revealed in the comparison between TALENs and TALE 
Repressors. An inverse relationship was identified between TALE domain length and level 
of repression induced, and the same can be said for TALENs, when the length of both 
TALEN monomers, plus the spacer is added together (Figure 6.22). The target site for 
TALEN 15/16 is a total of 57 bp DNA and is the shortest TALEN pair in our set. TALENs 
13/14 and 21/22 also performed well, and both of these TALENs bind 74 bp in total. 
These shorter TALE domains may have easier access to their target sites than their larger 
counterparts. The prospect of gaining higher activity levels from shorter domains is 
interesting as this would result in less labour in terms of TALE construction. Shorter TALE 
domains, targeting a shorter DNA sequence, may come at a cost of reduced specificity 
and the balance in terms of activity and specificity must be carefully managed. 
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Figure 6.22 Relationship between target site length and TALE activity 
Scatter plot illustrating the inverse relationship between (A) TALE repressor domain length and 
repression of VEZF1 (average of two biological replicates) and (B) total TALEN target length 
(TALE domains + spacer) and cleavage activity of v2 TALENs, based on scoring system in Table 
6.1. 
TALEN pair 15/16 is centred around a 15 bp spacer, which has been demonstrated to be 
optimal since beginning this study (Miller et al., 2011, Lei et al., 2012). I do not see a clear 
relationship between spacer size and TALEN performance in our analyses. The modest 
activity demonstrated by most TALENs has made it difficult to attribute differences in 
activity to a single design characteristic, which is shared by several TALEN pairs.  There is 
also no correlation between genomic target location and activity of both TALENs and 
TALEREPs (Figure 6.23). Target site accessibility was taken into account in the design of 
TALE domains but there does not seem to be an optimal targeting location within the 
VEZF1 promoter to facilitate the greatest level of gene repression or DNA cleavage. 
 
Figure 6.23 Genomic target site location does not determine TALE activity 
Scatter plot demonstrating that there is no correlation between (A) TALE repressor domain 
target site and repression of VEZF1 (average of two biological replicates) and (B) TALEN target 
site and cleavage activity of v2 TALENs, based on scoring system in Table 6.1. Location on gene 
is expressed as most 5’ base of TALEREP binding site and as centre of TALEN target site 
(domains + spacer). 
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Codon optimisation can be seen to have generally improved activity of TALENs, compare 
TALEN 15/16 v1 to v2 (Figure 6.13 lane 2 and lane 3). Overall, more distinctive banding 
can be observed in RFLP assays of DNA treated with codon optimised TALENs, for 
example TALEN 13/14 v2 (Figure 6.10, lane 3) and TALEN 17/18 v2 (Figure 6.16, lane 3). 
Performance of TALENs in v3 architectures is similar to that of v2 (Figure 6.13, lanes 3 & 4 
and Figure 6.16, lanes 6 & 7), demonstrating that obligate heterodimer FokI domains, 
including Sharkey, have similar activity levels as WT FokI. 
Sequencing analysis of TALEN-mediated mutations in TALEN 15/16 treated cells has 
demonstrated that it is possible to utilise NHEJ as a means of generating large scale 
deletions. Due to its target location in the VEZF1 promoter, there is every likelihood that 
the resulting mutant cells will have reduced VEZF1 expression as compared to WT.  The 
two large deletions observed (Figure 6.20) would be appropriate to knock out gene 
function, at least on one allele.  However, in a polyclonal population of cells, no reduction 
in VEZF1 expression was observed (Figure 6.17). This enforces the need to generate 
monoclonal lines from TALEN targeted cells, allowing for a large deletion to be 
propagated throughout a cell line.  Should nuclease-mediated DSB events only occur on 
one allele within a cell, as is most common (Santiago et al., 2008, Kwon et al., 2013), a 
second round of targeting may be performed and monoclonal lines generated from re-
targeted cells.  Our RFLP assay design would allow for easy identification of both homo- 
and heterozygous targeted lines. 
From the results, it has been demonstrated that at least five of our assembled TALENs to 
disrupt the VEZF1 promoter are functional, and that one pair, TALEN 15/16 is capable of 
mediating mutations with high efficiency.  The lack of effect on VEZF1 expression from 
NHEJ-mediated gene disruption demonstrates the “lottery” in using NHEJ alone as a 
means of genome editing. The mutations created by NHEJ repair induced by TALEN 15/16 
reveal there may be potential to create a VEZF1 knockout through the generation of 
monoclonal lines, although this may require two rounds of TALEN targeting. Coupled with 
the advancements planned for the targeting vector (Chapter 5), these results 
demonstrate that generation of a VEZF1 gene knockout by TALEN-mediated DSBs is 
within grasp.  
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7 Chapter 7 
Summary and Conclusions 
7.1 Summary of work presented in this thesis 
This study has described strategies to direct repression or mutation of VEZF1 using 
custom DNA binding proteins. Previously, RNAi-mediated knockdown of VEZF1 was found 
to be insufficient to deplete protein binding levels sufficiently to study the effects of 
VEZF1 on its many gene targets (Strogantsev, 2009). The VEZF1 gene promoter was 
targeted using ZFNs and TALEs fused to repressor and nuclease domains. TALE Repressors 
reduced VEZF1 expression to as little as 12% of WT expression levels and nucleases 
disrupted the VEZF1 gene promoter, with some TALENs resulting in over 65% mutation 
rates.  Analysis of TALEN-mediated mutations revealed that, in some cases, the VEZF1 
promoter had been removed during DSB repair via NHEJ. This study has identified an 
interesting correlation between TALE domain length and level of activity, both as 
repressors and nucleases. The findings and reagents described here can be applied to 
future approaches to modify any desired gene of interest. 
7.2 TALE-mediated Repression of VEZF1 
Ten TALE proteins which target the VEZF1 gene promoter were designed and assembled. 
The TALE proteins constructed were between 16 – 29 RVDs in length, in order to 
determine the optimal TALE design constraints. Each of the designed TALEs was 
assembled into a custom made expression vector, which mediated expression of our 
TALEs as repressor proteins utilising a SID-repressor protein. TALE-Repressors were 
transfected into HEK293 cells and VEZF1 repression was demonstrated by six of the ten 
TALE-Repressors constructed. Interestingly, I observed a correlation between TALE 
domain length and level of repression achieved. The longest TALE domains promoted the 
least repression of VEZF1, while the greatest knockdown was achieved using the shortest 
TALEs of our set.  
This inverse correlation is not a phenomenon which has been previously reported in 
studies employing either TALE Repressors or TALE Activators. This observation, however, 
has been reported in one study using TALE Nucleases (see Section 7.3). 
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TALE domains constructed and fused to transcriptional repression domains, tend to be 
around 20 RVDs in length and achieve between 2 and 10 fold repression (Cong et al., 
2012, Garg et al., 2012, Mahfouz et al., 2012). In this study, repression of down to 12% of 
WT levels was achieved using the shortest TALE domain constructed. This may be due to 
shorter TALEs perhaps finding easier access to their target sites by facing less competition 
with other endogenous transcription factors, or perhaps DNA-binding affinity of a TALE 
may decrease with TALE length. Another possibility is that the higher activity observed is 
due to higher expression of these shorter TALEs, which has not been assessed in this 
study. The utilisation of shorter TALE domains in order to gain higher levels of gene 
repression is a recommendation that must be considered carefully, as this cannot come at 
the expense of target specificity. The greatest level of repression observed in this study 
was mediated by a TALE which is 16 RVDs in length, which should be sufficient to target a 
unique DNA sequence within the human genome. The utilisation of TALE domains shorter 
than this may result in high levels of cytotoxicity, as has been observed with TALE 
nucleases of this length (Reyon et al., 2012b).  
This project arose through the difficulties in creating a robust VEZF1 knockdown and TALE 
Repressors do offer an alternative approach to this aim. The experiment described in 
Chapter 4, using TALE Repressors in HEK293 cells, has since been repeated by a colleague 
and analysis has been performed at later time points to determine if continuation of the 
experiment for a longer time period would promote greater levels of knockdown. 
However, this has revealed that the repressive effects of TALE-Repressors are becoming 
silenced when left for longer periods of time. This suggests that, in order to analyse cells 
at their greatest level of knockdown, samples must be collected at early time points, or 
that selection must be administered to retain high levels of repression. Employing a 
combination of TALE Repressors and RNAi has been demonstrated to have a synergistic 
effect, resulting in almost complete target gene repression (Garg et al., 2012). Following 
the levels of VEZF1 gene repression achieved with TALE Repressors 13 and 21/23, work is 
now ongoing in the West Lab to assess the level of VEZF1 repression attainable by 
combining with RNAi. This may facilitate the development of a robust and constitutive 
VEZF1 knockdown. 
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7.3 Nuclease-mediated modification of the VEZF1 Promoter 
Three pairs of ZFNs and the six pairs of TALENs were assembled to target the VEZF1 gene 
promoter. Originally, it was intended to create a VEZF1 knockout via HDR mediated 
removal of the VEZF1 promoter and insertion of a transgene. However, gene targeting 
experiments revealed high levels of random integration of the targeting vector, 
pTRGT_VEZF1. The designed nucleases were therefore used to promote NHEJ-mediated 
VEZF1 knockout, without the use of a targeting vector system. 
In this study, it was not possible to perform analysis of nuclease-mediated NHEJ using 
generic mismatch assays CelI and T7EI as both enzymes displayed high levels of non-
specific cleavage activity. While not a widely reported issue, analysis of TALEN-induced 
DNA mutations has now moved largely to the use of RFLP assays and this is now 
incorporated as a standard consideration in TALEN design approaches, such as TALE-NT 
(Doyle et al., 2012). 
Restriction fragment length polymorphism (RFLP) assays were developed to determine 
the level of nuclease-mediated NHEJ. Unfortunately, it was not possible to develop RFLP 
assays to determine the mutagenic activity of ZFNs used in this project, due to the nature 
of the restriction enzyme recognition sites found in the ZFN spacers. This demonstrates 
the need to consider the design of mutation detection assays at the initial TALEN and ZFN 
design stage. However, RFLP assays developed to asses TALEN activity have demonstrated 
that all TALEN pairs constructed in this project are functional, although to varying 
degrees. It is clear that codon optimisation improves TALEN activity and that obligate 
heterodimer FokI domains which include the Sharkey mutations can perform at similar 
levels to those with the WT FokI domain and this is in agreement with the findings of 
similar studies (Miller et al., 2011, Sanjana et al., 2012, Zhang et al., 2011). 
One TALEN pair, TALEN 15/16 was very efficient at directing mutagenesis of the VEZF1 
gene promoter. This TALEN pair binds the DNA sequence at the TSS of VEZF1. Sequence 
analysis of targeted cells revealed large scale deletions of the VEZF1 promoter, which 
would be sufficient to create a VEZF1 knockout. Interestingly, TALEN pair 15/16 was the 
shortest TALEN pair of all those designed, binding a total of 42 bp excluding spacer. This 
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observation is in parallel with the observation made using TALE repressors – the shortest 
TALEs drive the greatest level of activity. 
The observation that the greatest level of target site mutation was achieved using the 
shortest TALE domain, has been previously reported in another study (Reyon et al., 
2012b). TALEN disruption of a GFP reporter gene was analysed 2 and 5 days post-
transfection. Shorter TALENs (8 - 10 RVDs to each TALE) were found to mediate greater 
GFP disruption when compared to longer TALENs (14 - 19 RVDs per TALE domain) at 2 
days post-transfection. However, when quantified 5 days post-transfection, GFP 
disruption mediated by the shorter length TALENs had significantly reduced, while 
mutagenicity by longer TALENs was fairly consistent. The initial high levels of GFP 
disruption observed when using shorter TALENs suggests that shorter TALENs can be 
more cytotoxic. The short TALEs used by Reyon et al. (2012b) are much shorter by the 
TALE domains used in this study while the same correlation between TALE length and 
activity has been observed. However, the results of both the study conducted by Reyon et 
al. (2012b) and data presented in this thesis recommend the use of TALE domains of 
around the same length. I would recommend each TALE domain be up to around 20 RVDs 
in length to reduce cytotoxicity (as observed in Reyon et al. (2012b)), maintain target site 
specificity and offer greater chance of improved functionality. 
7.4 CRISPR-Cas9 Technology 
During the course of this work, another gene targeting technology was developed which 
utilises the RNA-guided endonuclease Cas9 to create DSBs at a predefined target locus. 
The CRISPR-Cas9 gene targeting system offers an alternative platform for gene targeting, 
operating via a different mode of DNA recognition to ZFN and TALEN technologies. 
The CRISPR-Cas9 system is an adaptable immune response used by many bacteria to 
protect from invading DNA of viruses or plasmids via RNA guided DNA cleavage (Jinek et 
al., 2012, Hsu et al., 2014). Short segments of foreign DNA spacers are inserted between 
CRISPRs (Clustered Regulatory Short Interspaced Palindromic Repeats). Once transcribed, 
CRISPR arrays are processed into CRISPR-RNAs (crRNAs) which harbour a unique 
sequence, transcribed from the invading DNA. The crRNA then hybridises with 
transactivating crRNA (tracrRNA), collectively forming a short guide RNA (sgRNA, Figure 
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7.1). The sgRNA then forms a complex with Cas9 nuclease (Deltcheva et al., 2011). The 
CRISPR-Cas9 complex is directed to the desired DNA target site via twenty variable 
nucleotides at the 5’ end of the sgRNA. DNA specificity of the CRISPR-Cas9 platform is 
driven by these twenty nucleotides, which bind the intended DNA target site via standard 
Watson-Crick base pairing (Gasiunas et al., 2012, Jinek et al., 2012). The designed DNA 
target site must be adjacent to a short sequence called the protospacer adjacent motif 
(PAM) and DNA cleavage occurs 3 nucleotides 5’ of this motif (Harrison et al., 2014). Cas9-
mediated DSBs can then be repaired by NHEJ or HDR, performing targeted genome 
manipulations. 
Web based design tools are now available to select target DNA sequences within a region 
or gene of interest. Once designed, the sgRNA sequences can then be ordered as two 
short oligos and cloned into an expression vector, many flavours of which are now 
available through www.addgene.org.  
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Figure 7.1 Overview of CRISPR-Cas9 System for Targeted Gene Editing 
Cartoon depicting the engineered CRISPR-Cas9 system, which is composed of a fusion of crRNA 
and tracrRNA to form an sgRNA. The sgRNA forms a complex with Cas9 DNA nuclease. The 
sgRNA directs Cas9 to the target DNA cleavage site, which is complimentary to sequences in 
the first 20 nucleotides in the crRNA (Sander and Joung, 2014). 
CRISPR-Cas9 technology has been used to successfully manipulate many genes in a variety 
of cell types and model organisms including cultured human cells, human pluripotent 
stem cells, zebrafish, fruit files and rats (reviewed in (Hsu et al., 2014). CRISPR-Cas9 
technology offers the potential for higher rates of gene targeting than ZFNs and TALENs, 
with generally around 30% of cells in a targeted population harbouring evidence of Cas9 
mediated DNA cleavage repair (Gasiunas and Siksnys, 2013). 
The CRISPR-Cas9 technology offers the opportunity to introduce multiple DSBs in parallel 
by expression of multiple sgRNAs to various locations. This adaptation, known as 
multiplexing, has been used to target up to 5 genes simultaneously and offers a unique 
advantage of the CRISPR-Cas9 platform over ZFNs and TALENs. Multiplexing can be 
exploited to direct large scale targeted deletion of a desired gene or to knock out multiple 
genes in parallel (Cong et al., 2013, Mali et al., 2013). 
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Modified Cas9 endonucleases have been developed which allow the use of the CRISPR-
Cas9 platform as a single stranded DNA nickase and as a fusion to a transcriptional 
regulators, such as activators and repressors. Cas9 nickases can be utilised to promote 
DNA repair via HDR rather than NHEJ, inserting targeted gene mutations (Gasiunas et al., 
2012, Jinek et al., 2012). Transcriptional regulation directed by CRISPR-Cas9 has been 
demonstrated to enhance or repress transcription to levels of around 5-20 fold activation 
and around 5 - 15 fold repression of target genes in human cells. Furthermore, several 
studies have demonstrated a synergistic effect of when multiplexed CRISPR-
transcriptional regulators are used simultaneously (Cheng et al., 2013, Gilbert et al., 2013, 
Maeder et al., 2013a, Perez-Pinera et al., 2013). 
CRISPR-Cas9 technology is largely in its infancy and still faces similar challenges those 
encountered with ZFN and TALEN platforms. High levels of off target cleavage have been 
reported in some studies. There are ongoing studies investigating ways to improve 
efficiency and activity of CRISPR-Cas9 technology (Fu et al., 2013, Fu et al., 2014, Hsu et 
al., 2013). CRISPRs will undoubtedly benefit from some of the groundwork already 
covered in the development of ZFN and TALEN technologies and the advances in this 
platform will occur rapidly. The West Lab has now constructed CRISPRs to target VEZF1 
and is utilising knowledge gained from targeting strategy design and mutation screening 
in this study to develop further strategies to target VEZF1 and other genes. Future 
genome modification projects conducted by the West lab will now incorporate the design 
of RFLP assay as part of initial gene targeting strategy design processes. From the issues 
faced in this study, it is evident that careful consideration must be taken in both the 
design of PCR primers and selection of restriction enzymes when designing RFLP mutation 
detection assays. For ease of analysis, it is recommended that PCR products be 1 - 1.5 kb 
in length and restriction enzymes chosen cleave this PCR amplicon into up to 5 fragments. 
Furthermore, it is useful to design the assay such that the restriction enzyme which 
cleaves in the TALEN spacer also cleaves at least once more in the PCR product, ensuring 
an internal control for enzyme functionality. Lastly, the choice of other restriction 
enzymes should also be carefully calculated. Both enzymes must be suitable for use in the 
double digest reactions and digest product resolution, including mutant fragment 
detection, should be considered as part of the genome modification design strategy from 
the first step. The implementation of design parameters recommended here have 
allowed CRISPR projects in the West Lab to progress much faster and have generated 
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results for analysis of the biological effect of VEZF1 mutation in a much shorter timescale 
than would have been possible without the knowledge and experience gained from 
genome engineering strategies described in this thesis. 
7.5 Conclusions 
Prior to this study, attempts at creating a VEZF1 knockdown had been insufficient for loss 
of function, resulting in depletion of VEZF1 protein binding at around only half of its 
putative target genes (Strogantsev, 2009). This project described the design, assembly 
and assessment of genome modification tools to target the VEZF1 gene promoter. 
Engineered DNA binding modules constructed in this study have been used to successfully 
repress and modify the VEZF1 promoter. Investigations carried out have enabled the 
development of recommended parameters to aid in the design of successful TALE 
domains. The knowledge and reagents described here have paved the way for future 
creation of a VEZF1 knockout for investigation. Furthermore, many of the vector systems 
constructed for this project are amenable for insertion of any designed TALE to enable 
future studies of any desired target gene. 
The jury is, so far, still out on whether CRISPR technology will surpass TALENs as the 
method of choice for targeted gene modification. However, ZFNs are to date the only of 
these methods to have been tested in human trials. It is apparent, however, that the 
lessons learned in assessment of ZF and TALE technologies will spur the progress of 
CRISPRs and keep genome modification at the very cutting edge of science. 
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8 Appendix I 
      Primer Sequences 
Primer Name Sequence 
pCR8_F1 TTGATGCCTGGCAGTTCCCT 
pCR8_R1 CGAACCGAACAGGCTTATGT 
RFP5_Nhe_Age GATCGCTAGCACCGGTCGCCACCATGAGCG 
RFP3_Bam_Not GATCGCGGCCGCTTAGGATCCTCTGTGCCCCAGTTTGCTAG 
VEZF1_5’arm_H3F GATCAAGCTTGTTCTGGGGGTGAAGGAG 
VEZF1_5’arm_AscR GATCGGCGCGCCTCGGAGCTCAGCCAGTGC 
VEZF1_3’arm_H3F GATCAAGCTTGTACTGGGGGCCCCCCCGGG 
VEZF1_3’arm_AscR GATCGGCGCGCCGAGAGCTGGACAGAGGGAGA 
FokI_CelI_Cont F GCACCATGGGACCTAAGAAA 
FokI_CelI_Cont R GCGATGCAATTTCCTCATTT 
hVEZF1pro-374 F CTCCGCTGAGGGTCTAACAG 
hVEZF1pro+895 R CAGAGGGAGAAGGTGTCAGC 
M13 F GTAAAACGACGGCCAGT 
M13 R AACAGCTATGACCATG 
β-Actin_F (qRT-PCR) TGCTGCGCTCGTTGTTGA 
β-Actin_R (qRT-PCR) TCGCCGGGGACGATG 
VEZF1_F (qRT-PCR) 
 
AAAGGATCGCATGACCTACC 
VEZF1_R (qRT-PCR) AATGATCAGGCCTCGAGAAG 
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9 Appendix II 
Sequencing Data 
A. ZF35 
XbaI XmaI ZF7 ZF23 ZF42 BamHI 
CGACGATAAATCTAGACCCGGGGAGAAGCCGCATATTTGCCACATCCAAGGCTGTGGG
AAGGTGTACGGCCGTAGCGATGACCTGACACGTCACTTGCGCTGGCATACCGGGGAGC
GGCCATTTATGTGTACCTGGTCATACTGTGGGAAACGCTTCACACGTAGCGATGACCT
GCAACGTCACAAACGTACACACACCGGGGAGAAGAAATTTGCCTGCCCTGAGTGTCCT
AAGCGCTTCATGCGTAGCGATGACCTGACACGTCATATCAAGACCCACACCGGTGGAT
CCCAACTAGTCAAAAGTGAACTGGAGGAGAA 
B. ZF36 
XbaI XmaI ZF6 ZF30 ZF50 BamHI 
GACGACGATAAATCTAGACCCGGGGAGAAGCCGCATATTTGCCACATCCAAGGCTGTG
GGAAGGTGTACGGCGAGCGCGGTACACTTGCACGTCACTTGCGCTGGCATACCGGGGA
GCGGCCATTTATGTGTACCTGGTCATACTGTGGGAAACGCTTCACAGATCGTAGCGCA
CTGGCACGTCACAAACGTACACACACCGGGGAGAAGAAATTTGCCTGCCCTGAGTGTC
CTAAGCGCTTCATGCAAAGCAGCGCACTGACACGTCATATCAAGACCCACACCGGTGG
ATCCCAACTAGTCAAAAGTGAACTGGAGGAGAA 
C. ZF37 
XbaI XmaI ZF11 ZF26 ZF42 BamHI 
GGATGACGACGATAAATCTAGACCCGGGGAGAAGCCGCATATTTGCCACATCCAAGGC
TGTGGGAAGGTGTACGGCCGTAGCGATCACCTGGCACGTCACTTGCGCTGGCATACCG
GGGAGCGGCCATTTATGTGTACCTGGTCATACTGTGGGAAACGCTTCACAGATCGTAG
CCACCTCGCACGTCACAAACGTACACACACCGGGGAGAAGAAATTTGCCTGCCCTGAG
TGTCCTAAGCGCTTCATGCGTAGCGATGACCTGACACGTCATATCAAGACCCACACCG
GTGGATCCCAACTAGTCAAAAGTGAACTGGAGGAGA 
D. ZF38 
XbaI XmaI ZF11 ZF23 ZF36 BamHI 
AAGGATGACGACGATAAATCTAGACCCGGGGAGAAGCCGCATATTTGCCACATCCAAG
GCTGTGGGAAGGTGTACGGCCGTAGCGATCACCTGGCACGTCACTTGCGCTGGCATAC
CGGGGAGCGGCCATTTATGTGTACCTGGTCATACTGTGGGAAACGCTTCACACGTAGC
GATGACCTGCAACGTCACAAACGTACACACACCGGGGAGAAGAAATTTGCCTGCCCTG
AGTGTCCTAAGCGCTTCATGCAAAGCGGGAACCTGGCACGTCATATCAAGACCCACAC
CGGTGGATCCCAACTAGTCAAAAGTGAACTGGAGGAGAA 
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E. ZF43 
XbaI XmaI ZF98 ZF91 ZF132 ZF78 BamHI 
CCTCTAGACCCGGGGAGAAGCCTTACAAATGCCCAGAATGTGGAAAGAGTTTTAGCCA
TACTGGACACCTCCTTGAACACCAGAGAACACATACCGGGGAGAAGCCTTACAAATGC
CCAGAATGTGGAAAGAGTTTTAGCAGGGCAGATAATCTCACAGAACACCAGAGAACAC
ATACCGGGGAGAAGCCTTTCCAGTGCAAGACCTGCCAGCGGAAATTCAGCCGGAGCGA
CCACCTGAAGACCCACACCCGGACACACACCGGGGAGAAGCCTTACAAATGCCCAGAA
TGTGGAAAGAGTTTTAGCTCTCCTGCTGATCTCACAAGACACCAGAGAACACATACCG
GTGGATCCTCTGCACAGTAGT 
F. ZF44 
XbaI XmaI ZF108 ZF139 ZF108 ZF108 BamHI 
AAATCTAGACCCGGGGAGAAGCCTTACACGTGCAGCGACTGCGGCAAGGCATTTCGCG
ACAAGTCCTGCCTGAACCGCCACAGACGCACCCACACCGGGGAGAAGCCTTACGAGTG
CAACTACTGCGGCAAGACGTTCAGCGTGAGCTCCACGCTCATTCGCCACCAGCGCATC
CACACCGGGGAGAAGCCTTACACGTGCAGCGACTGCGGCAAGGCATTTCGCGACAAGT
CCTGCCTGAACCGCCACAGACGCACCCACACCGGGGAGAAGCCTTACACGTGCAGCGA
CTGCGGCAAGGCATTTCGCGACAAGTCCTGCCTGAACCGCCACAGACGCACCCACACC
GGTGGATCCCAACTAGTCAAAAG 
G. FokI KK-S 
XbaI HindIII BamHI FokI E490K,I538K - S418P,K441E 
ACGACGATAAATCTAGATAGTAAGCTTGGATCCCAACTAGTCAAAAGTGAACTGGAGG
AGAAGAAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATT
AATTGAAATTGCCAGAAATCCCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAA
TTTTTTATGAAAGTTTATGGATATAGAGGTGAACATTTGGGTGGATCAAGGAAACCGG
ACGGAGCAATTTATACTGTCGGATCTCCTATTGATTACGGTGTGATCGTGGATACTAA
AGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCAAGCAGATGAAATGCAACGATAT
GTCAAAGAAAATCAAACACGAAACAAACATATCAACCCTAATGAATGGTGGAAAGTCT
ATCCATCTTCTGTAACGGAATTTAAGTTTTTATTTGTGAGTGGTCACTTTAAAGGAAA
CTACAAAGCTCAGCTTACACGATTAAATCATAAGACTAATTGTAATGGAGCTGTTCTT
AGTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTAACCTTAG
AGGAAGTGAGACGGAAATTTAATAACGGCGAGATAAACTTTTAAGGGCCCTTCGAAGG
TAAGCCTATCCCTAACC 
H. FokI EL-S 
XbaI HindIII BamHI FokI Q486E,I499L - S418P,K441E 
ACGACGATAAATCTAGATAGTAAGCTTGGATCCCAACTAGTCAAAAGTGAACTGGAGG
AGAAGAAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATT
AATTGAAATTGCCAGAAATCCCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAA
TTTTTTATGAAAGTTTATGGATATAGAGGTGAACATTTGGGTGGATCAAGGAAACCGG
ACGGAGCAATTTATACTGTCGGATCTCCTATTGATTACGGTGTGATCGTGGATACTAA
AGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCAAGCAGATGAAATGGAGCGATAT
GTCAAAGAAAATCAAACACGAAACAAACATCTCAACCCTAATGAATGGTGGAAAGTCT
ATCCATCTTCTGTAACGGAATTTAAGTTTTTATTTGTGAGTGGTCACTTTAAAGGAAA
CTACAAAGCTCAGCTTACACGATTAAATCATAAGACTAATTGTAATGGAGCTGTTCTT
AGTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTAACCTTAG
AGGAAGTGAGACGGAAATTTAATAACGGCGAGATAAACTTTTAAGGGCCCTTCGAAGG
TAAGCCTATCCCTAACC 
 
186 
 
References 
AITSEBAOMO, J., KINGSLEY-KALLESEN, M. L., WU, Y., QUERTERMOUS, T. & PATTERSON, C. 
2001. Vezf1/DB1 is an endothelial cell-specific transcription factor that regulates 
expression of the endothelin-1 promoter. J Biol Chem, 276, 39197-205. 
AYER, D. E., LAHERTY, C. D., LAWRENCE, Q. A., ARMSTRONG, A. P. & EISENMAN, R. N. 
1996. Mad proteins contain a dominant transcription repression domain. Mol Cell 
Biol, 16, 5772-81. 
BABON, J. J., MCKENZIE, M. & COTTON, R. G. 2003. The use of resolvases T4 endonuclease 
VII and T7 endonuclease I in mutation detection. Mol Biotechnol, 23, 73-81. 
BAE, K. H., KWON, Y. D., SHIN, H. C., HWANG, M. S., RYU, E. H., PARK, K. S., YANG, H. Y., 
LEE, D. K., LEE, Y., PARK, J., KWON, H. S., KIM, H. W., YEH, B. I., LEE, H. W., SOHN, S. 
H., YOON, J., SEOL, W. & KIM, J. S. 2003. Human zinc fingers as building blocks in 
the construction of artificial transcription factors. Nat Biotechnol, 21, 275-80. 
BATEMAN, A., BIRNEY, E., CERRUTI, L., DURBIN, R., ETWILLER, L., EDDY, S. R., GRIFFITHS-
JONES, S., HOWE, K. L., MARSHALL, M. & SONNHAMMER, E. L. 2002. The Pfam 
protein families database. Nucleic Acids Res, 30, 276-80. 
BEERLI, R. R., SEGAL, D. J., DREIER, B. & BARBAS, C. F. 1998. Toward controlling gene 
expression at will: Specific regulation of the erbB-2/HER-2 promoter by using 
polydactyl zinc finger proteins constructed from modular building blocks. Proc 
Natl Acad Sci U S A. 
BELL, A., WEST, A. & FELSENFELD, G. 1999. The protein CTCF is required for the enhancer 
blocking activity of vertebrate insulators. Cell, 98, 387-96. 
BEUMER, K. J., TRAUTMAN, J. K., BOZAS, A., LIU, J. L., RUTTER, J., GALL, J. G. & CARROLL, 
D. 2008. Efficient gene targeting in Drosophila by direct embryo injection with 
zinc-finger nucleases. Proc Natl Acad Sci U S A, 105, 19821-6. 
BEUMER, K. J., TRAUTMAN, J. K., CHRISTIAN, M., DAHLEM, T. J., LAKE, C. M., HAWLEY, R. 
S., GRUNWALD, D. J., VOYTAS, D. F. & CARROLL, D. 2013. Comparing zinc finger 
nucleases and transcription activator-like effector nucleases for gene targeting in 
Drosophila. G3 (Bethesda), 3, 1717-25. 
BIBIKOVA, M., CARROLL, D., SEGAL, D. J., TRAUTMAN, J. K., SMITH, J., KIM, Y. G. & 
CHANDRASEGARAN, S. 2001. Stimulation of homologous recombination through 
targeted cleavage by chimeric nucleases. Mol Cell Biol, 21, 289-97. 
BIBIKOVA, M., GOLIC, M., GOLIC, K. & CARROLL, D. 2002. Targeted chromosomal cleavage 
and mutagenesis in Drosophila using zinc-finger nucleases. Genetics, 161, 1169-75. 
BITINAITE, J., WAH, D. A., AGGARWAL, A. K. & SCHILDKRAUT, I. 1998. FokI dimerization is 
required for DNA cleavage. Proc Natl Acad Sci U S A, 95, 10570-5. 
BOCH, J., SCHOLZE, H., SCHORNACK, S., LANDGRAF, A., HAHN, S., KAY, S., LAHAYE, T., 
NICKSTADT, A. & BONAS, U. 2009. Breaking the code of DNA binding specificity of 
TAL-type III effectors. Science, 326, 1509-12. 
BOGDANOVE, A. J., SCHORNACK, S. & LAHAYE, T. 2010. TAL effectors: finding plant genes 
for disease and defense. Curr Opin Plant Biol, 13, 394-401. 
BRENNEMAN, M., GIMBLE, F. S. & WILSON, J. H. 1996. Stimulation of intrachromosomal 
homologous recombination in human cells by electroporation with site-specific 
endonucleases. Proc Natl Acad Sci U S A, 93, 3608-12. 
BULTMANN, S., MORBITZER, R., SCHMIDT, C. S., THANISCH, K., SPADA, F., ELSAESSER, J., 
LAHAYE, T. & LEONHARDT, H. 2012. Targeted transcriptional activation of silent 
oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic 
modifiers. Nucleic Acids Res, 40, 5368-77. 
187 
 
BÜTTNER, D. & BONAS, U. 2002. NEW EMBO MEMBER’S REVIEW: Getting across—
bacterial type III effector proteins on their way to the plant cell. Embo j. Oxford, 
UK. 
CADE, L., REYON, D., HWANG, W. Y., TSAI, S. Q., PATEL, S., KHAYTER, C., JOUNG, J. K., 
SANDER, J. D., PETERSON, R. T. & YEH, J. R. 2012. Highly efficient generation of 
heritable zebrafish gene mutations using homo- and heterodimeric TALENs. 
Nucleic Acids Res, 40, 8001-10. 
CARLSON, D. F., TAN, W., LILLICO, S. G., STVERAKOVA, D., PROUDFOOT, C., CHRISTIAN, M., 
VOYTAS, D. F., LONG, C. R., WHITELAW, C. B. & FAHRENKRUG, S. C. 2012. Efficient 
TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci U S A, 109, 17382-
7. 
CARPENTER, A. E., MEMEDULA, S., PLUTZ, M. J. & BELMONT, A. S. 2005. Common Effects 
of Acidic Activators on Large-Scale Chromatin Structure and Transcription. Mol Cell 
Biol. 
CARROLL, D. 2011. Genome engineering with zinc-finger nucleases. Genetics, 188, 773-82. 
CERMAK, T., DOYLE, E. L., CHRISTIAN, M., WANG, L., ZHANG, Y., SCHMIDT, C., BALLER, J. 
A., SOMIA, N. V., BOGDANOVE, A. J. & VOYTAS, D. F. 2011. Efficient design and 
assembly of custom TALEN and other TAL effector-based constructs for DNA 
targeting. Nucleic Acids Res, 39, e82. 
CHEN, S., OIKONOMOU, G., CHIU, C. N., NILES, B. J., LIU, J., LEE, D. A., ANTOSHECHKIN, I. & 
PROBER, D. A. 2013. A large-scale in vivo analysis reveals that TALENs are 
significantly more mutagenic than ZFNs generated using context-dependent 
assembly. Nucleic Acids Res, 41, 2769-78. 
CHENG, A. W., WANG, H., YANG, H., SHI, L., KATZ, Y., THEUNISSEN, T. W., RANGARAJAN, 
S., SHIVALILA, C. S., DADON, D. B. & JAENISCH, R. 2013. Multiplexed activation of 
endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. 
Cell Res, 23, 1163-71. 
CHOULIKA, A., PERRIN, A., DUJON, B. & NICOLAS, J. F. 1995. Induction of homologous 
recombination in mammalian chromosomes by using the I-SceI system of 
Saccharomyces cerevisiae. Mol Cell Biol, 15, 1968-73. 
CHRISTIAN, M., CERMAK, T., DOYLE, E. L., SCHMIDT, C., ZHANG, F., HUMMEL, A., 
BOGDANOVE, A. J. & VOYTAS, D. F. 2010. Targeting DNA double-strand breaks 
with TAL effector nucleases. Genetics, 186, 757-61. 
CHUNG, J. H., WHITELEY, M. & FELSENFELD, G. 1993. A 5' element of the chicken beta-
globin domain serves as an insulator in human erythroid cells and protects against 
position effect in Drosophila. Cell, 74, 505-14. 
CONG, L., RAN, F. A., COX, D., LIN, S., BARRETTO, R., HABIB, N., HSU, P. D., WU, X., JIANG, 
W., MARRAFFINI, L. A. & ZHANG, F. 2013. Multiplex genome engineering using 
CRISPR/Cas systems. Science, 339, 819-23. 
CONG, L., ZHOU, R., KUO, Y. C., CUNNIFF, M. & ZHANG, F. 2012. Comprehensive 
interrogation of natural TALE DNA-binding modules and transcriptional repressor 
domains. Nat Commun, 3, 968. 
CONNELLY, J., BARKER, J., PRUETT-MILLER, S. & PORTEUS, M. 2010. Gene correction by 
homologous recombination with zinc finger nucleases in primary cells from a 
mouse model of a generic recessive genetic disease. Mol Ther, 18, 1103-10. 
CORNU, T., THIBODEAU-BEGANNY, S., GUHL, E., ALWIN, S., EICHTINGER, M., JOUNG, J. & 
CATHOMEN, T. 2008. DNA-binding specificity is a major determinant of the activity 
and toxicity of zinc-finger nucleases. Mol Ther, 16, 352-8. 
CROCKER, J. & STERN, D. L. 2013. TALE-mediated modulation of transcriptional enhancers 
in vivo. Nat Methods, 10, 762-7. 
188 
 
DAVIS, D. & STOKOE, D. 2010. Zinc finger nucleases as tools to understand and treat 
human diseases. BMC Med, 8, 42. 
DAVIS, G. D. & PRUETT-MILLER, S. M. 2010. ZFN Donor Design -- Codon and Single Base 
Genome Editing Using Zinc Finger Nucleases. Biowire -- A Look into the Future of 
Genome Editing. Fall 2010 ed. Sigma Life Science: Sigma Aldrich. 
DAWSON, J. F. 2007. Electronic Publishing as a Course Context for a Capstone Project on 
Protein Design. Journal of Electronic Publishing, 10. 
DELTCHEVA, E., CHYLINSKI, K., SHARMA, C. M., GONZALES, K., CHAO, Y., PIRZADA, Z. A., 
ECKERT, M. R., VOGEL, J. & CHARPENTIER, E. 2011. CRISPR RNA maturation by 
trans-encoded small RNA and host factor RNase III. Nature, 471, 602-7. 
DESJARLAIS J R & BERG, J. M. 1993. Use of a zinc-finger consensus sequence framework 
and specificity rules to design specific DNA binding proteins. Proc Natl Acad Sci U S 
A., 15, 2256–2260. 
DICKSON, J., GOWHER, H., STROGANTSEV, R., GASZNER, M., HAIR, A., FELSENFELD, G. & 
WEST, A. 2010. VEZF1 elements mediate protection from DNA methylation. PLoS 
Genet, 6, e1000804. 
DOYLE, E. L., BOOHER, N. J., STANDAGE, D. S., VOYTAS, D. F., BRENDEL, V. P., VANDYK, J. 
K. & BOGDANOVE, A. J. 2012. TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: 
tools for TAL effector design and target prediction. Nucleic Acids Res, 40, W117-
22. 
DOYON, Y., VO, T. D., MENDEL, M. C., GREENBERG, S. G., WANG, J., XIA, D. F., MILLER, J. 
C., URNOV, F. D., GREGORY, P. D. & HOLMES, M. C. 2011. Enhancing zinc-finger-
nuclease activity with improved obligate heterodimeric architectures. Nat 
Methods, 8, 74-9. 
DREIER, B., BEERLI, R. R., SEGAL, D. J., FLIPPIN, J. D. & BARBAS, C. F., 3RD 2001. 
Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA 
sequences and their use in the construction of artificial transcription factors. J Biol 
Chem, 276, 29466-78. 
DREIER, B., FULLER, R. P., SEGAL, D. J., LUND, C. V., BLANCAFORT, P., HUBER, A., KOKSCH, 
B. & BARBAS, C. F., 3RD 2005. Development of zinc finger domains for recognition 
of the 5'-CNN-3' family DNA sequences and their use in the construction of 
artificial transcription factors. J Biol Chem, 280, 35588-97. 
DREIER, B., SEGAL, D. J. & BARBAS, C. F., 3RD 2000. Insights into the molecular recognition 
of the 5'-GNN-3' family of DNA sequences by zinc finger domains. J Mol Biol, 303, 
489-502. 
DURAI, S., MANI, M., KANDAVELOU, K., WU, J., PORTEUS, M. & CHANDRASEGARAN, S. 
2005. Zinc finger nucleases: custom-designed molecular scissors for genome 
engineering of plant and mammalian cells. Nucleic Acids Res, 33, 5978-90. 
ELLIOTT, B., RICHARDSON, C., WINDERBAUM, J., NICKOLOFF, J. & JASIN, M. 1998. Gene 
conversion tracts from double-strand break repair in mammalian cells. Mol Cell 
Biol, 18, 93-101. 
ELROD-ERICKSON, M., BENSON, T. E. & PABO, C. O. 1998. High-resolution structures of 
variant Zif268-DNA complexes: implications for understanding zinc finger-DNA 
recognition. Structure, 6, 451-64. 
EMERSON, R. O. & THOMAS, J. H. 2009. Adaptive Evolution in Zinc Finger Transcription 
Factors. PLoS Genet., 5, 1-12. 
FAIRALL, L., SCHWABE, J. W., CHAPMAN, L., FINCH, J. T. & RHODES, D. 1993. The crystal 
structure of a two zinc-finger peptide reveals an extension to the rules for zinc-
finger/DNA recognition. Nature, 366, 483-7. 
189 
 
FU, Y., FODEN, J. A., KHAYTER, C., MAEDER, M. L., REYON, D., JOUNG, J. K. & SANDER, J. D. 
2013. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in 
human cells. Nat Biotechnol, 31, 822-6. 
FU, Y., SANDER, J. D., REYON, D., CASCIO, V. M. & JOUNG, J. K. 2014. Improving CRISPR-
Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol, 32, 279-84. 
GAJ, T., GERSBACH, C. A. & BARBAS, C. F., 3RD 2013. ZFN, TALEN, and CRISPR/Cas-based 
methods for genome engineering. Trends Biotechnol, 31, 397-405. 
GAO, X., TSANG, J. C., GABA, F., WU, D., LU, L. & LIU, P. 2014. Comparison of TALE 
designer transcription factors and the CRISPR/dCas9 in regulation of gene 
expression by targeting enhancers. Nucleic Acids Res, 42, e155. 
GARG, A., LOHMUELLER, J. J., SILVER, P. A. & ARMEL, T. Z. 2012. Engineering synthetic TAL 
effectors with orthogonal target sites. Nucleic Acids Res, 40, 7584-95. 
GASIUNAS, G., BARRANGOU, R., HORVATH, P. & SIKSNYS, V. 2012. Cas9-crRNA 
ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity 
in bacteria. Proc Natl Acad Sci U S A, 109, E2579-86. 
GASIUNAS, G. & SIKSNYS, V. 2013. RNA-dependent DNA endonuclease Cas9 of the CRISPR 
system: Holy Grail of genome editing? Trends Microbiol, 21, 562-7. 
GEISSLER, R., SCHOLZE, H., HAHN, S., STREUBEL, J., BONAS, U., BEHRENS, S. E. & BOCH, J. 
2011. Transcriptional activators of human genes with programmable DNA-
specificity. PLoS One, 6, e19509. 
GERALD, D., ADINI, I., SHECHTER, S., PERRUZZI, C., VARNAU, J., HOPKINS, B., 
KAZEROUNIAN, S., KURSCHAT, P., BLACHON, S., KHEDKAR, S., BAGCHI, M., 
SHERRIS, D., PRENDERGAST, G. C., KLAGSBRUN, M., STUHLMANN, H., RIGBY, A. C., 
NAGY, J. A. & BENJAMIN, L. E. 2013. RhoB controls coordination of adult 
angiogenesis and lymphangiogenesis following injury by regulating VEZF1-
mediated transcription. Nat Commun, 4, 2824. 
GILBERT, L. A., LARSON, M. H., MORSUT, L., LIU, Z., BRAR, G. A., TORRES, S. E., STERN-
GINOSSAR, N., BRANDMAN, O., WHITEHEAD, E. H., DOUDNA, J. A., LIM, W. A., 
WEISSMAN, J. S. & QI, L. S. 2013. CRISPR-mediated modular RNA-guided 
regulation of transcription in eukaryotes. Cell, 154, 442-51. 
GOWHER, H., STUHLMANN, H. & FELSENFELD, G. 2008. Vezf1 regulates genomic DNA 
methylation through its effects on expression of DNA methyltransferase Dnmt3b. 
Genes Dev, 22, 2075-84. 
GRONER, A. C., MEYLAN, S., CIUFFI, A., ZANGGER, N., AMBROSINI, G., DENERVAUD, N., 
BUCHER, P. & TRONO, D. 2010. KRAB-zinc finger proteins and KAP1 can mediate 
long-range transcriptional repression through heterochromatin spreading. PLoS 
Genet, 6, e1000869. 
GUO, J., GAJ, T. & BARBAS, C. R. 2010. Directed evolution of an enhanced and highly 
efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol, 400, 96-107. 
HALL, D. B. & STRUHL, K. 2002. The VP16 activation domain interacts with multiple 
transcriptional components as determined by protein-protein cross-linking in vivo. 
J Biol Chem, 277, 46043-50. 
HANDEL, E. M., ALWIN, S. & CATHOMEN, T. 2009. Expanding or restricting the target site 
repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant 
of target site selectivity. Mol Ther, 17, 104-11. 
HARDY, S., LEGAGNEUX, V., AUDIC, Y. & PAILLARD, L. 2010. Reverse genetics in 
eukaryotes. Biol Cell, 102, 561 - 580. 
HARRISON, M. M., JENKINS, B. V., O'CONNOR-GILES, K. M. & WILDONGER, J. 2014. A 
CRISPR view of development. Genes Dev, 28, 1859-72. 
190 
 
HAUSCHILD-QUINTERN, J., PETERSEN, B., COST, G. J. & NIEMANN, H. 2013. Gene knockout 
and knockin by zinc-finger nucleases: current status and perspectives. Cell Mol Life 
Sci, 70, 2969-83. 
HIRAI, H., TANI, T. & KIKYO, N. 2010. Structure and functions of powerful transactivators: 
VP16, MyoD and FoxA. Int J Dev Biol, 54, 1589-96. 
HOCKEMEYER, D., WANG, H., KIANI, S., LAI, C. S., GAO, Q., CASSADY, J. P., COST, G. J., 
ZHANG, L., SANTIAGO, Y., MILLER, J. C., ZEITLER, B., CHERONE, J. M., MENG, X., 
HINKLEY, S. J., REBAR, E. J., GREGORY, P. D., URNOV, F. D. & JAENISCH, R. 2011. 
Genetic engineering of human pluripotent cells using TALE nucleases. Nat 
Biotechnol, 29, 731-4. 
HOLT, N., WANG, J., KIM, K., FRIEDMAN, G., WANG, X., TAUPIN, V., CROOKS, G., KOHN, D., 
GREGORY, P., HOLMES, M. & CANNON, P. 2010. Human hematopoietic 
stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control 
HIV-1 in vivo. Nat Biotechnol, 28, 839-47. 
HSU, P. D., LANDER, E. S. & ZHANG, F. 2014. Development and applications of CRISPR-
Cas9 for genome engineering. Cell, 157, 1262-78. 
HSU, P. D., SCOTT, D. A., WEINSTEIN, J. A., RAN, F. A., KONERMANN, S., AGARWALA, V., LI, 
Y., FINE, E. J., WU, X., SHALEM, O., CRADICK, T. J., MARRAFFINI, L. A., BAO, G. & 
ZHANG, F. 2013. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat 
Biotechnol, 31, 827-32. 
HUANG, P., XIAO, A., ZHOU, M., ZHU, Z., LIN, S. & ZHANG, B. 2011. Heritable gene 
targeting in zebrafish using customized TALENs. Nat Biotechnol. United States. 
ISALAN, M. 2012. Zinc-finger nucleases: how to play two good hands. Nat Methods, 9, 32-
4. 
ISALAN, M., CHOO, Y. & KLUG, A. 1997. Synergy between adjacent zinc fingers in 
sequence-specific DNA recognition. Proc Natl Acad Sci U S A, 94, 5617-21. 
ISALAN, M., KLUG, A. & CHOO, Y. 1998. Comprehensive DNA recognition through 
concerted interactions from adjacent zinc fingers. Biochemistry, 37, 12026-33. 
IVANOV, A. V., PENG, H., YURCHENKO, V., YAP, K. L., NEGOREV, D. G., SCHULTZ, D. C., 
PSULKOWSKI, E., FREDERICKS, W. J., WHITE, D. E., MAUL, G. G., SADOFSKY, M. J., 
ZHOU, M. M. & RAUSCHER, F. J., 3RD 2007. PHD domain-mediated E3 ligase 
activity directs intramolecular sumoylation of an adjacent bromodomain required 
for gene silencing. Mol Cell, 28, 823-37. 
JACOBS, G. & MICHAELS, G. 1990. Zinc finger gene database. New Biol, 2, 583. 
JASIN, M. 1996. Genetic manipulation of genomes with rare-cutting endonucleases. 
Trends Genet, 12, 224-8. 
JINEK, M., CHYLINSKI, K., FONFARA, I., HAUER, M., DOUDNA, J. A. & CHARPENTIER, E. 
2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial 
immunity. Science, 337, 816-21. 
JOUNG, J. K. & SANDER, J. D. 2013. TALENs: a widely applicable technology for targeted 
genome editing. Nat Rev Mol Cell Biol, 14, 49-55. 
KADAMB, R., MITTAL, S., BANSAL, N., BATRA, H. & SALUJA, D. 2013. Sin3: insight into its 
transcription regulatory functions. Eur J Cell Biol, 92, 237-46. 
KAY, S., BOCH, J. & BONAS, U. 2005. Characterization of AvrBs3-like effectors from a 
Brassicaceae pathogen reveals virulence and avirulence activities and a protein 
with a novel repeat architecture. Mol Plant Microbe Interact, 18, 838-48. 
KAY, S., HAHN, S., MAROIS, E., HAUSE, G. & BONAS, U. 2007. A bacterial effector acts as a 
plant transcription factor and induces a cell size regulator. Science, 318, 648-51. 
191 
 
KIM, H., LEE, H., KIM, H., CHO, S. & KIM, J. 2009. Targeted genome editing in human cells 
with zinc finger nucleases constructed via modular assembly. Genome Res, 19, 
1279-88. 
KIM, J. H., LEE, S. R., LI, L. H., PARK, H. J., PARK, J. H., LEE, K. Y., KIM, M. K., SHIN, B. A. & 
CHOI, S. Y. 2011. High cleavage efficiency of a 2A peptide derived from porcine 
teschovirus-1 in human cell lines, zebrafish and mice. PLoS One, 6, e18556. 
KIM, J. S., LEE, H. J. & CARROLL, D. 2010. Genome editing with modularly assembled zinc-
finger nucleases. Nat Methods. United States. 
KIM, Y. G., CHA, J. & CHANDRASEGARAN, S. 1996. Hybrid restriction enzymes: zinc finger 
fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A, 93, 1156-60. 
KIM, Y. G. & CHANDRASEGARAN, S. 1994. Chimeric restriction endonuclease. Proc Natl 
Acad Sci U S A, 91, 883-7. 
KOBAYASHI, N., BOYER, T. G. & BERK, A. J. 1995. A class of activation domains interacts 
directly with TFIIA and stimulates TFIIA-TFIID-promoter complex assembly. Mol 
Cell Biol, 15, 6465-73. 
KOYANO-NAKAGAWA, N., NISHIDA, J., BALDWIN, D., ARAI, K. & YOKOTA, T. 1994. 
Molecular cloning of a novel human cDNA encoding a zinc finger protein that 
binds to the interleukin-3 promoter. Mol Cell Biol, 14, 5099-107. 
KUHNERT, F., CAMPAGNOLO, L., XIONG, J. W., LEMONS, D., FITCH, M. J., ZOU, Z., KIOSSES, 
W. B., GARDNER, H. & STUHLMANN, H. 2005. Dosage-dependent requirement for 
mouse Vezf1 in vascular system development. Dev Biol, 283, 140-56. 
KULINSKI, J., BESACK, D., OLEYKOWSKI, C. A., GODWIN, A. K. & YEUNG, A. T. 2000. CEL I 
enzymatic mutation detection assay. Biotechniques, 29, 44-6, 48. 
KWON, D. N., LEE, K., KANG, M. J., CHOI, Y. J., PARK, C., WHYTE, J. J., BROWN, A. N., KIM, 
J. H., SAMUEL, M., MAO, J., PARK, K. W., MURPHY, C. N. & PRATHER, R. S. 2013. 
Production of biallelic CMP-Neu5Ac hydroxylase knock-out pigs. Sci Rep, 3, 1981. 
LAMB, B. M., MERCER, A. C. & BARBAS, C. F., 3RD 2013. Directed evolution of the TALE N-
terminal domain for recognition of all 5' bases. Nucleic Acids Res, 41, 9779-85. 
LEE, H., KIM, E. & KIM, J. 2010. Targeted chromosomal deletions in human cells using zinc 
finger nucleases. Genome Res, 20, 81-9. 
LEE, M. S., GIPPERT, G. P., SOMAN, K. V., CASE, D. A. & WRIGHT, P. E. 1989. Three-
dimensional solution structure of a single zinc finger DNA-binding domain. Science, 
245, 635-7. 
LEI, Y., GUO, X., LIU, Y., CAO, Y., DENG, Y., CHEN, X., CHENG, C. H., DAWID, I. B., CHEN, Y. 
& ZHAO, H. 2012. Efficient targeted gene disruption in Xenopus embryos using 
engineered transcription activator-like effector nucleases (TALENs). Proc Natl Acad 
Sci U S A, 109, 17484-9. 
LI, H., HAURIGOT, V., DOYON, Y., LI, T., WONG, S. Y., BHAGWAT, A. S., MALANI, N., 
ANGUELA, X. M., SHARMA, R., IVANCIU, L., MURPHY, S. L., FINN, J. D., KHAZI, F. R., 
ZHOU, S., PASCHON, D. E., REBAR, E. J., BUSHMAN, F. D., GREGORY, P. D., 
HOLMES, M. C. & HIGH, K. A. 2011a. In vivo genome editing restores haemostasis 
in a mouse model of haemophilia. Nature, 475, 217-21. 
LI, L., WU, L. P. & CHANDRASEGARAN, S. 1992. Functional domains in Fok I restriction 
endonuclease. Proc Natl Acad Sci U S A, 89, 4275-9. 
LI, T., HUANG, S., JIANG, W. Z., WRIGHT, D., SPALDING, M. H., WEEKS, D. P. & YANG, B. 
2011b. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI 
DNA-cleavage domain. Nucleic Acids Res, 39, 359-72. 
LI, T., HUANG, S., ZHAO, X., WRIGHT, D. A., CARPENTER, S., SPALDING, M. H., WEEKS, D. P. 
& YANG, B. 2011c. Modularly assembled designer TAL effector nucleases for 
192 
 
targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res, 
39, 6315-25. 
LIEBER, M. R. 2010. The mechanism of double-strand DNA break repair by the 
nonhomologous DNA end-joining pathway. Annu Rev Biochem, 79, 181-211. 
LIU, J., LI, C., YU, Z., HUANG, P., WU, H., WEI, C., ZHU, N., SHEN, Y., CHEN, Y., ZHANG, B., 
DENG, W. M. & JIAO, R. 2012. Efficient and specific modifications of the 
Drosophila genome by means of an easy TALEN strategy. J Genet Genomics, 39, 
209-15. 
LIU, Q., XIA, Z., ZHONG, X. & CASE, C. C. 2002. Validated zinc finger protein designs for all 
16 GNN DNA triplet targets. J Biol Chem, 277, 3850-6. 
LLOYD, A., PLAISIER, C., CARROLL, D. & DREWS, G. 2005. Targeted mutagenesis using zinc-
finger nucleases in Arabidopsis. Proc Natl Acad Sci U S A, 102, 2232-7. 
LOW, C. M. 2013. Genomic interactions of the transcription factor VEZF1. PhD, University 
of Glasgow. 
LOZZIO, C. B. & LOZZIO, B. B. 1975. Human chronic myelogenous leukemia cell-line with 
positive Philadelphia chromosome. Blood, 45, 321-34. 
MAEDER, M., THIBODEAU-BEGANNY, S., OSIAK, A., WRIGHT, D., ANTHONY, R., 
EICHTINGER, M., JIANG, T., FOLEY, J., WINFREY, R., TOWNSEND, J., UNGER-
WALLACE, E., SANDER, J., MÜLLER-LERCH, F., FU, F., PEARLBERG, J., GÖBEL, C., 
DASSIE, J., PRUETT-MILLER, S., PORTEUS, M., SGROI, D., IAFRATE, A., DOBBS, D., 
MCCRAY, P. J., CATHOMEN, T., VOYTAS, D. & JOUNG, J. 2008. Rapid "open-source" 
engineering of customized zinc-finger nucleases for highly efficient gene 
modification. Mol Cell, 31, 294-301. 
MAEDER, M., THIBODEAU-BEGANNY, S., SANDER, J., VOYTAS, D. & JOUNG, J. 2009. 
Oligomerized pool engineering (OPEN): an 'open-source' protocol for making 
customized zinc-finger arrays. Nat Protoc, 4, 1471-501. 
MAEDER, M. L., LINDER, S. J., CASCIO, V. M., FU, Y., HO, Q. H. & JOUNG, J. K. 2013a. 
CRISPR RNA-guided activation of endogenous human genes. Nat Methods, 10, 
977-9. 
MAEDER, M. L., LINDER, S. J., REYON, D., ANGSTMAN, J. F., FU, Y., SANDER, J. D. & JOUNG, 
J. K. 2013b. Robust, synergistic regulation of human gene expression using TALE 
activators. Nat Methods, 10, 243-5. 
MAHFOUZ, M. M., LI, L., PIATEK, M., FANG, X., MANSOUR, H., BANGARUSAMY, D. K. & 
ZHU, J. K. 2012. Targeted transcriptional repression using a chimeric TALE-SRDX 
repressor protein. Plant Mol Biol, 78, 311-21. 
MAK, A. N., BRADLEY, P., CERNADAS, R. A., BOGDANOVE, A. J. & STODDARD, B. L. 2012. 
The crystal structure of TAL effector PthXo1 bound to its DNA target. Science, 335, 
716-9. 
MALI, P., YANG, L., ESVELT, K. M., AACH, J., GUELL, M., DICARLO, J. E., NORVILLE, J. E. & 
CHURCH, G. M. 2013. RNA-guided human genome engineering via Cas9. Science, 
339, 823-6. 
MARGOLIN, J. F., FRIEDMAN, J. R., MEYER, W. K., VISSING, H., THIESEN, H. J. & RAUSCHER, 
F. J., 3RD 1994. Kruppel-associated boxes are potent transcriptional repression 
domains. Proc Natl Acad Sci U S A, 91, 4509-13. 
MILLER, J., MCLACHLAN A D & KLUG, A. 1985. Repetitive zinc-binding domains in the 
protein transcription factor IIIA from Xenopus oocytes. EMBO, 4, 1609 - 1614. 
MILLER, J. C., HOLMES, M. C., WANG, J., GUSCHIN, D. Y., LEE, Y. L., RUPNIEWSKI, I., 
BEAUSEJOUR, C. M., WAITE, A. J., WANG, N. S., KIM, K. A., GREGORY, P. D., PABO, 
C. O. & REBAR, E. J. 2007. An improved zinc-finger nuclease architecture for highly 
specific genome editing. Nat Biotechnol, 25, 778-85. 
193 
 
MILLER, J. C., TAN, S., QIAO, G., BARLOW, K. A., WANG, J., XIA, D. F., MENG, X., PASCHON, 
D. E., LEUNG, E., HINKLEY, S. J., DULAY, G. P., HUA, K. L., ANKOUDINOVA, I., COST, 
G. J., URNOV, F. D., ZHANG, H. S., HOLMES, M. C., ZHANG, L., GREGORY, P. D. & 
REBAR, E. J. 2011. A TALE nuclease architecture for efficient genome editing. Nat 
Biotechnol, 29, 143-8. 
MIYASHITA, H., KANEMURA, M., YAMAZAKI, T., ABE, M. & SATO, Y. 2004. Vascular 
endothelial zinc finger 1 is involved in the regulation of angiogenesis: possible 
contribution of stathmin/OP18 as a downstream target gene. Arterioscler Thromb 
Vasc Biol, 24, 878-84. 
MOEHLE, E., ROCK, J., LEE, Y., JOUVENOT, Y., DEKELVER, R., DEKELVER, R., GREGORY, P., 
URNOV, F. & HOLMES, M. 2007. Targeted gene addition into a specified location in 
the human genome using designed zinc finger nucleases. Proc Natl Acad Sci U S A, 
104, 3055-60. 
MORBITZER, R., ROMER, P., BOCH, J. & LAHAYE, T. 2010. Regulation of selected genome 
loci using de novo-engineered transcription activator-like effector (TALE)-type 
transcription factors. Proc Natl Acad Sci U S A, 107, 21617-22. 
MOSCOU, M. J. & BOGDANOVE, A. J. 2009. A simple cipher governs DNA recognition by 
TAL effectors. Science, 326, 1501. 
MUSSOLINO, C., MORBITZER, R., LUTGE, F., DANNEMANN, N., LAHAYE, T. & CATHOMEN, 
T. 2011. A novel TALE nuclease scaffold enables high genome editing activity in 
combination with low toxicity. Nucleic Acids Res, 39, 9283-93. 
OLEYKOWSKI, C. A., BRONSON MULLINS, C. R., GODWIN, A. K. & YEUNG, A. T. 1998. 
Mutation detection using a novel plant endonuclease. Nucleic Acids Res, 26, 4597-
602. 
PAPWORTH, M., KOLASINSKA, P. & MINCZUK, M. 2006. Designer zinc-finger proteins and 
their applications. Gene, 366, 27-38. 
PARRAGA, G., HORVATH, S. J., EISEN, A., TAYLOR, W. E., HOOD, L., YOUNG, E. T. & KLEVIT, 
R. E. 1988. Zinc-dependent structure of a single-finger domain of yeast ADR1. 
Science, 241, 1489-92. 
PATTANAYAK, V., RAMIREZ, C. L., JOUNG, J. K. & LIU, D. R. 2011. Revealing off-target 
cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods, 8, 
765-70. 
PAVLETICH, N. P. & PABO, C. O. 1991. Zinc finger-DNA recognition: crystal structure of a 
Zif268-DNA complex at 2.1 A. Science, 252, 809-17. 
PEREZ, E. E., WANG, J., MILLER, J. C., JOUVENOT, Y., KIM, K. A., LIU, O., WANG, N., LEE, G., 
BARTSEVICH, V. V., LEE, Y. L., GUSCHIN, D. Y., RUPNIEWSKI, I., WAITE, A. J., 
CARPENITO, C., CARROLL, R. G., ORANGE, J. S., URNOV, F. D., REBAR, E. J., ANDO, 
D., GREGORY, P. D., RILEY, J. L., HOLMES, M. C. & JUNE, C. H. 2008. Establishment 
of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. 
Nat Biotechnol, 26, 808-16. 
PEREZ-PINERA, P. 2013. Synergistic and tunable human gene activation by combinations 
of synthetic transcription factors. 10, 239-42. 
PEREZ-PINERA, P., KOCAK, D. D., VOCKLEY, C. M., ADLER, A. F., KABADI, A. M., POLSTEIN, 
L. R., THAKORE, P. I., GLASS, K. A., OUSTEROUT, D. G., LEONG, K. W., GUILAK, F., 
CRAWFORD, G. E., REDDY, T. E. & GERSBACH, C. A. 2013. RNA-guided gene 
activation by CRISPR-Cas9-based transcription factors. Nat Methods, 10, 973-6. 
PEREZ-PINERA, P., OUSTEROUT, D. G., BROWN, M. T. & GERSBACH, C. A. 2012. Gene 
targeting to the ROSA26 locus directed by engineered zinc finger nucleases. 
Nucleic Acids Res, 40, 3741-52. 
194 
 
PORTEUS, M. & BALTIMORE, D. 2003. Chimeric nucleases stimulate gene targeting in 
human cells. Science, 300, 763. 
PRUETT-MILLER, S. M., CONNELLY, J. P., MAEDER, M. L., JOUNG, J. K. & PORTEUS, M. H. 
2008. Comparison of zinc finger nucleases for use in gene targeting in mammalian 
cells. Mol Ther, 16, 707-17. 
RAMIREZ, C. L., FOLEY, J. E., WRIGHT, D. A., MULLER-LERCH, F., RAHMAN, S. H., CORNU, T. 
I., WINFREY, R. J., SANDER, J. D., FU, F., TOWNSEND, J. A., CATHOMEN, T., VOYTAS, 
D. F. & JOUNG, J. K. 2008. Unexpected failure rates for modular assembly of 
engineered zinc fingers. Nat Methods. United States. 
REYON, D., KHAYTER, C., REGAN, M. R., JOUNG, J. K. & SANDER, J. D. 2012a. Engineering 
designer transcription activator-like effector nucleases (TALENs) by REAL or REAL-
Fast assembly. Curr Protoc Mol Biol, Chapter 12, Unit 12.15. 
REYON, D., TSAI, S. Q., KHAYTER, C., FODEN, J. A., SANDER, J. D. & JOUNG, J. K. 2012b. 
FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol, 
30, 460-5. 
SANDER, J., ZABACK, P., JOUNG, J., VOYTAS, D. & DOBBS, D. 2007. Zinc Finger Targeter 
(ZiFiT): an engineered zinc finger/target site design tool. Nucleic Acids Res, 35, 
W599-605. 
SANDER, J. D., CADE, L., KHAYTER, C., REYON, D., PETERSON, R. T., JOUNG, J. K. & YEH, J. 
R. 2011a. Targeted gene disruption in somatic zebrafish cells using engineered 
TALENs. Nat Biotechnol. United States. 
SANDER, J. D., DAHLBORG, E. J., GOODWIN, M. J., CADE, L., ZHANG, F., CIFUENTES, D., 
CURTIN, S. J., BLACKBURN, J. S., THIBODEAU-BEGANNY, S., QI, Y., PIERICK, C. J., 
HOFFMAN, E., MAEDER, M. L., KHAYTER, C., REYON, D., DOBBS, D., LANGENAU, D. 
M., STUPAR, R. M., GIRALDEZ, A. J., VOYTAS, D. F., PETERSON, R. T., YEH, J. R. & 
JOUNG, J. K. 2011b. Selection-free zinc-finger-nuclease engineering by context-
dependent assembly (CoDA). Nat Methods, 8, 67-9. 
SANDER, J. D. & JOUNG, J. K. 2014. CRISPR-Cas systems for editing, regulating and 
targeting genomes. Nat Biotechnol, 32, 347-55. 
SANGAMO BIOSCIENCES, I. 2013. Sangamo Biosciences Presents Clinical Data From HIV 
Study Demonstrating Sustained Control of Viremia. Reduction of Viral Load at or 
Below Limit of Detection Ongoing at 14 Weeks. 
SANJANA, N. E., CONG, L., ZHOU, Y., CUNNIFF, M. M., FENG, G. & ZHANG, F. 2012. A 
transcription activator-like effector toolbox for genome engineering. Nat Protoc, 
7, 171-92. 
SANTIAGO, Y., CHAN, E., LIU, P. Q., ORLANDO, S., ZHANG, L., URNOV, F. D., HOLMES, M. 
C., GUSCHIN, D., WAITE, A., MILLER, J. C., REBAR, E. J., GREGORY, P. D., KLUG, A. & 
COLLINGWOOD, T. N. 2008. Targeted gene knockout in mammalian cells by using 
engineered zinc-finger nucleases. Proc Natl Acad Sci U S A, 105, 5809-14. 
SARGENT, R. G., BRENNEMAN, M. A. & WILSON, J. H. 1997. Repair of site-specific double-
strand breaks in a mammalian chromosome by homologous and illegitimate 
recombination. Mol Cell Biol, 17, 267-77. 
SCHORNACK, S., MEYER, A., ROMER, P., JORDAN, T. & LAHAYE, T. 2006. Gene-for-gene-
mediated recognition of nuclear-targeted AvrBs3-like bacterial effector proteins. J 
Plant Physiol, 163, 256-72. 
SCHORNACK, S., MINSAVAGE, G. V., STALL, R. E., JONES, J. B. & LAHAYE, T. 2008. 
Characterization of AvrHah1, a novel AvrBs3-like effector from Xanthomonas 
gardneri with virulence and avirulence activity. New Phytol, 179, 546-56. 
SEBASTIANO, V., MAEDER, M. L., ANGSTMAN, J. F., HADDAD, B., KHAYTER, C., YEO, D. T., 
GOODWIN, M. J., HAWKINS, J. S., RAMIREZ, C. L., BATISTA, L. F., ARTANDI, S. E., 
195 
 
WERNIG, M. & JOUNG, J. K. 2011. In situ genetic correction of the sickle cell 
anemia mutation in human induced pluripotent stem cells using engineered zinc 
finger nucleases. Stem Cells, 29, 1717-26. 
SEGAL, D. J., DREIER, B., BEERLI, R. R. & BARBAS, C. F., 3RD 1999. Toward controlling gene 
expression at will: selection and design of zinc finger domains recognizing each of 
the 5'-GNN-3' DNA target sequences. Proc Natl Acad Sci U S A, 96, 2758-63. 
SHIMIZU, Y., BHAKTA, M. S. & SEGAL, D. J. 2009. Restricted spacer tolerance of a zinc 
finger nuclease with a six amino acid linker. Bioorg Med Chem Lett, 19, 3970-2. 
SHIMIZU, Y., SOLLU, C., MECKLER, J. F., ADRIAENSSENS, A., ZYKOVICH, A., CATHOMEN, T. 
& SEGAL, D. J. 2011. Adding fingers to an engineered zinc finger nuclease can 
reduce activity. Biochemistry, 50, 5033-41. 
SMITH, J., BIBIKOVA, M., WHITBY, F. G., REDDY, A. R., CHANDRASEGARAN, S. & CARROLL, 
D. 2000. Requirements for double-strand cleavage by chimeric restriction enzymes 
with zinc finger DNA-recognition domains. Nucleic Acids Res, 28, 3361-9. 
SOLDNER, F., LAGANIERE, J., CHENG, A. W., HOCKEMEYER, D., GAO, Q., ALAGAPPAN, R., 
KHURANA, V., GOLBE, L. I., MYERS, R. H., LINDQUIST, S., ZHANG, L., GUSCHIN, D., 
FONG, L. K., VU, B. J., MENG, X., URNOV, F. D., REBAR, E. J., GREGORY, P. D., 
ZHANG, H. S. & JAENISCH, R. 2011. Generation of isogenic pluripotent stem cells 
differing exclusively at two early onset Parkinson point mutations. Cell, 146, 318-
31. 
STREUBEL, J., BLUCHER, C., LANDGRAF, A. & BOCH, J. 2012. TAL effector RVD specificities 
and efficiencies. Nat Biotechnol. United States. 
STROGANTSEV, R. S. 2009. Mapping and characterisation of genomic binding sites of the 
chromatin barrier protein VEZF1. Thesis (Ph D ), University of Glasgow. 
SUN, N., LIANG, J., ABIL, Z. & ZHAO, H. 2012. Optimized TAL effector nucleases (TALENs) 
for use in treatment of sickle cell disease. Mol Biosyst, 8, 1255-63. 
SUN, N. & ZHAO, H. 2013. Transcription activator-like effector nucleases (TALENs): a 
highly efficient and versatile tool for genome editing. Biotechnol Bioeng, 110, 
1811-21. 
SZCZEPEK, M., BRONDANI, V., BUCHEL, J., SERRANO, L., SEGAL, D. J. & CATHOMEN, T. 
2007. Structure-based redesign of the dimerization interface reduces the toxicity 
of zinc-finger nucleases. Nat Biotechnol, 25, 786-93. 
SZUREK, B., ROSSIER, O., HAUSE, G. & BONAS, U. 2002. Type III-dependent translocation 
of the Xanthomonas AvrBs3 protein into the plant cell. Mol Microbiol, 46, 13-23. 
TESSON, L., USAL, C., MENORET, S., LEUNG, E., NILES, B. J., REMY, S., SANTIAGO, Y., 
VINCENT, A. I., MENG, X., ZHANG, L., GREGORY, P. D., ANEGON, I. & COST, G. J. 
2011. Knockout rats generated by embryo microinjection of TALENs. Nat 
Biotechnol. United States. 
TOWNSEND, J. A., WRIGHT, D. A., WINFREY, R. J., FU, F., MAEDER, M. L., JOUNG, J. K. & 
VOYTAS, D. F. 2009. High-frequency modification of plant genes using engineered 
zinc-finger nucleases. Nature, 459, 442-5. 
TSUJI, S., FUTAKI, S. & IMANISHI, M. 2013. Creating a TALE protein with unbiased 5'-T 
binding. Biochem Biophys Res Commun, 441, 262-5. 
TSUJI, T. & NIIDA, Y. 2008. Development of a simple and highly sensitive mutation 
screening system by enzyme mismatch cleavage with optimized conditions for 
standard laboratories. Electrophoresis, 29, 1473-83. 
TUMBAR, T., SUDLOW, G. & BELMONT, A. S. 1999. Large-Scale Chromatin Unfolding and 
Remodeling Induced by VP16 Acidic Activation Domain. J Cell Biol, 145, 1341-54. 
196 
 
URNOV, F., MILLER, J., LEE, Y., BEAUSEJOUR, C., ROCK, J., AUGUSTUS, S., JAMIESON, A., 
PORTEUS, M., GREGORY, P. & HOLMES, M. 2005. Highly efficient endogenous 
human gene correction using designed zinc-finger nucleases. Nature, 435, 646-51. 
URNOV, F., REBAR, E., HOLMES, M., ZHANG, H. & GREGORY, P. 2010. Genome editing 
with engineered zinc finger nucleases. Nat Rev Genet, 11, 636-46. 
UTLEY, R. T., IKEDA, K., GRANT, P. A., COTE, J., STEGER, D. J., EBERHARTER, A., JOHN, S. & 
WORKMAN, J. L. 1998. Transcriptional activators direct histone acetyltransferase 
complexes to nucleosomes. Nature, 394, 498-502. 
VAN DEN ACKERVEKEN, G., MAROIS, E. & BONAS, U. 1996. Recognition of the bacterial 
avirulence protein AvrBs3 occurs inside the host plant cell. Cell, 87, 1307-16. 
VAN OEVELEN, C., WANG, J., ASP, P., YAN, Q., KAELIN, W. G., JR., KLUGER, Y. & DYNLACHT, 
B. D. 2008. A role for mammalian Sin3 in permanent gene silencing. Mol Cell, 32, 
359-70. 
VAN RENSBURG, R., BEYER, I., YAO, X. Y., WANG, H., DENISENKO, O., LI, Z. Y., RUSSELL, D. 
W., MILLER, D. G., GREGORY, P., HOLMES, M., BOMSZTYK, K. & LIEBER, A. 2013. 
Chromatin structure of two genomic sites for targeted transgene integration in 
induced pluripotent stem cells and hematopoietic stem cells. Gene Ther, 20, 201-
14. 
VOIT, R. A., HENDEL, A., PRUETT-MILLER, S. M. & PORTEUS, M. H. 2014. Nuclease-
mediated gene editing by homologous recombination of the human globin locus. 
Nucleic Acids Res, 42, 1365-78. 
WERNER, J. & GOSSEN, M. 2014. Modes of TAL effector-mediated repression. Nucleic 
Acids Res, 42, 13061-73. 
WILSON, K. A., MCEWEN, A. E., PRUETT-MILLER, S. M., ZHANG, J., KILDEBECK, E. J. & 
PORTEUS, M. H. 2013. Expanding the Repertoire of Target Sites for Zinc Finger 
Nuclease-mediated Genome Modification. Mol Ther Nucleic Acids, 2, e88. 
WOLFE, S. A., GREISMAN, H. A., RAMM, E. I. & PABO, C. O. 1999. Analysis of zinc fingers 
optimized via phage display: evaluating the utility of a recognition code. J Mol Biol, 
285, 1917-34. 
WOLFE, S. A., NEKLUDOVA, L. & PABO, C. O. 2000. DNA recognition by Cys2His2 zinc 
finger proteins. Annu Rev Biophys Biomol Struct, 29, 183-212. 
WRIGHT, D. A., THIBODEAU-BEGANNY, S., SANDER, J. D., WINFREY, R. J., HIRSH, A. S., 
EICHTINGER, M., FU, F., PORTEUS, M. H., DOBBS, D., VOYTAS, D. F. & JOUNG, J. K. 
2006. Standardized reagents and protocols for engineering zinc finger nucleases 
by modular assembly. Nature Protocols, 1, 1637 - 1651. 
XIAO, H., PEARSON, A., COULOMBE, B., TRUANT, R., ZHANG, S., REGIER, J. L., 
TRIEZENBERG, S. J., REINBERG, D., FLORES, O., INGLES, C. J. & ET AL. 1994. Binding 
of basal transcription factor TFIIH to the acidic activation domains of VP16 and 
p53. Mol Cell Biol, 14, 7013-24. 
XIONG, J. W., LEAHY, A., LEE, H. H. & STUHLMANN, H. 1999. Vezf1: A Zn finger 
transcription factor restricted to endothelial cells and their precursors. Dev Biol, 
206, 123-41. 
YANG, L., MEI, Q., ZIELINSKA-KWIATKOWSKA, A., MATSUI, Y., BLACKBURN, M. L., 
BENEDETTI, D., KRUMM, A. A., TABORSKY, G. J., JR. & CHANSKY, H. A. 2003. An 
ERG (ets-related gene)-associated histone methyltransferase interacts with 
histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem J, 
369, 651-7. 
YUSUFZAI, T. M. & FELSENFELD, G. 2004. The 5'-HS4 chicken beta-globin insulator is a 
CTCF-dependent nuclear matrix-associated element. Proc Natl Acad Sci U S A, 101, 
8620-4. 
197 
 
ZHANG, F., CONG, L., LODATO, S., KOSURI, S., CHURCH, G. M. & ARLOTTA, P. 2011. 
Efficient construction of sequence-specific TAL effectors for modulating 
mammalian transcription. Nat Biotechnol, 29, 149-53. 
ZHANG, Z., XIANG, D., HERIYANTO, F., GAO, Y., QIAN, Z. & WU, W. S. 2013. Dissecting the 
Roles of miR-302/367 Cluster in Cellular Reprogramming Using TALE-based 
Repressor and TALEN. Stem Cell Reports. 
ZHU, W., YANG, B., CHITTOOR, J. M., JOHNSON, L. B. & WHITE, F. F. 1998. AvrXa10 
contains an acidic transcriptional activation domain in the functionally conserved 
C terminus. Mol Plant Microbe Interact, 11, 824-32. 
ZOU, J., MALI, P., HUANG, X., DOWEY, S. N. & CHENG, L. 2011. Site-specific gene 
correction of a point mutation in human iPS cells derived from an adult patient 
with sickle cell disease. Blood, 118, 4599-608. 
ZOU, Z., OCAYA, P. A., SUN, H., KUHNERT, F. & STUHLMANN, H. 2010. Targeted Vezf1-null 
mutation impairs vascular structure formation during embryonic stem cell 
differentiation. Arterioscler Thromb Vasc Biol, 30, 1378-88. 
 
